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ABSTRACT  
   
Development of the cerebral cortex requires the complex integration of 
extracellular stimuli to affect changes in gene expression. Trophic stimulation activates 
specialized intracellular signaling cascades to instruct processes necessary for the elaborate 
cellular diversity, architecture, and function of the cortex. The canonical 
RAS/RAF/MEK/ERK (ERK/MAPK) cascade is a ubiquitously expressed kinase pathway 
that regulates crucial aspects of neurodevelopment. Mutations in the ERK/MAPK pathway 
or its regulators give rise to neurodevelopmental syndromes termed the “RASopathies.” 
RASopathy individuals present with neurological symptoms that include intellectual 
disability, ADHD, and seizures. The precise cellular mechanisms that drive neurological 
impairments in RASopathy individuals remain unclear. In this thesis, I aimed to 1) address 
how RASopathy mutations affect neurodevelopment, 2) elucidate fundamental 
requirements of ERK/MAPK in GABAergic circuits, and 3) determine how aberrant 
ERK/MAPK signaling disrupts GABAergic development. 
Here, I show that a Noonan Syndrome-linked gain-of-function mutation Raf1L613V, 
drives modest changes in astrocyte and oligodendrocyte progenitor cell (OPC) density in 
the mouse cortex and hippocampus. Raf1L613V mutant mice exhibited enhanced 
performance in hippocampal-dependent spatial reference and working memory and 
amygdala-dependent fear learning tasks. However, we observed normal perineuronal net 
(PNN) accumulation around mutant parvalbumin-expressing (PV) interneurons. Though 
PV-interneurons were minimally affected by the Raf1L613V mutation, other RASopathy 
mutations converge on aberrant GABAergic development as a mediator of neurological 
dysfunction. 
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I therefore hypothesized interneuron expression of the constitutively active 
Mek1S217/221E (caMek1) mutation would be sufficient to perturb GABAergic circuit 
development. Interestingly, the caMek1 mutation selectively disrupted crucial PV-
interneuron developmental processes. During embryogenesis, I detected expression of 
cleaved-caspase 3 (CC3) in the medial ganglionic eminence (MGE). Interestingly, adult 
mutant cortices displayed a selective 50% reduction in PV-expressing interneurons, but not 
other interneuron subtypes. PV-interneuron loss was associated with seizure-like activity 
in mutants and coincided with reduced perisomatic synapses. Mature mutant PV-
interneurons exhibited somal hypertrophy and a substantial increase in PNN accumulation. 
Aberrant GABAergic development culminated in reduced behavioral response inhibition, 
a process linked to ADHD-like behaviors. Collectively, these data provide insight into the 
mechanistic underpinnings of RASopathy neuropathology and suggest that modulation of 
GABAergic circuits may be an effective therapeutic option for RASopathy individuals. 
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CHAPTER 1 
INTRODUCTION 
The human brain is the most complex organ assembled through evolution. At its 
most complicated, the brain orchestrates incredible behavioral feats including the initiation 
and cessation of motor movement, the integration of sensory experience, and the storage 
of short- and long-term memories, all while performing basic autonomic functions essential 
for sustained life. The cerebral cortex is responsible for higher order cognitive functions 
that make us uniquely human. By volume, the human cortex accounts for approximately 
77% of brain weight and is organized into sulci and gyri that allow for improved surface 
area and enhanced computational power compared to other organisms (Trends in 
Neurosciences, 18:471-474, 1995). The proper formation of the cortex requires advanced 
coordination of molecular and cellular events during both embryonic and neonatal 
development. 
 The activation of specific intracellular signaling cascades is necessary to give rise 
to the cellular and functional diversity of the cerebral cortex. In particular, the Extracellular 
Regulated Kinase (ERK/MAPK) pathway is a highly conserved and ubiquitously 
expressed signaling cascade that coordinates numerous aspects of cortical development 
including the regulation of neural progenitor cell division, neuronal fate, migration, and 
survival (Samuels et al., 2009). The ERK/MAPK cascade consists of four core constituents, 
RAS, RAF, MEK, and ERK, all of which are expressed to different degrees within 
individual neural cell types. MAPK3/ERK1 and MAPK1/ERK2 constitute the principal 
kinases of the core cascade and exhibit high levels of sequence homology and functional 
redundancy (Fremin et al., 2015). 
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In the brain, the canonical ERK/MAPK pathway is initiated through binding of 
specific ligands, such as growth factors, to Receptor Tyrosine Kinases (RTKs) in the 
extracellular space. Factors such as Fibroblast Growth Factor 8 (FGF8) and Brain Derived 
Neurotrophic Factor (BDNF) are essential for the establishment and refinement of cortical 
circuits (Huang et al., 1999; Toyoda et al., 2010). Upon ligand binding in the extracellular 
space, RTKs undergo an intracellular autophosphorylation event that recruits a complex of 
associated proteins including the Son of Sevenless (SOS) Guanine Nucleotide Exchange 
Factor (GEF). SOS isoforms facilitate the conversion of GDP- to GTP-bound RAS, leading 
to a conformational change in RAS to an active state. Through the RAS binding domain 
(RBD), RAS-GTP then recruits and activates the RAF kinases. The RAF isoforms then 
phosphorylate the substrates MEK1 and MEK2 (MEK1/2) at serine residues 218/222 
(Lavoie and Therrien, 2015). MEK1/2 kinase activity leads to subsequent phosphorylation 
and activation of the ERK1/2 proteins, the principal kinases of the ERK/MAPK pathway. 
Phosphorylated ERK1/2 controls many cellular functions through both cytosolic and 
nuclear targets, allowing the cascade to regulate gene expression through numerous 
downstream effectors. 
Importantly, dysregulation of the ERK/MAPK cascade has been implicated in 
several neurodevelopmental diseases. Fragile X and Angelman Syndromes, as well as some 
forms of schizophrenia, have all been indirectly linked to alterations in ERK/MAPK 
signaling (Fazzari et al., 2010; Filonova et al., 2014; McMillan et al., 2012). In addition, 
1% of all Autism Spectrum Disorder (ASD) cases directly involve copy number variants 
of 16p11.2, a locus of 11 genes which includes the MAPK3/ERK1 gene (Pucilowska et al., 
2018; Pucilowska et al., 2015; Vithayathil et al., 2018). A family of neurodevelopmental 
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diseases, popularly called Neuro-Cardio-Facio-Cutaneous (NCFC) Syndromes or the 
“RASopathies,” arise from mutations in the core constituents and regulators of the 
ERK/MAPK cascade (Figure 1) (Tidyman and Rauen, 2016). Collectively, the 
RASopathies affect approximately 1 in 2000 live births with varying degrees of 
neurological symptoms. Individuals with mutations in ERK/MAPK pathway components 
typically exhibit distinct neurological, craniofacial, and cardiac abnormalities. 
Neurological symptoms consist of intellectual disability, issues with motor commands, 
autism prevalence, and seizures (Adviento et al., 2014; Rauen et al., 2013). Collectively, 
abnormal ERK/MAPK pathway activity has emerged as a potential master regulator of 
neurological phenotypes across multiple disorders. Therefore, therapeutic measures 
designed to target this cascade may be particularly effective treatment options for a number 
of individuals suffering from neurological symptoms associated with aberrant ERK/MAPK 
activity. 
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Figure 1. Mutations in regulators and core kinases of the ERK/MAPK cascade lead 
to the RASopathies. Ligand binding to RTKs in the extracellular space leads to the 
activation of the RAS isoforms. RAS binding to the RAF isoforms leads to the 
phosphorylation of MEK, which can then phosphorylate and activate the principal ERK1/2 
isoforms. ERK1/2 can affect changes in gene expression through multiple means. 
Mutations in NF1, SOS1, Shp2, BRAF, CRAF, MEK1, MEK2, ERK1, and ERK2 are 
linked to a series of neurodevelopmental disorders termed the RASopathies. Pictures of 
RASopathy patients are adapted from the laboratory of Katherine A. Rauen (Rauen et al., 
2013). 
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RASopathy-linked mutations differentially affect CNS cell populations 
Despite a common pathogenic mechanism linking numerous developmental disease 
states to dysregulated ERK/MAPK signaling, the underlying contributions of individual 
cell types to neurocognitive abnormalities observed in ERK/MAPK-linked disorders 
remain incompletely understood. Thus, study of the basic requirements of ERK/MAPK in 
diverse neural cell populations will be necessary to fully understand disease 
neuropathogenesis. A comprehensive understanding of the cell-specific consequences of 
altered ERK/MAPK pathway activity on cortical circuitry will be fundamental to the 
development of new therapeutics for these individuals.  
Mutations in nearly all core constituents and regulators of the ERK/MAPK cascade 
are sufficient to drive neurological dysfunction. In particular, genes such as SYNGAP1, 
NF1, SOS1, PTPN11, SHOC2, K-RAS, H-RAS, BRAF, RAF1, and MEK1 have been 
reported in patient cases of the RASopathies (Pierpont et al., 2009; Rodriguez-Viciana et 
al., 2006; Tidyman and Rauen, 2016; Tidyman and Rauen, 2009). However, it is unclear 
how individual cortical cell types are affected by mutations in these genes. This is due in 
part to the variable expression of ERK/MAPK pathway components in distinct cortical 
populations. For example, SYNGAP1 expression is enriched in cortical projection neurons 
(PNs) but lowly expressed in cortical GABAergic interneurons (CINs) (Mardinly et al., 
2016). As a consequence, neurological phenotypes related to changes in SYNGAP1 protein 
function are severe when PNs are selectively affected (Ozkan et al., 2014). These 
phenotypes include increased seizure susceptibility, anxiolytic behaviors, and deficits in 
fear learning. Conversely, no significant neurological abnormalities are observed when 
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CINs are selectively mutated (Ozkan et al., 2014). Therefore, individual types of cortical 
neurons may regulate distinct aspects of neuropathogenesis on a mutation-specific basis. 
Furthermore, loss of a negative regulator of RAS signaling, neurofibromin, leads 
to differential neurocognitive outcomes when conditionally deleted from glutamatergic or 
GABAergic neurons. Intellectual disability is commonly observed in patient cases of NF1 
and other RASopathies, and is typically thought to be mediated by changes in hippocampal 
function (Rauen et al., 2013). Interestingly, loss of NF1 from postmitotic glutamatergic 
neurons was not sufficient to alter hippocampal-dependent spatial reference memory (Cui 
et al., 2008). However, conditional deletion of NF1 from post-mitotic GABAergic neurons 
led to deficits in hippocampal learning and memory and associated defects in long term 
potentiation (LTP) (Cui et al., 2008). Collectively, these data from two upstream regulators 
of RAS activity suggest that the neuropathogenesis of specific RASopathy disease states 
is controlled by distinct populations of neural cell types. 
Neurofibromin is highly expressed in non-neuronal glial cell populations, and thus 
these cells are likely involved in NF1 neuropathogenesis (Loo et al., 2019; Mardinly et al., 
2016). This is substantiated by post-mortem patient studies, where brain tissue of 
individuals with Neurofibromatosis type 1 (NF1) revealed high densities of glial fibrillary 
acidic protein-expressing (GFAP) reactive astrocytes across multiple brain regions 
(Nordlund et al., 1995; Rizvi et al., 1999). Indeed, loss of neurofibromin in glial progenitors 
of the CNS drives reactive astrogliosis and increased risk of tumor formation, another 
common phenotype observed in clinical cases of NF1 (Rauen et al., 2013; Rauen et al., 
2015; Zhu et al., 2005). Loss of NF1 function specifically in post-mitotic neurons is 
similarly sufficient to increase numbers of GFAP+ astrocytes (Zhu et al., 2001). 
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Furthermore, oligodendrocyte progenitor cell (OPC) pool expansion is frequently observed 
in the CNS of NF1 mouse models (Bennett et al., 2003). OPC expansion may lead to 
changes in myelinogenesis and potentially underlie white matter abnormalities in NF1 
patients (Ishii et al., 2013; Koini et al., 2017). Therefore, glia appear to play a central role 
in the pathogenesis of NF1 and modulation of their functions within neural circuits may 
alleviate some neurological symptoms. 
Despite clear evidence for individual cell type contributions to RASopathy 
pathogenesis, it is difficult to understand how mutations in genes such as Syngap1, Nf1, 
Sos1, and the Ras isoforms drive neurological defects. Mutations that lead to aberrant RAS 
signaling drive alterations in pathway activity through multiple intracellular cascades 
(Figure 2) (Anastasaki and Gutmann, 2014; Brown et al., 2012; Hegedus et al., 2007; Kaul 
et al., 2015). While ERK/MAPK is often considered the classic kinase pathway activated 
by RAS, other parallel molecular cascades such as PI3K, Rho/ROCK, and cAMP are often 
adversely affected (Anastasaki and Gutmann, 2014; Brown et al., 2012; Hegedus et al., 
2007; Kaul et al., 2015). Pharmacological modulation of each of these intracellular 
cascades is sufficient to reverse some aspects of neuropathogenesis.  
Studying mutations in upstream regulators of RAS signaling poses difficulty in 
understanding how unique downstream cascades mediate neurological phenotypes. 
Mutations in the RAS effector BRAF, of which the encoded BRAF protein has selective 
binding affinity for MEK isoforms, drive profound behavioral deficits in RASopathy 
individuals with cardio-facio-cutaneous (CFC) Syndrome (Pierpont et al., 2010b). 
Mutations in BRAF are often associated with strong biochemical activation of the MEK 
and ERK isoforms (Rodriguez-Viciana et al., 2006), which may therefore significantly 
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alter critical cellular events during brain development. Mutations in other RAF isoforms, 
such as RAF1, have been documented in clinical RASopathy cases (Pandit et al., 2007; 
Razzaque et al., 2007). These patients often exhibit behavioral deficits, though biochemical 
activation of downstream ERK/MAPK components in response to RAF1 mutations appears 
to be weak relative to most BRAF mutations (Rodriguez-Viciana et al., 2006; Wu et al., 
2011). In addition, mutations in canonical components of the ERK/MAPK cascade are 
associated with greater severity of behavioral complications in comparison to mutations in 
upstream regulators of RAS (Pierpont et al., 2010b). Thus, examining the neurological 
ramifications associated with mutations in kinases downstream of RAS will be insightful 
in determining the specific effects of ERK/MAPK signaling to the neuropathogenesis of 
the RASopathies. 
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Figure 2. Parallel cascades are affected by mutations upstream of RAS. The majority 
of RASopathy mutations are found in upstream regulators of the canonical ERK/MAPK 
pathway. Dysregulation of RAS activity leads to differential activation of other 
intracellular signaling cascades such as PI3K/AKT/mTOR, cAMP, and Rho/ROCK in 
addition to canonical ERK/MAPK. It is therefore difficult to understand how each of these 
cell signaling pathways contributes to the neurological phenotypes observed in the 
RASopathies. 
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ERK/MAPK in the CNS – MAP of pallial development 
Canonical ERK/MAPK activity instructs the development of cortical cell 
populations. Previous research has elucidated several roles for the cascade in the 
development of dorsal-derived cell populations, such as cortical excitatory neurons and 
glia (Li et al., 2012b; Pucilowska et al., 2012; Pucilowska et al., 2008; Pucilowska et al., 
2015; Xing et al., 2016). The dorsal pallium of the cerebral cortex contains fate-restricted 
radial glia populations that reside in the ventricular and subventricular zones (VZ, SVZ) 
and give rise to elaborate cortical columns (Haueis, 2016; Mountcastle, 1997; Rakic, 1974). 
Radial glia divide asymmetrically to produce glutamatergic cortical projection neurons 
(PNs) in inside-out fashion (Greig et al., 2013). Radial migration of nascent PNs along 
radial glial fibers generate six functionally diverse cortical layers, where newly born 
neurons migrate beyond the previously established layer in a process called lamination 
(Cooper, 2008). Deep layer 5/6 cortical excitatory neurons primarily form long-range 
subcortical projections, whereas upper layer 2/3 glutamatergic neurons project intra-
cortically across the corpus callosum to the opposite hemisphere (Greig et al., 2013). 
Cortical PNs are produced from E11 to approximately E15.5, where radial glia shift to 
gliogenesis and begin the production of astrocytes. This neuro/gliogenic “switch” requires 
complex interactions between extracellular matrix molecules and their coinciding signaling 
pathways (Miller and Gauthier, 2007). Cardiotrophin 1 (CT-1) activation of JAK-STAT is 
a key mediator of cortical astrogenesis (Barnabé-Heider et al., 2005). Upregulation of glial 
genes is also mediated by bone morphogenetic proteins (BMPs) and Delta/Notch signaling 
(Miller and Gauthier, 2007). Collectively, BMPs and Delta/Notch activate the Smad family 
of transcription factors, which positively regulate gliogenic genes (Gomes et al., 2003). In 
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addition, BMP signaling during the gliogenic period upregulates the helix-loop-helix 
transcription factor Id1, which represses neurogenesis (Nakashima et al., 2001).  
The ERK/MAPK signaling cascade is similarly integral to the onset of gliogenesis, 
as radial glia lacking the kinases MAP2K1 and MAP2K2 (MAP2K1/2) lead to cortices 
completely devoid of astrocytes (Li et al., 2012b). Reinstatement of the ERK/MAPK target 
and Ets transcription family member, Erm, was sufficient to rescue gliogenesis in the 
developing cortex (Li et al., 2012b). Conversely, expression of a constitutively active 
MAP2K1 (herein referred to as caMek1) allele in radial glia promoted an early shift into 
gliogenesis and a significant overproduction of astrocytes, likely at the expense of some 
cortical PNs (Li et al., 2012b). Although many signaling molecules, kinases, and 
transcription factors are involved in corticogenesis, ERK/MAPK appears to be a central 
regulator of cortical cell number and controls crucial temporal aspects of early brain 
development. 
In addition to its roles in neuro- and gliogenesis, ERK/MAPK signaling is required 
in postnatal processes necessary for cortical maturation. Post-mitotic layer 2/3 PNs require 
ERK/MAPK for elaborate dendritic complexity and axonal outgrowth processes, though 
ERK/MAPK is not necessary for their long-term survival (Pucilowska et al., 2012; Xing et 
al., 2016). Cortices lacking ERK/MAPK fail to form the corpus callosum (Li et al., 2012b), 
though this may be due to combinatorial effects of not only pallial-generated neurons but 
also astrocytes and oligodendrocytes. Conversely, canonical ERK/MAPK activity is 
critical to the survival of layer 5 CTIP2+ subcortical PNs, where loss of ERK/MAPK drives 
the cleaved caspase 3-mediated death of a subset of these cells (Xing et al., 2016). 
Interestingly, enhanced MEK1 activity delays layer 5 PN axonal extension into the 
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neonatal spinal cord and increases arborization (Xing et al., 2016). Collectively, normal 
ERK/MAPK signaling is essential for the early establishment of pallial-derived neurons 
and glia to produce functional cortical circuits. 
 
CINs are generated in the ganglionic eminences of the embryonic subpallium 
Approximately 20% of cortical neurons utilize the neurotransmitter γ-aminobutyric 
acid (GABA), the primary inhibitory neurotransmitter in the Central Nervous System 
(CNS) (Sahara et al., 2012). Cortical GABAergic interneurons (CINs) are a population of 
locally connecting cells provide the inhibitory balance to cortical glutamatergic excitation. 
CINs have well-defined roles in cortical formation, maintenance of critical period 
plasticity, and modulation of behavioral output (Hensch, 2005a; Hensch, 2005b; Huang et 
al., 2007; Lehmann et al., 2012; Markram et al., 2004). An estimated 22 different CIN 
subtypes exist in the mature cortex which can be classified by their differing biochemical, 
morphological, and electrophysiological properties in addition to distinct patterns of 
connectivity (Fino et al., 2013; Rudy et al., 2011). The differences in these properties allow 
CIN subtypes to perform a variety of functions essential for basic cortical computation.  
The rich diversity of CIN subtypes are generated by radial glia inhabiting the medial 
and caudal ganglionic eminences of the subpallium (MGE and CGE respectively), and to 
a lesser extent, the preoptic area (POA) (Gelman et al., 2009; Wonders and Anderson, 
2006). Progenitors of the MGE require the homeobox transcription factor Nkx2.1 to 
generate CINs during embryogenesis (Sussel et al., 1999). Nkx2.1-/- mutant mice do not 
develop the MGE and instead form a single, continuous lateral ganglionic eminence (LGE). 
In adulthood, mice lacking Nkx2.1 function exhibit a significant reduction in CIN density, 
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further establishing Nkx2.1 as an essential mediator of the CIN lineage (Sussel et al., 1999; 
Wonders and Anderson, 2006). Furthermore, mutant cortices exhibit reduced Lhx6-
expressing cells, another key determinant of the MGE-derived cell fate (Sussel et al., 1999). 
Nearly 70% of CINs arise from the MGE and can be biochemically classified by non-
overlapping expression of the calcium chelator, parvalbumin (PV), or the neuropeptide, 
somatostatin (SST) (Miyoshi et al., 2015). More recent studies suggest that the location of 
MGE progenitors within the VZ and SVZ and rostro-caudal location is sufficient to bias 
nascent CINs toward differential fates (McKenzie et al., 2019; Petros et al., 2015). 
Interestingly, no known transcriptional markers currently exist to differentiate CIN 
subtypes in the early stages of neurogenesis (Lim et al., 2018; Mayer et al., 2018; Mi et al., 
2018; Sandberg et al., 2018). Transcriptional analyses seem to indicate that unspecified, 
yet biased progenitors give rise to the rich diversity of mature CINs. Importantly, MGE 
CIN fates appear to be patterned, at least in part, by non-canonical Wnt signaling from 
multiple sources across the eminence (McKenzie et al., 2019). 
In the adult cortex, PV and SST-CINs comprise the most populous and functionally 
diverse CIN subtypes. PV-CINs exhibit either a basket or chandelier morphology and high 
frequency firing rates unlike that of other CINs (Butt et al., 2005; DeFelipe et al., 2013; 
Rudy and McBain, 2001). Distinct PV-CIN morphologies coincide with differential 
patterns of connectivity: basket cell axon terminals primarily target the soma of PNs, 
whereas chandelier synaptic contacts are formed on the PN axon initial segment (Fino et 
al., 2013). The fast-spiking (FS) properties characteristic of PV-CINs are driven by the 
expression of fast-inactivating Kv3.1 and Kv3.2 potassium channels (Rosato-Siri et al., 
2015; Rudy and McBain, 2001). The differential expression of ion channels is fundamental 
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to the acquisition of specific firing rates and contributes to the rich diversity of CIN 
subtypes. The high metabolic demand of the FS firing rate requires PV-CINs to maintain 
high densities of mitochondria compared to other neuron populations (Kann et al., 2014). 
SST-expressing interneurons comprise the second most abundant CIN subtype and 
can be identified electrophysiologically as burst-spiking nonpyramidal cells or by low 
threshold-spiking firing patterns (Butt et al., 2005). In contrast to PV basket or chandelier 
cells, SST Martinotti cells primarily innervate the dendrites of cortical PNs and thus are 
important for the fine-tuning of neural activity through cortical circuits (Fino et al., 2013). 
SST-CIN signaling is important for the early activity-dependent maturation of cortical 
circuits. During neonatal development, GABA signaling exerts “excitatory” properties 
until the expression of the chloride ion channel KCC2, whereupon GABA exerts inhibitory 
effects (Ben-Ari, 2002). Premature inhibition by GABA during the first postnatal week 
disrupts cortical PN dendritic arborization, a process likely mediated by SST-CINs 
(Cancedda et al., 2007). Thus, the normal development and maturation of SST-CINs is 
essential to the sculpting of cortical circuits. 
In comparison to the MGE, the caudal ganglionic eminence (CGE) generates 30% 
of CINs that have a distinct genetic profiles and laminar allocations (Miyoshi et al., 2015). 
Gsh1, ER81, and Prox1 are all crucial to the proper migration and maturation of CGE-
derived CINs (Hernandez-Miranda et al., 2010; Miyoshi et al., 2015). Fate-mapping 
revealed that CINs originating from the CGE integrate primarily into the superficial layers 
of the cortex (Miyoshi and Fishell, 2011; Miyoshi et al., 2010). These CINs can be 
distinguished from MGE-derived CINs by expression of 5HTr3A, in conjunction with other 
markers such as the calcium binding protein calretinin (CR), Reelin, and Vasoactive 
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Intestinal Polypeptide (VIP) (Miyoshi et al., 2015). Both MGE- and CGE-derived CINs 
require expression of Dlx1/2 and Dlx5/6 genes, which constitute the master regulators of 
GABAergic identity. Mice lacking these genes exhibit subtype-specific CIN loss due to 
alterations in both specification and migration (Cobos et al., 2005; Le et al., 2007; Long et 
al., 2009; Wang et al., 2010). 
CINs utilize distinct migratory trajectories compared to PNs. Nascent CINs 
undergo an initial wave of tangential migration along the marginal zone and ventricular 
surfaces of the developing embryonic pallium (Metin et al., 2006). Tangential migration is 
guided by a series of chemotaxic cues such as Slit1 and Enfa5, which are highly expressed 
in the VZ of the MGE and function as chemorepellents to direct nascent CINs into the 
subpallial mantle zones (Marin, 2013; Zimmer et al., 2008). Chemorepulsion by 
semaphorin/neuropilin signaling is equally essential to CIN migration and inhibit early 
termination of migratory processes in the striatum (Marin and Rubenstein, 2001). 
GABAergic progenitors that are unresponsive to these signaling mechanisms tend to 
acquire a striatal identity and terminate migration in this region (Marin and Rubenstein, 
2001).  
Tangential migration to the cortex is also mediated by netrin-1, which is required 
for CIN migration through the cortical plate (Stanco et al., 2009). Classic trophic factors 
such as BDNF and NT4 function to increase the motility of immature CINs and are thus 
essential during early migratory stages (Polleux et al., 2002). Sustained tangential 
migration requires PI3K pathway activity and is not dependent on canonical ERK/MAPK 
signaling (Polleux et al., 2002). Neuregulin-1 (NRG1) and its associated receptor, ErbB4, 
act as an early chemorepellent (Li et al., 2012a). ErbB4 is enriched in the GABAergic 
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progenitors and remains highly expressed in mature PV-CINs. GABAergic precursors shift 
to radial migration in late embryogenesis to invade the cortical lamina. The shift from 
tangential to radial migration is mediated by the activation of ERBB4 by neuregulin 3 
(NRG3), which drives cortical plate invasion of tangentially-migrating CINs (Bartolini et 
al., 2017). Cell adhesion mechanisms, such as formation of gap junctions between CINs 
and the radial glial fibers, are necessary for the shift to radial migration (Elias et al., 2007; 
Marin et al., 2010). GABAergic precursor leading processes sequester high concentrations 
of integrins and the connexins Cx43 and Cx26 at contact points with radial glia (Elias et 
al., 2007; Huang, 2009; Kawauchi, 2015; Marin et al., 2010). CINs in the cortical lamina 
then undergo activity-dependent pruning, where GABAergic cell number is refined by a 
wave of Bax-dependent cell death during the first postnatal week (Southwell et al., 2012). 
This programmed cell death event ensures the proper balance between excitation and 
inhibition necessary for normal function of the cerebral cortex. 
Maturing CINs that survive cortical pruning are important in maturation processes 
such as critical period plasticity (Hensch, 2005a; Hensch, 2005b; Morishita et al., 2015). 
The maturation of GABAergic circuits is closely coupled with experience-dependent 
plasticity in a complex molecular process mediated by BDNF (Castrén et al., 1992; Huang 
et al., 1999). Indeed, formation of GABAergic perisomatic synapses around cortical PNs 
is regulated trophic factors such as BDNF and NRG1 (Chattopadhyaya et al., 2004; Fazzari 
et al., 2010; Huang et al., 1999). Importantly, fast-spiking PV-CIN populations have 
enriched ERBB4 expression in comparison to other CINs and have high synaptogenic 
affinity for PN soma and axon initial segments (DeFelipe et al., 2013; Fino et al., 2013; 
Rudy et al., 2011).  
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PV-CINs effectively gate the end of critical period plasticity in the CNS. During 
the second postnatal week, PV-CINs become encapsulated within an ECM structure of 
sequestered chondroitin sulfate proteoglycans called the perineuronal net (PNN) (Hensch, 
2005a). Abnormal onset, extent, and function of the PNN during development is thought 
drastically perturb critical period plasticity and alter cortical output (Steullet et al., 2017). 
Disruption of ECM remodeling and PNN formation is commonly observed in many 
neurodevelopmental disorders and is therefore thought to contribute broadly to human 
neurocognitive phenotypes (Krencik et al., 2015; Steullet et al., 2017). Furthermore, 
astrocyte-directed RASopathy mutations drive enhanced PNN sequestering around PV-
CINs (Krencik et al., 2015). Thus, it has been proposed that dysregulation of this essential 
process is a central mediator of RASopathy neuropathogenesis. The GABAergic 
contributions to this bidirectional process have not been explored in the context of the 
RASopathies.  
How aberrant ERK/MAPK signaling affects brain development and gives rise to 
neurological symptoms of the RASopathies is poorly understood. Here, I aimed to 1) 
address how a unique RASopathy mutation affects brain development, 2) understand the 
fundamental requirements of ERK/MAPK in developing GABAergic circuits, and 3) 
determine how pathological ERK/MAPK signaling during GABAergic development 
disrupts function of the mouse cerebral cortex. 
To address these aims, I provide the first neurological characterization of a Noonan 
Syndrome-linked Raf1L613V mouse model. I show that Raf1L613V mutant mice have modest 
but significant increases in astrocyte and oligodendrocyte progenitor cell number. Unlike 
past RASopathy mouse models, Raf1L613V mice exhibited enhanced performance in spatial 
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reference, working, and fear learning, and thus represent the first germline RASopathy 
mouse model with learning and memory improvements. 
Dysfunctional GABAergic circuitry has been broadly implicated as a potential 
driver of neurological impairments in many neurodevelopmental disorders. To determine 
how GABAergic circuits contribute to the neurological deficits in the RASopathies, we 
employed Cre-dependent conditional mutagenesis to either 1) hyperactivate, or 2) delete 
ERK/MAPK within developing GABAergic interneurons. I show that increased 
ERK/MAPK signaling in developing GABAergic circuits disrupts the establishment of 
PV-expressing CIN density, with minimal effects on other CIN subtypes. Reduced PV-
CIN density was due to an early embryonic cell death event mediated by cleaved-caspase 
3 near the ganglionic eminences during neurogenesis. Interestingly, increased MEK1 
activity was not sufficient to alter basic physiological development of PV-CINs, which 
maintained fast-spiking signatures. Hyperactive ERK/MAPK in PV-CINs led to a shocking 
increase in PNN accumulation, a critical extracellular structure associated with cortical 
maturation. Hyperactive mutant mice had significant impairments in prefrontal cortex-
mediated behavioral response inhibition, a set of behaviors linked to ADHD-like 
phenotypes.  
Conversely, deletion of ERK/MAPK from developing CINs had minimal effects of 
PV-CINs, but substantial alterations in SST-CIN specification. ERK1/2 deletion from 
GABAergic circuits resulted in global changes in activity-dependent gene expression, 
suggesting that normal ERK/MAPK signaling in developing CINs is required for the 
normal maturation of the cerebral cortex. Taken together, this work argues for increased 
study of patient specific mutations and implicates defective GABAergic circuits as a 
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primary contributor to the RASopathies. Thus, modulation of inhibitory signaling may be 
particularly impactful for treating the neurological symptoms of some RASopathy 
individuals. 
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CHAPTER 2 
 
The Noonan Syndrome-linked Raf1L613V mutation drives increased glial number in the 
mouse cortex and enhanced learning. 
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Abstract 
 
RASopathies are a family of related syndromes caused by mutations in regulators 
of the RAS/Extracellular Regulated Kinase 1/2 (ERK1/2) signaling cascade that often 
result in neurological deficits. RASopathy mutations in upstream regulatory components, 
such as NF1, PTPN11/SHP2, and RAS have been well-characterized, but mutation-specific 
differences in the pathogenesis of nervous system abnormalities remain poorly understood, 
especially those involving mutations downstream of RAS. Here, we assessed cellular and 
behavioral phenotypes in mice expressing a Raf1L613V gain-of-function mutation associated 
with the RASopathy, Noonan Syndrome. We report that Raf1L613V/wt mutants do not exhibit 
a significantly altered number of excitatory or inhibitory neurons in the cortex. However, 
we observed a significant increase in the number of specific glial subtypes in the forebrain. 
The density of GFAP+ astrocytes was significantly increased in the adult Raf1L613V/wt cortex 
and hippocampus relative to controls. OLIG2+ oligodendrocyte progenitor cells were also 
increased in number in mutant cortices, but we detected no significant change in 
myelination. Behavioral analyses revealed no significant changes in voluntary locomotor 
activity, anxiety-like behavior, or sociability. Surprisingly, Raf1L613V/wt mice mutants 
performed better than controls in select aspects of the water radial-arm maze, Morris water 
maze, and cued fear conditioning tasks. Overall, these data show that increased astrocyte 
and oligodendrocyte progenitor cell (OPC) density in the cortex coincides with enhanced 
cognition in Raf1L613V/wt mutants and further highlight the distinct effects of RASopathy 
mutations on nervous system development and function. 
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Introduction 
The canonical RAS/RAF/MEK/ERK (aka ERK1/2 or MAPK3/MAPK1) 
intracellular signaling cascade is a crucial regulator of specific aspects of neural 
development and synaptic function (Cui et al., 2008; Fremin et al., 2015; Ishii et al., 2013; 
Kushner et al., 2005; Lee et al., 2014; Li et al., 2012b; Newbern et al., 2008; Xing et al., 
2016). Mutations that lead to altered ERK1/2 signaling give rise to a group of human 
developmental syndromes, commonly referred to as “RASopathies” (Rauen et al., 2013). 
Cardiac, craniofacial, and neurological abnormalities, such as developmental delay, 
hypotonia, intellectual/cognitive disability, and epilepsy, are often observed in individuals 
with RASopathies, in addition to an increased risk of autism (Adviento et al., 2014; Alfieri 
et al., 2010; Jindal et al., 2015; Mitra et al., 2017). Autism-like phenotypes and changes in 
ERK1/2 activity have also been detected in mouse models of Angelman (MIM: 105830), 
Rett (MIM: 312750), and Fragile X (MIM: 300624) syndromes (Filonova et al., 2014; 
Greer et al., 2010; Michalon et al., 2012; Xu et al., 2014; Yashiro et al., 2009). The majority 
of RASopathy mutations lead to hyperactive signaling and are concentrated in classic 
components of Receptor Tyrosine Kinase (RTK)-linked intracellular signaling cascades. 
These include ‘upstream’ regulators of multiple cascades (PTPN11 (MIM: 176876), NF1 
(MIM: 162200), SHOC2 (MIM: 602775), SOS1/2 (MIM: 182530, 601247), SYNGAP1 
(MIM: 603384), SPRED1 (MIM: 609291), SPRY1 (MIM: 602465), K/N/HRAS (MIM: 
190070, 164790, 190020)), and relatively ‘downstream’ kinases in the core ERK1/2 
pathway (BRAF/RAF1 (MIM: 164757, 164760), MEK1/2 (MIM: 176872, 601263), 
ERK1/2 (MIM: 601795, 176948)) (Alfieri et al., 2010; Cesarini et al., 2009; Pierpont et al., 
2009; Tartaglia et al., 2011; Tidyman and Rauen, 2016). Individuals with Noonan 
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Syndrome (MIM: 163950) comprise ~50% of all RASopathy cases and mutations have 
been observed in multiple genes, including PTPN11/SHP2, SOS1, SHOC2, KRAS, NRAS, 
LZTR1 (MIM: 600574), RAF1/CRAF, and MAP2K1/MEK1 (Chen et al., 2014; Jindal et al., 
2015; Tidyman and Rauen, 2016). While the genetic cause for most RASopathies is known, 
therapeutic options remain limited, due in part to an incomplete understanding of disease 
neuropathogenesis. 
RASopathies are often associated with diminished intellectual functioning and 
neuropsychiatric impairment, but these phenotypes are highly variable (Jindal et al., 2015; 
Pierpont et al., 2009; Pierpont et al., 2010b; Pierpont et al., 2013; Tartaglia et al., 2001). 
Individuals with mutations in kinases downstream of RAS (e.g. RAF, MEK) generally 
exhibit more pronounced neurocognitive deficits in comparison to mutations in upstream 
regulators of RAS activity (Pierpont et al., 2009; Tartaglia et al., 2002; Tartaglia et al., 
2001; Zenker et al., 2004). This is perhaps surprising since upstream mutations could lead 
to abnormalities in multiple parallel signaling cascades, including AKT/mTOR, 
RHO/ROCK, and PKA, in addition to ERK1/2 (Anastasaki and Gutmann, 2014; Brown et 
al., 2012; Castellano and Downward, 2011; Kaul et al., 2015). Pharmacological modulation 
of ROCK, NOTCH, PKC, or cAMP/PKA signaling appear to mitigate select cellular 
defects in animal models, indicating ERK1/2-independent contributions to RASopathy 
pathogenesis (Anastasaki and Gutmann, 2014; Brown et al., 2012; Langdon et al., 2012; 
López-Juárez et al., 2017; Titus et al., 2017). Nonetheless, animal model studies have 
demonstrated that pharmacological inhibitors of hyperactive ERK1/2 signaling reverse 
many RASopathy-linked phenotypes. It is unclear whether ERK/MAPK inhibitors should 
be utilized in response to mutations that are linked to variable neurocognitive outcomes. 
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For example, RAF1L613V individuals mostly present with intellectual impairment (Denayer 
et al., 2010; Pandit et al., 2007; Razzaque et al., 2007), but RAF1L613V individuals with 
normal IQ (Kobayashi et al., 2010) and even increased IQ (E. Ciara et al., 2009, ASHG, 
abstract) have also been observed. Further study of mutated components downstream of 
RAS (i.e., RAF or MEK) might assist in defining the specific contributions of altered 
ERK1/2 signaling to the cellular and behavioral defects in RASopathies.  
Studies of the developmental effects of ERK1/2 and RASopathy mutations in 
model organisms have identified alterations in embryonic stages of neurogenesis and 
gliogenesis (Gauthier et al., 2007; Li et al., 2012b; Li et al., 2012c; Paquin et al., 2009; 
Pucilowska et al., 2012; Pucilowska et al., 2008; Samuels et al., 2008). Abnormalities in 
cortical neuron morphology and synaptic plasticity during postnatal periods have also been 
implicated in learning deficits (Brown et al., 2012; Cui et al., 2008; Kushner et al., 2005; 
Lee et al., 2014; Lush et al., 2008; Paquin et al., 2009; Pucilowska et al., 2012; Sanchez-
Ortiz et al., 2014; Thomas and Huganir, 2004; Xing et al., 2016). ERK1/2 activation in 
neurons promotes specific forms of synaptic plasticity and learning (Thomas and Huganir, 
2004). When expressed selectively in mature glutamatergic neurons, the Costello 
Syndrome-associated HrasG12V+/- mutation enhanced phosphorylated-ERK1/2 (p-ERK1/2) 
levels, increased LTP, and resulted in improved performance in spatial learning and 
contextual fear conditioning (Kushner et al., 2005). However, germline HrasG12V mice do 
not exhibit differences in LTP and display diminished spatial learning capabilities 
(Schreiber et al., 2017). These findings hint at distinct contributions of neuronal vs non-
neuronal changes to plasticity and learning in the RASopathies that likely vary at different 
stages of development. 
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Glial cells are critical for the proper formation, maturation, and plasticity of neural 
circuits (Molofsky et al., 2012). ERK1/2 signaling is an important mediator of gliogenesis, 
glial proliferation, and function (Andreadi et al., 2012; Breunig et al., 2015; Gauthier et al., 
2007; Gutmann et al., 2001; Hegedus et al., 2007; Krencik et al., 2015; Li et al., 2012b; 
Nordlund et al., 1995). For example, a hallmark feature of post-mortem Neurofibromatosis 
Type 1 (NF1) (MIM: 162200) patient forebrains and mouse models of NF1 is an increased 
number of GFAP+ reactive astrocytes (Gutmann et al., 1999; Nordlund et al., 1995; Rizvi 
et al., 1999; Zhu et al., 2005). Additionally, diffusion tensor imaging (DTI) analyses have 
identified white matter differences in individuals with NF1 and the autism-linked 16p11.2 
microduplication (MIM: 614671), which includes ERK1 (Filges et al., 2014; Koini et al., 
2017). Collectively, these data speak to an important, yet poorly understood role for 
astrocyte and oligodendrocyte dysfunction in RASopathy neuropathogenesis. 
Here we studied the establishment of neuronal and glial number and behavior in 
mice heterozygous for a Raf1L613V variant linked to Noonan Syndrome in humans (Pandit 
et al., 2007; Razzaque et al., 2007; Wu et al., 2011). Raf1L613V/wt heterozygous mice exhibit 
embryonic lethality on a pure C57Bl/6J background but survive on a mixed C57Bl/6J x 
129S1 background with notable deficits in cardiac and craniofacial development (Wu et 
al., 2011; Wu et al., 2012). Even though Noonan Syndrome is associated with a range of 
neurological abnormalities, nervous system development has not been evaluated in 
Raf1L613V/wt mouse mutants. Here, we report increases in GFAP+-astrocyte and OLIG2+-
oligodendrocyte-progenitor cell (OPC) density in the mature forebrains of Raf1L613V/wt mice 
without a significant difference in cortical neuron density. Remarkably, Raf1L613V/wt mutant 
mice exhibit moderate enhancements in spatial reference memory, spatial working 
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memory, and fear learning tasks. Taken together, our data show that the Noonan 
Syndrome-linked Raf1L613V/wt mutation increases the number of two glial subtypes and 
enhances distinct aspects of cognition.  
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Materials and Methods 
 
Mice and Genotyping  
Animal experiments were performed in accordance with NIH guidelines for the use 
and care of laboratory animals and established protocols approved by the Institutional 
Animal Care and Use Committee at the University of North Carolina–Chapel Hill and 
Arizona State University (Protocol#17-1521R). All mice examined in this study were 
euthanized via CO2 inhalation or fully anesthetized with avertin prior to transcardial 
perfusion as described in the AVMA Guidelines on Euthanasia. The generation of mice 
harboring the Raf1L613V knock-in mutation has been previously described (Wu et al., 2011). 
Due to embryonic lethality when backcrossed onto the C57Bl/6J genetic background (Wu 
et al., 2011), these experiments utilized mice maintained on a C57Bl/6J x 129S1 mixed 
background (JAX Stock # 101043). Mice were housed under standard laboratory 
conditions with ad libitum access to food and water on a 12-hour light/dark cycle in vivaria 
at UNC and ASU. For PCR genotyping, we utilized a single primer set to amplify a 560bp 
fragment of the Raf1L613V allele and a 500bp wild-type allele from genomic DNA samples 
(Forward (5’-3’): AGTCAGCCTAGAGGCCACTGTTA, Reverse (5’-3’): 
CTCCAATTTTCACCGTGAGGC). 
 
Tissue Preparation and Immunohistochemistry 
 Mice were fully anesthetized and transcardially perfused with cold 4% PFA in 1X 
PBS. Brains were then dissected, post-fixed overnight, mounted in a 3% agarose block, 
and sectioned on a EMS 7000smz-2 vibrating microtome. For most experiments, brains 
from a littermate control/mutant pair were sectioned, immunolabeled, and imaged in 
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parallel. Tissue sections were collected in PBS, permeabilized in 0.2% Triton X-100 in 
PBS, and incubated in a blocking solution consisting of 5% Normal Donkey Serum and 
0.2% Triton X-100 in PBS. Primary antibodies were then diluted in blocking solution and 
incubated with tissue sections at 4C for 24-48 hours while rocking gently. The primary 
antibodies used were: rabbit anti-p-ERK (1:1000, Cell Signaling 4370), mouse anti-
RBFOX3/NeuN (1:1000, Millipore MAB377), goat anti-Parvalbumin (1:1000, Swant 
PVG-214), rabbit anti-GFAP (1:1000, Abcam ab7260), rabbit anti-ACSBG1 (1:500, 
Abcam ab65154), mouse anti-S100β (1:1000, Sigma SAB1402349), rabbit anti-IBA1 
(1:1000, Wako 019-19741), rabbit anti-OLIG2 (1:1000, Millipore AB9610), rat anti-MBP 
(1:1000, Abcam ab7349), rabbit anti-PDGFRα (1:1000, Santa Cruz sc-338), rabbit anti-
NG2 (1:500, Millipore AB5320), mouse anti-CC1 (1:500, Calbiochem), rabbit anti-Arc 
(1:1000, Synaptic Systems 156 003), rabbit anti-TNFα (1:2000, Bio-Rad), and biotinylated 
WFA (20µg/mL, Vector). Tissue sections were then washed in 0.2% Triton in PBS and 
incubated in fluorescently-conjugated secondary antibodies including donkey anti-rabbit, 
donkey anti-rat, donkey anti-mouse, and donkey anti-goat IgGs conjugated to Alexa Fluor 
488, 555, 568, or 647 dyes (Invitrogen). For WFA labeling, a streptavidin-conjugated 488 
secondary antibody was used. Brain slices were then slide mounted, coverslipped in 
Fluoromount (EMS #17984), and stored at 4C prior to imaging. 
 
Electron Microscopy 
  P60 mice were anesthetized, transcardially perfused with 2% paraformaldehyde, 
2% glutaraldehyde in 0.1M PB and post-fixed overnight. A 3mm x 1mm x 1mm block was 
sub-dissected from the genu of the corpus callosum for myelination assessment. Tissue 
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blocks were then washed 3x with PB before a 2 hr secondary fixation with 1% osmium 
tetroxide in 0.1M PB. Tissue blocks were washed 3x with deionized water and stored at 
4C overnight. The next day, the tissue blocks were returned to room temperature and 
dehydrated in a series of three acetone washes, increasing in 20% increments per wash. 
The tissue blocks were then infiltrated with Spurr’s epoxy resin three times at increasing 
increments of 25% pure resin, and sectioned in a Leica Ultracut-R microtome at a section 
thickness of 70nm, stained with 2% uranyl acetate in 50% ethanol for six minutes, and then 
moved to Sato’s lead citrate for four minutes. Genu sections were visualized in a Philips 
CM12 TEM at 80kV, and images were captured with a Gatan model 791 slow-scan CCD 
camera in the Biological Electron Microscopy Facility at Arizona State University. 
 
Image Analysis and Quantification  
 For immunofluorescent analyses, images were collected on a Leica SP5 or Zeiss 
LSM800 confocal microscope from at least three different tissue sections per mouse and 
at least three mice per group. Confocal optical sections for quantification are typically 
collected from a z-axis region between 5-15 µm from the surface of the tissue section. 
Following optimization of image brightness and contrast, regions of interest (ROI) were 
outlined in images of anatomically matched sections using standard neuroanatomical 
boundaries. The number of labeled cells was determined by a blinded observer in at least 
three individual ROIs per mouse spanning all layers of a cortical or hippocampal column 
contained within a specified sub-region. The number of cells was divided by the area of 
the ROI and averaged across all ROIs from an individual brain to estimate the density of 
labeled cells in a single mouse brain. To calculate relative density, the average density was 
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normalized to the age-matched littermate control processed in parallel. Results were 
analyzed for statistical significance using the Students t-test. 
 For myelination analysis, electron micrographs within a cross-section of the genu 
of the corpus callosum were assessed for axon area, g-ratio, and the proportion of 
myelinated to unmyelinated axons. Axon g-ratios were calculated as the cross-sectional 
diameter of the axon excluding the myelin sheath, divided by the total diameter of the 
axonal fiber including the myelin sheath. The numbers of myelinated and unmyelinated 
axons were counted within a given image, and the proportion of myelinated to 
unmyelinated axons was calculated for mutants and controls. Results are reported as the 
average ± SEM and compared using the Student’s t-test.  
 
Western Blotting 
Cortices were dissected and lysed in RIPA buffer (0.05M Tris-HCl, pH 7.4, 0.5M 
NaCl, 0.25% deoxycholic acid, 1% NP-40, and 1mM EDTA, Millipore), supplemented 
with 0.1% SDS, protease inhibitor cocktail (Sigma) and phosphatase inhibitor cocktails II 
and III (Sigma). Lysates were cleared by centrifugation, and protein concentration was 
determined. Equal amounts of protein were denatured in reducing sample buffer, separated 
by SDS-PAGE gels, and transferred to PVDF membranes (Bio-Rad). Blots were blocked 
with 5% BSA in TBS containing 0.5% Tween 20 (TBS-T) for 1 h at room temperature, 
then incubated overnight at 4°C with primary antibodies. The primary antibodies used 
were: rabbit anti-p-ERK1/2 (Thr202/Tyr204) (Cell Signaling Technology, Inc), rabbit anti-
ERK1/2 (CST), rabbit anti-MEK1/2 (Ser217/221) (CST), rabbit MEK1/2 (CST), rabbit 
anti-DUSP6 (Abcam ab76310), rabbit anti-SPRY2 (Abcam ab85670), and anti-GAPDH 
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(Cell Signaling Technology, Inc.). After washing with TBS-T, membranes were incubated 
with HRP-conjugated secondary antibodies in 5% milk in TBS-T for 2 h at room 
temperature. Blots were washed with TBS-T, and detection was performed with 
SuperSignal West Pico chemiluminescent substrate (Thermo Scientific). 
 
Behavior 
 All behavior experiments were performed at ASU with mice kept on a standard 
light cycle in a room dedicated to behavioral assessment. The experimenter was blinded to 
the mouse genotype during animal testing and data analysis. No statistically significant 
difference was observed between male and female mice; therefore, results were pooled for 
presentation. 
 
Open Field, Elevated Plus, and Social Approach Assay 
 The open field, elevated plus, and social approach tests were performed on 23 
control (6 male, 17 female) and 31 mutant (16 male, 15 female) mice with at least three 
days between different behavioral assays. The open field was used to test voluntary 
locomotive and anxiety-like behaviors. The apparatus consisted of a 40x40cm arena 
enclosed by 30cm high opaque walls. A single 60W bulb was positioned to brightly 
illuminate the center of the chamber with dim lighting near the walls. Mice were placed 
into the apparatus and video recorded for a total of 10 minutes. Video data were analyzed 
for distance traveled and time spent in the center quadrant.   
The elevated plus maze was constructed from black Plexiglas, elevated 81cm off 
the ground, and oriented in a plus formation with two 12x55cm open arms and two 
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12x55cm closed arms extending from an open 12x12cm center square. Closed arm walls 
were 40cm high extending from the base of the arm at the center square. The apparatus was 
lit with a 60W bulb with light concentrated on the center square. At the beginning of each 
trial, mice were placed in the center square, facing the south open arm, and recorded while 
freely exploring for 5 minutes.   
The social approach apparatus contained three 20x30x30cm chambers (total 
dimensions 60x30x30cm) connected by open doorways. Prior to experimental social trials, 
mice were habituated to the apparatus and allowed to freely explore all three chambers for 
5 minutes. At the end of the 5 minutes, mice were removed and placed in their home cage. 
A sex- and age-matched stimulus mouse was then placed into a small empty cage in 
chamber 1 of the apparatus. The experimental mouse was reintroduced to the center 
chamber (chamber 2) of the apparatus and recorded while freely exploring for 10 minutes. 
The time spent in the chamber with the stimulus mouse (chamber 1) or the empty chamber 
(chamber 3) was then measured.  
Video recordings of the open field, elevated plus, and social approach tests were 
collected and quantified in ImageJ using publicly available plugins (Komada et al., 2008) 
followed by statistical analysis using the Student’s t-test. 
 
Water Radial-Arm Maze 
 The water radial-arm maze (WRAM) was used to evaluate spatial working and 
reference memory (Bimonte-Nelson, 2015; Hyde et al., 2000). The maze consisted of an 
eight-arm apparatus (each arm 38.1 × 12.7cm) filled with opaque, room temperature water. 
Water temperature was consistently between 18–20°C for testing. Extra maze spatial cues 
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were present to aid mice in spatial navigation. In the win-shift version of WRAM, mice (n 
= 19 control, 15 mutant, all female) were required to find hidden platforms (10 cm 
diameter) submerged at the end of four out of the eight arms. Platform location patterns 
were assigned to each subject and stayed constant for a particular mouse across all testing 
days, but varied among subjects. Mice received four trials per day for 18 days.  
Trials began with the subject being released from the start arm and given 2 min to 
locate a platform. Arm entries were manually recorded when the mouse’s body crossed the 
threshold of the mouth of the arm. Once a platform was found, the animal remained on it 
for 15 seconds and was returned to its heated testing cage for a 30s inter-trial interval (ITI). 
During the ITI, the just-found platform was removed from the maze, and the water was 
cleaned to remove any debris and obscure olfactory cues. The mouse was then placed back 
into the start arm and given another 2 min trial to locate a platform. Because a platform is 
removed from the maze for the remainder of the day after discovery, mice must maintain 
several items of information in order to effectively solve the task, thus increasingly taxing 
the working memory system as trials progress within a day. The number of arm entries into 
non-platformed arms is quantified as errors as the dependent measure of spatial memory in 
the task (Fig. 7B). Errors are further divided into particular error types. Working Memory 
Correct (WMC) errors are defined as all entries into arms that previously contained a 
platform within a day. Reference Memory (RM) errors are first entries into arms that never 
contained a platform, and Working Memory Incorrect (WMI) errors are all subsequent 
entries into arms that never contained a platform within a day. WMC, REF, and WMI errors 
are summed for a total error score. All errors were quantified using orthogonal measures 
of working and reference memory, as previously reported (Bimonte-Nelson et al., 2015; 
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Hyde et al., 2000). Data were analyzed using Statview statistical software with a repeated 
measures ANOVA followed by Fisher’s LSD post-hoc test, when indicated. 
 
Morris Water Maze 
 Five days after the last day of WRAM testing, spatial reference memory was 
evaluated in the same cohort of mice using the Morris water maze (MM) (n = 19 control, 
15 mutant, all female). The apparatus was a round tub (188cm diameter) filled with opaque, 
room temperature water (18–20°C), and contained a submerged platform (10cm diameter) 
in the northeast quadrant. The platform location remained fixed across all days and trials, 
with spatial cues available to aid the animals in spatial navigation, testing spatial reference 
memory (Morris et al., 1982). Mice received four trials per day for five days. At the 
beginning of each trial, mice were placed into the tub from one of four starting points 
(north, south, east or west). The order of the drop-off location varied semi-randomly across 
days, but was the same within a day for all subjects. MM performance was recorded using 
a video camera and tracking system (Ethovision; Noldus Instruments; Wageningen, The 
Netherlands). Mice had 60s to locate the platform, where they remained for 15s before 
being placed back into a heated cage for an ITI of 5–8min. A probe trial was given on the 
fifth day of testing, during which the platform was removed and mice were given 60s to 
swim freely in the maze. Following the first probe trial day, a reversal task was carried out 
for two consecutive days. Specifically, the platform location was moved from the northeast 
quadrant to the opposite, southwest quadrant, where it remained across all reversal task 
trials. Mice then received four trials per day for two days. A second probe trial followed 
the last baseline trial on day two of the reversal task. For acute behavioral stimulation of 
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Arc expression, a separate subset of mice (n=4 mutants, 4 controls) were placed in the 
Morris maze for 5-trials with 15 minutes between trials in one day and sacrificed 60 
minutes after the end of the 5th trial for immunohistochemical analyses. Data were analyzed 
using Statview statistical software with a repeated measures ANOVA followed by Fisher’s 
LSD post-hoc test, when indicated. 
 
Visible platform task 
 After completion of cognitive behavioral testing on the WRAM and MM, mice 
were evaluated using the visible platform control task to assess locomotor and visual 
performance. The apparatus was a rectangular tub (100 × 60cm) filled with clear room 
temperature water (18–20°C). A black platform (10cm wide) was positioned 4cm above 
the surface of the water. A ring of opaque curtains surrounded the tub, blocking all obvious 
spatial cues. Animals received three trials in one day. The drop off location remained the 
same across trials; however, the platform location varied semi-randomly across three 
locations. Each mouse had 90s to locate the platform, where it remained for 15s before 
being placed back into a heated cage for an ITI of 5–8min. 
 
Fear Conditioning   
Control (n=11, 3 male, 8 female) and Raf1L613V/wt (n=9, 2 male, 7 female) adult mice 
were placed in test cages (12"Wx10"Dx12"H: Coulbourn Instruments, E10-18TC) housed 
within a sound-attenuating cabinet (Coulbourn, E10-23, white, 31.5” W x 21” D x 20” H) 
with an attached video camera that recorded behavior for offline scoring of all fear 
conditioning procedures.  Seventy-five (75) dB tones of 30 second duration were produced 
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by a frequency generator (Coulbourn, E12-01 or H12-07) and delivered through a speaker 
(Coulbourn, H12-01R) on the side panel. Video recordings were analyzed for the number 
of seconds mice spent freezing, a species-typical fear response that is defined by the 
absence of all movement except those associated with respiration, during the 30 sec prior 
to, and during, tone presentation. An animal shock generator (Coulbourn, H13-15) 
produced an electrical current (0.25mA, 1 sec) evenly delivered to metal bars in the cage 
flooring (Coulbourn, E10-11R/M-TC-SF). All stimuli were controlled using Graphic State 
software (v 3.0) installed on a computer connected to a stimuli output controller system 
(Coulbourn, H02-08).  
Training and testing were performed in two distinct contexts (A and B) with varying 
rooms and investigator appearance. Context A had silver, metal walls on the sides, clear 
Plexiglas front and back with yellow paper located outside, metal bar shock floor, white 
drop pan, and cleaned with grapefruit scented cleaner (Method®, Target Inc.). For testing 
in context B, the chambers had walls covered with vertical black and white striped inserts, 
a cross-hatched non-shock metal grid floor, black drop pans, and cleaned with 70% 
isopropyl alcohol. Mice were acclimated to the testing room for 20 min and to each of the 
two contexts for 10 min on the three days prior to training.  In the training session for 
Context A, mice were presented with three trials of an auditory tone that co-terminated 
with presentation of a foot shock. Twenty-four (24) and 48 hours later, mice were tested 
for memory by undergoing three tone-only trials in context B at each time point. Mice then 
underwent an extinction paradigm where tones were repeatedly presented (maximum of 
16) until total freezing was less than 10 seconds during tone presentation. One week later, 
spontaneous recovery was assessed by presenting them with three presentations of the tone 
  38 
to determine whether freezing to tone was due to associative or non-associative processes. 
After this testing was complete, we performed a shock intensity test, where shocks were 
gradually increased from a minimum of 0.08mA until the mouse elicited a clear startle 
response. Statistical analysis was conducted using Students t-test or repeated measures 
ANOVA, followed by post-hoc tests in SPSS. 
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Results 
 
Cortical neuron number is normal in Raf1L613V/wt mutant mice 
We generated Raf1L613V/wt heterozygous mice on mixed C57Bl/6J x 129S1 background. 
Past work has shown that embryonic and cardiac fibroblasts from Raf1L613V/wt mice do not 
exhibit a difference in basal ERK1/2 activity but show a significant stimulus-dependent 
increase in levels of p-ERK1/2 following treatment with different RTK-linked trophic cues, 
including EGF, FGF2, PDGF, and IGF-1 (Wu et al., 2011; Wu et al., 2012). Western blot 
assessment of whole cortical lysates revealed no relative difference in basal p-MEK, MEK, 
p-ERK1/2 or total ERK1/2 levels between Raf1L613V/wt and control adult mice (Fig. 1A, n 
= 5). Moreover, we detected no change in the negative feedback regulators SPRY2 and 
DUSP6 in cortical lysates from Raf1L613V/wt and control mice (Supplemental Fig. 1A; n = 
5). Raf1L613V/wt and control mice also showed comparable patterns of hippocampal p-
ERK1/2 labeling (Supplemental Fig. 1B, C). A subpopulation of layer 2 cortical excitatory 
neurons receives high levels of glutamatergic input, a known activator of ERK1/2 
signaling, and expresses increased levels of FOS, an immediate early gene product 
regulated, in part, by ERK1/2 activity (Thomas and Huganir, 2004; Yassin et al., 2010). In 
agreement with previous work, we noted many p-ERK1/2-labeled neurons in layer 2/3 of 
sensory cortex in adult control mice (Cancedda et al., 2003; Pham et al., 2004; Suzuki et 
al., 2004). However, mutant mice exhibited a significantly larger number of p-ERK1/2 
labeled neurons in layer 2 of the sensory cortex compared to age-matched controls (Fig. 
1B-E, F; n = 4, p < 0.01). These data are consistent with the anatomically restricted, local 
increases in p-ERK1/2 observed in HRasG12V mice (Schreiber et al., 2017), and suggest that 
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the Raf1L613V mutation drives an increase in stimulus-dependent ERK1/2 signaling in a 
subset of endogenously active cortical neurons. 
ERK1/2 signaling in radial glia regulates the trajectory of cortical neurogenesis and 
cortical excitatory neuron number (Li et al., 2012a; Lush et al., 2008; Pucilowska et al., 
2012). We assessed the number of cells in Raf1L613V/wt and control cortices expressing a 
well-established neuronal marker, RBFOX3/NeuN, which is highly expressed in nearly all 
excitatory neurons in the cortex (Fig. 1G-J). The relative density of RBFOX3/NeuN+ 
neurons in the adult sensory cortex was unchanged, suggesting no significant alterations to 
neurogenesis (Fig. 1K; n = 3). GABAergic neurons comprise ~20% of the total neuron 
population in the cortex and express relatively low levels of RBFOX3/NeuN. We 
immunolabeled for parvalbumin (PV) and somatostatin (SST) to assess the density of the 
two largest cortical GABAergic neuron subpopulations. PV-expressing GABAergic 
neurons were distributed normally in cortical layers with no significant alterations in 
density (Fig. 1L-O, P; n = 3). Taken together, our data indicate that the Raf1L613V/wt mutation 
does not alter the distribution and number of mature excitatory and inhibitory neurons in 
the adult cortex. 
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Figure 1. Raf1L613V/wt mutants do not exhibit significant alterations in cortical neuron 
density. A: Western blots of P21 whole cortical lysates from Raf1L613V/wt cortices exhibit 
no relative change in the total levels of MEK1/2 or ERK1/2 or the phosphorylation of 
MEK1/2 or ERK1/2, as measured by the ratio of phosphorylated to total protein (mean ± 
SEM, n = 5). B-F: Representative confocal images of p-ERK1/2 immunolabeling in adult 
(P60) sensory cortex reveals an increased density of p-ERK1/2-expressing pyramidal cells 
in mutant layer 2 (D-E), compared with littermate controls (B-C); quantification in F (mean 
± SEM, n=3, p < 0.01). G-K: Representative immunolabeled sections of sensory cortex 
showing NEUN-labeled neurons and DAPI-labeled nuclei. Raf1L613V/wt (I-J) cortical 
NEUN+ density does not significantly differ from controls (G-H), as quantified in K (mean 
± SEM, n = 3). L-P: Quantification of Parvalbumin-labeled cortical GABAergic neurons 
in control (L-M) and mutant (N-O) cortices reveals no significant alterations in cell density 
(P) (mean ± SEM, n = 3).  All scale bars = 50µm. 
 
Increased density of GFAP+ astrocytes in Raf1L613V/wt forebrains 
Altered glial number and function are observed in response to RASopathy-linked Nf1, 
Ptpn11/Shp2, and Ras mutations (Gutmann et al., 1999; Gutmann et al., 2001; Krencik et 
al., 2015; Li et al., 2012a; Nordlund et al., 1995; Rizvi et al., 1999). To determine if 
Raf1L613V/wt mutant mice display alterations in glial development, we immunolabeled for 
glial fibrillary acidic protein (GFAP) and Acyl-CoA synthetase bubblegum family member 
1 (ACSBG1), markers of fibrous and protoplasmic astrocytes, respectively, and the glial 
marker S100β (Cahoy et al., 2008). Astrocytes expressing these canonical markers were 
clearly labeled in adult forebrains from control and mutant mice (Fig. 2A-J).  In control 
cortices, GFAP+ astrocytes were enriched in the white matter, upper layer 1-2, and layer 6, 
though labeled profiles were occasionally detectable in the remaining cortical layers. We 
found a significantly increased density of GFAP+ astrocytes in Raf1L613V/wt sensory cortices 
across all layers, relative to littermate controls (Fig. 2A-D, M; n = 3, p < 0.05). In 
comparison to the cortex, GFAP+ astrocytes are present at a relatively higher abundance 
throughout the wild-type hippocampus. Assessment of the GFAP+ astrocyte population in 
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the CA1 region of the mutant hippocampus also revealed an increase in density (Fig. 2E-
H, M; n = 3, p < 0.01) in mutant mice. These data demonstrate that GFAP+ astrocyte 
number is increased in Raf1L613V/wt mutants across multiple brain regions. 
 In states of injury, gliosis is often characterized by an increased density of GFAP+ 
astrocytes, which usually coincides with microglial activation and proliferation (Molofsky 
et al., 2012). We therefore labeled for the activated microglia marker, IBA1, to assess the 
effects of Raf1L613V/wt in the cortex and hippocampus. We found that the density and 
distribution of IBA1+ activated microglia were evenly distributed across the cortical grey 
matter and did not significantly differ in density in mutants relative to littermate controls 
(Fig. 2K, L, N; n = 3). Additionally, no change in the relative density of activated microglia 
was observed in the mutant hippocampus (Fig. 2N; n = 3). In summary, the Raf1L613V/wt 
mutation is sufficient to induce an increased density of GFAP+ astrocytes, but not neurons 
or microglia. 
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Figure 2. Increased density of GFAP+ astrocytes, but not IBA1+ microglia, in 
Raf1L613V/wt cortex and hippocampus. A-D: Representative confocal images of GFAP-
immunolabeled control (A-B) or mutant (C-D) sensory cortices show a significantly 
increased density of GFAP+ astrocytes across cortical layers (M) of mutant mice (mean ± 
SEM, n = 3, *p < 0.05) (scale bar = 100µm). E-F: Coronal cross-sections of control (E, 
inset in G) and Raf1L613V/wt (F, inset in H) hippocampus following immunostaining for 
GFAP. Mutant hippocampal CA1 sub-regions demonstrate a significantly increased 
relative density of GFAP+ astrocytes, relative to littermate controls (M) (mean ± SEM, n = 
3, *p < 0.01) (scale bar = 50µm). I-J: Triple-labeled representative images of control (I) 
and mutant (J) cortex following staining for the grey matter astrocyte marker ACSBG1, 
pan-glial marker S100β, and DAPI (n=3). K-L, N: No significant change in the density of 
microglia in the cortex is observed in mutant mice (L) relative to controls (K); 
quantification in N (mean ± SEM, n = 3) (scale bar = 25um). 
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Raf1L613V drives enhanced oligodendrocyte progenitor cell density in the cortical grey and 
white matter but does not alter myelination  
Past work has linked hyperactive ERK1/2 signaling to alterations in oligodendrocyte 
development, including proliferation, differentiation, and myelination (Ehrman et al., 
2014; Ishii et al., 2013; Newbern et al., 2011). We first assessed the density of OPCs 
expressing PDGFRα in the adult Raf1L613V/wt cortex. Immunolabeling for PDGFRα 
revealed an increased density of OPCs in the adult sensory cortex (Fig. 3A-F, M; n = 3, p 
< 0.01). PDGFRα is downregulated by mature oligodendrocytes; thus, we also examined 
the relative number of cells expressing Olig2, an independent marker of the 
oligodendrocyte lineage. We found increased numbers of Olig2+ cells in the cortical grey 
matter of adult Raf1L613V/wt mutant mice (Fig. 3I, L, M; n = 7, p < 0.01), but not the 
hippocampus (control relative density 1; mutant relative density 1.06; p = 0.66; n = 3). 
Olig2 is expressed by oligodendrocyte progenitor cells (OPCs) and mature 
oligodendrocytes. We distinguished between myelinating and immature oligodendrocyte 
lineage cells by co-labeling with the mature myelinating oligodendrocyte marker, CC1 
(Fancy et al., 2009). As expected, all CC1+ cells present in the cortical grey matter co-
expressed Olig2, but a subpopulation of Olig2+ cells did not express detectable levels of 
CC1, consistent with immature OPCs. Raf1L613V/wt brains also had significantly increased 
densities of Olig2+/CC1- cells in the corpus callosum as compared to littermate controls 
(Fig. 3M-P, R; n = 5, p < 0.05). Even though there was an increase in oligodendrocyte 
progenitors, we detected no significant difference in the density of CC1-labeled mature 
myelinating oligodendrocytes in Raf1L613V/wt mutant cortices (Fig. 3H, K, Q; n = 3).  
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Figure 3. Raf1L613V/wt mutants show increased numbers of OPCs but not myelinating 
oligodendrocytes. A-F: Representative immunolabeled sections of control (A, inset in B-
C) and mutant (D, inset in E-F) sensory cortices reveal a significant relative increase in the 
number of PDGFRα+ cells in mutant mice (white arrow heads, mean ± SEM, n = 3, *p < 
0.01). G-L: Triple-labeled representative images of staining for the pan-oligodendrocyte 
marker, Olig2, mature myelinating marker, CC1, and DAPI. Note the increased density of 
Olig2+ cells in the Raf1L613V/wt sensory cortex (J-L), relative to controls (G-I), as quantified 
in M (mean ± SEM, n = 7, *p < 0.01). By contrast, analysis of CC1+ cells reveals no 
changes in the number of presumably mature, myelinating oligodendrocytes (Q) (mean ± 
SEM, n = 4). M-P: Assessment of Olig2+/CC1- oligodendrocyte lineage cells revealed a 
significant increase in the density in the mutant (N, P) medial corpus callosum relative to 
age-matched controls (M, O) (R; n = 5, p < 0.05). All scale bars = 50µm. 
 
Strong gain-of-function ERK1/2 signaling drives increased myelination in adult 
animals (Ishii et al., 2013). However, the pattern of myelin basic protein (MBP) 
immunolabeling in P60 Raf1L613V/wt cortices was indistinguishable from that of controls 
(Fig. 4A-B). We also observed no difference in cortical MBP immunolabeling between 
mutants and controls at P14, an early stage of cortical myelination (Supplemental Fig. 4A-
D). To quantify myelin thickness, we examined myelinated axons in the genu of the corpus 
callosum by electron microscopy (Fig. 4C-D). We did not detect a significant change in 
average axon area (Fig. 4E; n = 3) or the proportion of myelinated to unmyelinated axons 
(Fig. 4F; n = 3) in adult Raf1L613V/wt mutants.  Moreover, we did not observe a significant 
difference in g-ratio, a normalized measure of myelin thickness that takes into account 
differences in axon diameter (Fig. 4G-H; n = 3).  Collectively, these data indicate an 
increased number of OPCs in the mutant cortex without alterations in mature 
oligodendrocyte number or myelination. 
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Figure 4. Raf1L613V/wt cortices display normal myelination patterns. A-B: MBP-labeled 
regions of adult sensory cortices reveal no qualitative differences in the extent or pattern 
of myelination (n=3) (scale bar = 50µm). C-D: Representative electron micrographs of the 
genu of the corpus callosum in control (C) and mutant (D) mice reveal no difference in 
axon area (E) or the proportion of myelinated to unmyelinated axons (F) (mean ± SEM, n 
= 3) (scale bar = 200nm). G-H: Myelination, as quantified by g-ratio, was not significantly 
different in mutant mice relative to controls (mean ± SEM, n = 3). 
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To better understand the timing of increased OPC density in the adult cortex, we 
examined the cortical OPC pool in juvenile, P14 Raf1L613V/wt mice. Immunolabeling for 
PDGFRα (Fig. 5A-D; n = 3) and Olig2 (Fig. 5E-H; n = 3) revealed no significant 
differences in OPC number in the cortex between P14 mutant mice and littermate controls 
(Fig. 5O). Analysis of NG2-labeled, presumptive oligodendrocyte progenitors at P30 
similarly yielded no significant difference in density (Fig. 5I-L, P; n = 3). However, we 
detected a significant increase in the density of PDGFRα-expressing cells at P30, indicating 
that the OPC pool expansion occurs post-adolescence (Fig. 5 M, N, P; n = 3; p < 0.05). 
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Figure 5. P14 mutant cortices do not display increased densities of PDGFRα+ or 
OLIG2+ cells. A-H: Sensory cortices from P14 control (A-B, E-F, I-J) and Raf1L613V/wt (C-
D, G-H, K-L) mice, immunolabeled for PDGFRα (A-D) or OLIG2 (E-H), show no relative 
difference in OPC cell density (M) (mean ± SEM, n = 3). I-L: Immunolabeling for an 
alternate marker of OPCs, NG2, in P30 control (I-J) and mutant (K-L) brains also results 
in no changes in relative density of labeled cells (M) (mean ± SEM, n = 3). All scale bars 
= 50µm. 
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Raf1L613V/wt animals exhibit enhanced learning and memory 
 Individuals affected by the Raf1L613V mutation present with variable levels of 
intellectual function (Pandit et al., 2007; Razzaque et al., 2007; Denayer et al., 2010; 
Kobayashi et al., 2010; E. Ciara et al., 2009, ASHG, abstract).  The neurobehavioral 
characteristics of Raf1L613V/wt mutant mice are unknown.  RASopathies are often associated 
with behavioral phenotypes seen in autism, such as increased anxiety, decreased 
sociability, and locomotor impairments. We therefore exposed Raf1L613V/wt mutant mice to 
a behavioral battery to assess these behaviors, as well as learning and memory 
performance.  
Adult Raf1L613V/wt mutant displayed no abnormalities in three distinct tasks meant 
to assess anxiety-like behaviors, sociability, and locomotion compared to wild-type mice 
(Fig. 6) (Crawley, 1999; Silverman et al., 2010). In the open field assay, mutant mice did 
not display a significant difference in total distance traveled (Fig. 6A) or time spent in the 
center quadrant, demonstrating no deficit in voluntary locomotor ability or anxiety-like 
behavior (Fig. 6B-C; n=23 controls, 31 mutants). These data were consistent with a 
separate test of locomotor activity and anxiety, the elevated plus maze, where no significant 
change in locomotor activity (Fig. 6D) or time spent in the open arm was detected (Fig. 
6E-F; n=23 controls, 31 mutants). Finally, the social approach assay did not reveal a 
significant difference between mutant and control mice in total entries (Fig. 6G) or the time 
spent exploring the chamber with a novel mouse, indicating no deficit in sociability (Fig. 
6H-I; n=21 controls, 31 mutants). 
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Figure 6. Raf1L613V/wt mice have normal locomotor capabilities, anxiety-like behaviors, 
and sociability. Control (n=23) and Raf1L613V/wt (n=31) mice were tested on a battery of 
behavioral tasks including the open field, elevated plus, and social approach assays. A-C: 
In the open field test, controls and Raf1L613V/wt mice do not exhibit a difference in total 
distance traveled (A), center time (B) and percent center time (C) (mean ± SEM). D-F: 
Elevated plus maze testing of controls and Raf1L613V/wt mice reveals that total distance (D), 
percent open arm entries (E), and open arm stay time (F) are unaltered in mutant mice 
(mean ± SEM). G-I: In the social approach task, controls and Raf1L613V/wt mutants display 
similar performance, as measured by total entries (G), time in social side (H), and entries 
on social side (I) (mean ± SEM). 
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We next asked if Raf1L613V/wt mutant mice displayed altered performance in an eight-
armed water radial-arm maze (WRAM) swim task (Fig. 7A). Control (n=19) and mutant 
(n=15) mice both showed a statistically significant decrease in the number of total errors 
over 18 days of testing (main effect of day [F(17, 544) = 9.87, p < 0.0001]). Surprisingly, 
however, Raf1L613V/wt mutant mice committed significantly fewer total errors in the 
acquisition phase (days 1-6) in comparison to controls (Fig. 7B, main effect of genotype 
[F(1, 32) = 4.87, p < 0.05] *=Fisher’s PLSD p < 0.05). When errors were assessed by type, 
mutant mice made fewer working memory correct (WMC) errors, related to reentering an 
arm that previously had a platform within a day (Supplemental Fig. 7A) (main effect of 
genotype [F(1, 32) = 8.94, p < 0.01] *=Fisher’s PLSD p < 0.01). Moreover, we detected a 
marginal trial by treatment interaction for WMC errors during the acquisition phase, 
indicating that as working memory load increases, mutants tended to make fewer WMC 
errors than controls (Supplemental Fig. 7B) (marginal interaction of trial by genotype [F(2, 
64) = 2.83, p = 0.07], Trial 3 Only: [F(1, 32) = 6.83, p < 0.05], Trial 4 Only: [F(1, 32) = 5.82, p 
< 0.05]). Neither working-memory incorrect (WMI) nor reference memory (REF) errors 
significantly differed between genotypes during the acquisition phase (Supplemental Fig. 
7C; WMI [F(1, 32) = 2.05, p = 0.16], REF [F(1, 32) = 0.41, p = 0.53]). We did not observe 
significant differences between genotypes during the learning and asymptotic phases, once 
mice have successfully acquired the task and solve the maze at peak performance (i.e. 
asymptotic phase) (Fig. 7B; learning: [F(1, 32) = 0.05, p = 0.82]; asymptotic: [F(1, 32) = 2.26, 
p = 0.14]).   
Five days following the completion of WRAM testing, the same cohort of mice was 
tested in the Morris water maze.  Control and Raf1L613V/wt mutant mice exhibited improved 
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performance over time (Fig. 7C, main effect of day [F(4, 128) = 71.58, p < 0.0001]). However, 
mutant mice displayed enhanced performance relative to controls, as measured by swim 
distance to platform across all five days of testing (Fig. 7C [F(1, 32) = 4.59, p < 0.05] inset * 
= Fisher’s PLSD post-hoc p < 0.05). Analysis of individual days revealed that mutant mice 
performed better than controls on days 3, 4, and 5, as predicted by the enhanced 
performance during WRAM acquisition (Fig 7C, * = one-tailed t-test, p < 0.05). Mutant 
mice also demonstrated reduced swim distance to the platform on day 2 of reversal learning 
(Fig. 7D; * = one-tailed t-test, p < 0.05). Controls and mutants both displayed the expected 
target quadrant preference, as indicated by a significantly higher percent of total swim 
distance in the previously platformed quadrant during the probe trial for baseline and 
reversal task testing (Fig. 7E, Supplemental Figure 7D-E). Additionally, mutants and 
controls did not exhibit significant differences in the visible platform test, indicating intact 
visual and motoric capacity (Fig. 7F).  
We employed a tone-cued fear conditioning paradigm to examine amygdala-
dependent learning and memory. Control (n=11) and mutant (n=9) mice were placed in a 
testing cage fitted with a shock floor, and given a 30-second auditory tone, immediately 
followed by a foot-shock, for a total of three tone-foot shock pairings. Control and mutant 
mice displayed similar shock thresholds (Fig. 7H) and baseline time freezing during the 
30-second tone immediately prior to the first foot shock pairing (Fig. 7G). Control and 
mutant mice both exhibited an increase in average time freezing during the subsequent two 
tone presentations of the training phase (Fig. 7G; main effect of trial [F(3, 54) = 36.47, p <  
0.001] LSD post-hoc p < 0.001). No difference in freezing between genotypes was detected 
during training (Fig 7G; [F(1, 18) = 0.59, p = 0.45]).  Twenty-four (24) and 48-hrs after 
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acquiring the tone-foot shock association, mice were placed in a different context and 
tested for freezing behavior in response to the auditory tone without the paired foot shock. 
Raf1L613V/wt mice displayed significantly increased time freezing to tone in comparison to 
controls 24-hrs post-training (Fig. 7G; interaction between genotype and trial ([F(3,54) = 
3.43, p < 0.05] * = LSD post-hoc p < 0.05), but not at 48-hrs (Fisher’s LSD post-hoc p = 
0.11). A significant difference in time spent freezing to tone was not observed during 
extinction learning or in spontaneous recovery seven days post-extinction (Fig. 7I, 
Supplemental Fig 7F). Taken together, Raf1L613V/wt mice demonstrate moderately enhanced 
performance in hippocampal-dependent spatial working and reference memory tasks and 
amygdala-dependent fear memory. 
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Figure 7. Raf1L613V/wt animals exhibit enhanced spatial and working memory and fear 
learning. A: Schematic of an 8-armed water radial-arm maze (WRAM) used to examine 
adult control (n=19) and Raf1L613V/wt (n=15) mice. B: During the acquisition phase of 
WRAM testing between days 1-6, mutants execute significantly fewer total errors than 
controls (mean ± SEM, main effect of genotype [F(1, 32) = 4.87, p < 0.05] *=Fisher’s PLSD 
p < 0.05). C: In the Morris water maze (MWM), Raf1L613V/wt mice show a reduction in 
swim distance to platform on days 3, 4, and 5 relative to controls (mean ± SEM, * = one-
tailed t-test, p < 0.05). The inset graph shows the average across all 5 days of testing (mean 
± SEM, [F(1, 32) = 4.59, p < 0.05] * = Fisher’s PLSD p < 0.05). D: In the Morris maze 
reversal task, Raf1L613V/wt mice demonstrate reduced swim distance to platform on day 2 
(mean ± SEM, * = one-tailed t-test, p < 0.05). E: Probe trial analysis demonstrated 
significant preference for the NE target quadrant (mean ± SEM, [F(3, 96) = 89.90, p < 0.0001] 
* = Fisher’s PLSD p < 0.0001). F: In the visible platform task, we did not detect a 
significant effect of genotype (mean ± SEM, [F(1, 32) = 1.31, p = 0.26]). G: Naïve control 
(n=11) and mutant (n=9) animals were tested in tone-cued fear conditioning. Mutant 
animals do not differ significantly from controls in freezing behavior during the baseline 
or training phase; however, Raf1L613V/wt mice spent a significantly greater amount of time 
frozen to tone 24-hours post training (mean ± SEM, [F(3,54) = 3.429, p < 0.05] * = Fisher’s 
LSD post-hoc p < 0.05). No effect was detected 48-hours post training (mean ± SEM, 
Fisher’s LSD post-hoc p = 0.109). H: No significant differences in shock threshold were 
detected (mean ± SEM). I: Ratio of freezing to tone was unchanged at 24- and 48-hours 
post-training (mean ± SEM). 
 
Alterations in regulators of synaptic plasticity are not detectable in Raf1L613V/wt mutant 
mice 
To identify the mechanisms that drive enhanced behavioral performance in learning 
and memory assays in Raf1L613V/wt mice, we assessed the expression of ARC, TNFα, and 
perineuronal net components, known regulators of synaptic plasticity that have also been 
linked to altered ERK1/2 signaling (Han et al., 2013; Thomas and Huganir, 2004).  We 
subjected behaviorally naïve adult mice to five trials in the Morris water maze to activate 
the hippocampal circuit. Brains were collected 1 hour after the final trial and the number 
of ARC+ cells were assessed in the cortex and hippocampus. Raf1L613V/wt mice did not 
exhibit significant differences in ARC expression in comparison to controls in the cortex 
(Fig. 8A-D, n=4), or in the granule cell layer of the dentate gyrus (Fig. 8E-I, n = 4). 
  58 
We also examined the expression of putative astrocyte-derived modulators of synaptic 
plasticity. The astrocyte-secreted molecule, TNFα, is a major contributor to learning and 
memory (Camara et al., 2015; Camara et al., 2013; Han et al., 2013), and astrocyte-
mediated perineuronal net formation around PV+ GABAergic neurons is thought to 
contribute to RASopathy phenotypes (Krencik et al., 2015). We therefore assessed 
behaviorally-naïve Raf1L613V/wt mice for the expression of TNFα and a perineuronal net 
marker, wisteria floribunda agglutinin (WFA), in the hippocampus. Qualitative analysis of 
hippocampal TNFα revealed no apparent changes to the pattern of expression in the 
hippocampal region globally or in mutant S100+ glia ( Fig. 8J-O). We next examined the 
extent of WFA-labeling surrounding PV+ GABAergic neurons within the CA1 region of 
the hippocampus (Fig. 8P-U). We found that Raf1L613V/wt PV+ GABAergic neurons within 
the hippocampus displayed a similar extent and amount of WFA-labeling in comparison to 
controls (Fig. 8P-U, W; n = 35 mutant and 37 control neurons from 3 independent pairs). 
Therefore, Raf1L613V/wt mutant mice do not exhibit significant alterations in the expression 
of these three mediators of synaptic plasticity. 
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Figure 8. Normal expression of markers of synaptic plasticity in Raf1L613V/wt neurons 
and astrocytes. A-H: Control and mutant mice were subjected to a single 5-trial day of 
Morris Water Maze testing and collected 1-hour after completion of the 5th trial (n = 4). A-
D: Double immunolabeled sections of sensory cortex for the activity-dependent gene ARC 
and mature neuronal marker NEUN. We did not detect any differences in the pattern of 
Arc labeling in the cortex. (scale bar = 100 µm) E-I: Counts of labeled cells in the granular 
layers of the dentate gyrus reveal no change in the density of ARC+ cells (mean ± SEM, n 
= 4). J-W: Assessment of markers of astrocyte function in behaviorally naïve mice. J, K: 
Representative coronal sections of hippocampus immunolabeled for TNFα and S100β. L-
O: Confocal micrographs (63x) of TNFα- and S100β-labeled astrocytes indicates no 
qualitative change in the levels of TNFα in mutant hippocampi (n = 3). P, Q: Double 
immunolabeled coronal sections of hippocampus, stained with PV and the perineuronal net 
marker WFA (scale bar = 250µm). R-U: Representative images of CA1 hippocampal 
WFA-labeled neurons show no significant differences in the extent of perineuronal net 
formation (scale bar = 25µm). V: No significant differences in the number of WFA-labeled 
PV cells are seen (mean ± SEM, n = 3). W: Mutant (n = 35) and control (n = 37) PV 
neurons have a similar extent of surrounding WFA-labeled pixels (mean ± SEM).  
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Discussion 
Our study provides insight into the cellular and behavioral processes affected by a 
Noonan Syndrome-linked Raf1L613V mutation. In contrast to RASopathy-linked PTPN11 or 
RAS mutants, we found little evidence that Raf1L613V expression significantly alters global 
cortical excitatory or PV-expressing inhibitory neuron number (Gauthier et al., 2007; 
Paquin et al., 2009; Rooney et al., 2016). However, we detected an increased density of 
GFAP+ astrocytes in the mutant cortex and hippocampus (Gauthier et al., 2007; Li et al., 
2012a; Li et al., 2012b; Paquin et al., 2009; Pucilowska et al., 2008; Pucilowska et al., 
2012; Pucilowska et al., 2015; Samuels et al., 2008). OPC number was also increased in 
mutant cortices, though no significant change was observed in mature oligodendrocyte 
density or myelination. The increase in select glial subtypes did not correlate with a 
significant difference in locomotor ability, anxiety, or sociability. In contrast to many NF1 
and Noonan Syndrome mouse models, Raf1L613V/wt mice displayed moderately enhanced 
performance in three different learning and memory tasks. Overall, these data show that 
the ‘downstream’ RASopathy-linked Raf1L613V mutation increases the number of GFAP+ 
astrocytes and OPCs and improves aspects of learning and memory without significant 
alterations in basal behavioral measures of anxiety or sociability. 
Pharmacological inhibitors of RAS and MEK1/2 reverse several aspects of nervous 
system dysfunction in many RASopathy rodent models (Costa et al., 2002; Lee et al., 2014; 
Sanchez-Ortiz et al., 2014; Wu et al., 2011). However, clinical trials with pathway 
inhibitors, primarily statins in NF1 patients, have had limited success, possibly due to 
ERK1/2-independent pathways modified in response to mutations at the level of or 
upstream of RAS (Acosta et al., 2011; Anastasaki and Gutmann, 2014; Brown et al., 2012; 
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Hegedus et al., 2007; Kaul et al., 2015; Krab et al., 2008; Mainberger et al., 2013; Payne 
et al., 2016; van der Vaart et al., 2013). Defining the effects of mutations at multiple levels 
of the cascade may help resolve which processes are suitable for therapeutic targeting in 
all RASopathies or in a personalized, mutation-specific fashion. We show that a 
RASopathy mutation downstream of RAS, Raf1L613V, drives an increase in the number of 
GFAP+ astrocytes and OPCs. A CFC-Syndrome linked MEK1Y130C mutant has recently 
been shown to exhibit a comparable glial phenotype (Aoidi et al., 2018). Raf1L613V and 
Mek1Y130C mutations lead to enhanced ERK1/2 activity in biochemical assays, but to a 
lesser degree than many other RASopathy mutations (Jindal et al., 2017; Rodriguez-
Viciana et al., 2008; Wu et al., 2011). Nf1 and Ptpn11/Shp2 mutants show altered glial 
properties as well, including increased GFAP labeling and OPC number (Ehrman et al., 
2014; Nordlund et al., 1995; Rizvi et al., 1999; Zhu et al., 2005). Enhanced expression of 
glial markers may contribute to these results, but developing glia are known to utilize 
ongoing NF1 (MIM: 613113), PTPN11/SHP2, and ERK1/2 signaling to regulate glial 
proliferation (Ehrman et al., 2014; Rhee et al., 2016; Tien et al., 2012). In summary, our 
data further support the idea that astrocyte and OPC development is highly sensitive to 
upstream or downstream RASopathy mutations of varying strengths.  
 The precise aspect of glial development disrupted in RASopathies is not completely 
understood. Mutations that hyperactivate ERK1/2 signaling in neural stem cells have been 
shown to initiate premature gliogenesis, often at the expense of neurogenesis (Li et al., 
2014; Li et al., 2012a; Wang et al., 2012). Recent work on Costello Syndrome-associated 
H-RasG12V iPSCs also detected precocious astrocyte differentiation (Krencik et al., 2015). 
We found little evidence that cortical neuron density was altered in Raf1L613V/wt adult mice, 
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and multiple glial markers were relatively unchanged in P14 mutant cortices. Estimates of 
cellular density in RASopathy mutants by our group and others often rely upon two-
dimensional based approaches, which may be prone to certain technical and analytical 
artifacts. More rigorous systematic analysis with three-dimensional stereological methods, 
such as the optical fractionator or the recently developed isotropic fractionator, may be 
better-suited to reliably detect modest changes in cell number in samples of RASopathy 
brains. In the least, our data indicate the modification in the density of GFAP+ astrocytes 
and OPCs may occur during the late juvenile-young adult period in Raf1L613V/wt mutants. It 
is unclear whether the increased glial density arises from a deficit in ongoing glial 
progenitor proliferation or aberrant development of progenitor pools in the SVZ.  The 
expression of genes important for glial maturation has yet to be evaluated, such as the 
transient expression of Olig2 in GFAP-expressing astrocytes (Cai et al., 2007).  Finally, it 
will be important to examine whether the increase in glial density is cell autonomous and 
reversed by administration of pharmacological MEK1/2 inhibitors in adulthood.  
Noonan Syndrome is typically linked to intellectual disability and other 
neuropsychiatric conditions that vary in severity depending on the specific mutation 
(Rauen, 2013; Jindal et al., 2015; Pierpont et al., 2009).  RAF1L613V patients exhibit 
hallmark RASopathy features, such as hypertrophic cardiomyopathy and hypertelorism, 
but variable effects on intellectual capabilities that typically include impairment (Pandit et 
al., 2007; Razzaque et al., 2007; Denayer et al., 2010), but normal IQ (Kobayashi et al., 
2010). However, RAF1L613V individuals with increased IQ have also been reported (E. Ciara 
et al., 2009, ASHG, abstract).  Therefore, we asked whether Raf1L613V/wt mice exhibit 
aberrant neurobehavioral properties. We found that Raf1L613V/wt mutants had no significant 
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deficits in measures of locomotor, anxiety, or sociability that are often disrupted in models 
of neurocognitive syndromes. Additional behavioral characterization using paradigms 
employed in other mouse models of neurocognitive syndromes will be important in future 
studies, such as novel object recognition, sensory gating assays, or more detailed analyses 
of sociability that take into account novelty-related preference. However, we did observe 
somewhat unexpected effects in three behavioral learning and memory assays, where 
mutant mice exhibited enhanced performance during specific phases.  Our results show 
relatively improved performance of Raf1L613V/wt mutants during the early acquisition, but 
not late, stages of the WRAM, consistent with enhanced learning during the acquisition of 
this task.  However, mutants exhibit signs of enhanced memory following tone-cued fear 
conditioning, but not during the learning, or training, phase of this task. Further 
experimentation will be necessary to define how this mutation affects learning versus 
memory processes in specific circuits. However, to our knowledge, the Raf1L613V/wt mutant 
represents the first germline RASopathy mouse to display enhanced performance in these 
tasks.  It should be noted that hyperactivation of ERK1/2 has been linked to enhanced 
plasticity in certain contexts. Costello Syndrome patients with HRAS mutations exhibit 
increased TMS-induced plasticity (Dileone et al., 2010). Moreover, H-RasG12V 
overexpression specifically in CaMKII-expressing cortical and hippocampal excitatory 
neurons has been shown to enhance LTP and Morris water maze performance in mice 
(Kushner et al., 2005).  Raf1L613V/wt mice may provide another useful genetically-defined 
model to identify novel mechanisms of cognitive enhancement. 
Our data raise important questions regarding the contributions of RASopathic non-
neuronal cells to plasticity and learning. Most studies suggest the glial alterations seen in 
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RASopathies are detrimental to nervous system function. GFAP upregulation is a hallmark 
sign of reactive gliosis, which is associated with multiple neuropathological conditions and 
observed in post-mortem NF1 brain tissue and mouse models (Nordlund et al., 1995; Rizvi 
et al., 1999; Gutmann et al., 1999). H-RasG12S-expressing astrocytes disrupt perineuronal 
net formation and constrain critical period plasticity (Krencik et al., 2015). Diffusion 
Tensor Imaging (DTI) of individuals diagnosed with a RASopathy have detected enlarged 
white matter tracts and aberrant myelination, presumably due to changes in 
oligodendrocytes, that often correlate with learning disability (Koini et al., 2017; Legius et 
al., 1995; Loitfelder et al., 2015; Mayes et al., 2013; North et al., 1994). Oligodendrocyte-
specific NF1 deletion in mice has recently been shown to drive myelin decompaction and 
sensory gating defects (López-Juárez et al., 2017).  Both astrocytes and OPCs, however, 
are critical for maintaining nervous system homeostasis and promoting plastic changes 
important for learning and memory (Gibson et al., 2014; Han et al., 2013; Haydon and 
Nedergaard, 2014; McKenzie et al., 2014). Additionally, reactive gliosis is a graded 
response associated with specific pro-regenerative effects (Liddelow and Barres, 2017). It 
seems plausible the relatively subtle biochemical effect of the Raf1L613V/wt mutation may 
have led to mild changes in astrocyte function that minimized the negative consequences 
of complete activation of reactive gliosis.  In support of this, we saw little change in 
microglial number, which often coincides with increases in GFAP labeling, and we were 
unable to detect a difference in perineuronal net formation in adult Raf1L613V/wt forebrains. 
Secondly, the increase in OPC number did not lead to changes in mature myelinating 
oligodendrocyte density or overt deficits in myelination. Our results indicate that 
moderately enhanced GFAP+ astrocyte and OPC number is clearly not sufficient to impair 
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learning in Raf1L613V/wt mice.  Additional studies of conditional, glial-specific models will 
be important for evaluating to what extent the Raf1L613V-mediated increase in glial number 
is involved in enhancing cognition.  
The biological basis of heterogeneity between different RASopathy mutations is 
not completely understood (Jindal et al., 2015; Pierpont et al., 2009; Schreiber et al., 2017). 
Diverse levels of kinase activation between disease-linked mutations and the precise 
location of the mutated gene in the signaling network clearly contribute (Pierpont et al., 
2009; Rodriguez-Viciana et al., 2008; Rodriguez-Viciana et al., 2006). For example, 
studies of Noonan Syndrome-associated cardiac defects reveal that hypertrophic 
cardiomyopathy is observed in less than 20% of cases linked to PTPN11/SHP2 or SOS1 
mutations (Roberts et al., 2007; Sznajer et al., 2007), but greater than 90% of RAF1 
mutations (Pandit et al., 2007; Razzaque et al., 2007). Neurocognitive phenotypes tend to 
be more variable but ‘downstream’ mutations in BRAF, MEK1, or MEK2 generally result 
in more severe cognitive deficits than ‘upstream’ mutations (Cesarini et al., 2009; Pierpont 
et al., 2009; Pierpont et al., 2010b; Pierpont et al., 2013). Quantitative comparisons of 
common cellular phenotypes using IPSC-derived samples from individuals with different 
RASopathy mutations would be particularly useful (Krencik et al., 2015).  Nonetheless, 
the variability in neurocognitive function between individuals with the same gene mutation 
is significant. For example, two siblings with a P491S mutation in PTPN11 have been 
shown to have wide variation in language ability scores; one with severe impairment, the 
other just below average (Pierpont et al., 2010b). Individuals with an L613V mutation in 
RAF1 show a broad range of IQ scores that range from impairment to possibly higher than 
average (E. Ciara et al., 2009, ASHG, abstract; Denayer et al., 2010; Kobayashi et al., 2010; 
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Pandit et al., 2007; Razzaque et al., 2007). Genetic modifiers are likely influential, but 
difficult to identify in RASopathies due to extensive mutation heterogeneity. Further 
investigation of known strain-specific differences in RASopathy phenotypes provides a 
sensible alternative to identifying candidate modifiers (Schreiber et al., 2012; Wu et al., 
2011). Gene-environment interactions almost certainly modify neurocognitive outcomes 
but are poorly studied in the RASopathies. For example, the mildy higher basal state of 
astrocyte activation in Raf1L613V/wt mice may render increased susceptibility to damage 
following exposure to environmental intoxicants or neuropathogenic viral infections.  
Past studies have noted complex, sometimes paradoxical, changes in ERK1/2 
activity in response to pharmacological and genetic manipulations in specific contexts. In 
the fly embryo, gain-of-function mutations in Mek induce unanticipated decreases in 
ERK1/2 activity in certain body segments (Goyal et al., 2017). Studies of RAF inhibitors 
in cancer led to the discovery of complex compensatory interactions between BRAF and 
RAF1 that drive a paradoxical increase in ERK1/2 activation (Hatzivassiliou et al., 2010; 
Heidorn et al., 2010; Poulikakos et al., 2010). Indeed, the same compensatory upregulation 
of BRAF activity contributes to ERK1/2 hyperactivation in response to select kinase-
impairing Raf1D486N mutations (Wu et al., 2012). MEK1/2 inhibitors are clearly capable of 
reversing craniofacial and cardiac defects in Raf1L613V/wt mutant mice (Wu et al., 2011). In 
light of the enhanced learning and memory performance we observed in this strain, it will 
be interesting to examine whether pharmacological inhibitors of ERK1/2 signaling result 
in relative neurocognitive impairment in Raf1L613V/wt mutants. Overall, our data provide 
further support for mutation-specific approaches to the development of RASopathy 
therapeutics. 
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Supplemental Figures 
 
Supplemental Figure 1 (S1). Normal patterns of P-ERK1/2 expression in Raf1L613V/wt 
brains. A: Western blots of P21 whole control and Raf1L613V/wt cortical lysates showed no 
significant differences in the relative expression of SPRY2 or DUSP6 (mean ± SEM, n = 
5). B-C: Control (B) and Raf1L613V/wt (C) hippocampi displayed a similar pattern of p-
ERK1/2 immunolabeling. Scale bar = 200 µm.  
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Supplemental Figure 4 (S4). Juvenile Raf1L613V/wt cortices show normal extent of 
myelination. A-D: Representative double immunolabeled sections of P14 sensory cortex 
for MBP and DAPI showed no qualitative differences in the pattern of myelination between 
control (A, B) and mutant (C, D) cortices (scale bar = 50µm).  
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Supplemental Figure 7 (S7). Mutant mice exhibit enhanced spatial reference and 
working memory. A: Raf1L613V/wt animals commit significantly fewer working memory 
correct errors during the acquisition phase (mean ± SEM, main effect of genotype, 
acquisition [F(1,32) =8.94, p=0.005] *=Fisher’s PLSD p < 0.05; learning [F(1,32) = 0.05, 
p=0.82]; asymptotic [F(1,32) = 2.26, p=0.14]). B: Evaluation of working memory correct 
(WMC) errors during the acquisition phase indicate a marginal interaction of trial by 
genotype (solid lines) (mean ± SEM, [F(2, 64) = 2.83, p = 0.07]).  Individual analysis of trials 
3 and 4 reveal a main effect of genotype (Trial 3: [F(1, 32) = 6.83, p < 0.05], Trial 4: [F(1, 32) 
= 5.82, p < 0.05]). C: Mutant and control animals commit comparable numbers of working 
memory incorrect errors (mean ± SEM, acquisition [F(1,32) =2.04, p=0.16]; learning [F(1,32) 
= 0.43, p=0.51]; asymptotic [F(1,32) = 0.002, p=0.98]). Similarly, we observed no 
differences in reference memory errors between genotypes during the testing period (mean 
± SEM, acquisition [F(1,32) =0.41, p=0.52]; learning [F(1,32) = 0.03, p=0.85]; asymptotic 
[F(1,32) = 0.17, p=0.68]). D: No differences between mutant and control velocity were 
observed during the probe trial. E: Quadrant preference in the reversal probe trial is similar 
between mutant and control mice. F: No differences in spontaneous recovery are observed 
between control and Raf1L613V/wt animals after extinction. 
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Graphical Abstract. Hyperactive Mek1 signaling in cortical GABAergic interneurons 
causes embryonic parvalbumin-neuron death and defects in behavioral inhibition. 
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Abstract 
 Abnormal ERK/MAPK pathway activity is an important contributor to the 
neuropathogenesis of many disorders including Fragile X, Rett, 16p11.2 Syndromes, and 
the RASopathies. Individuals with these syndromes often present with intellectual 
disability, ADHD, autism, and epilepsy. However, the pathological mechanisms that 
underly these deficits are not fully understood. Here, we examined whether hyperactivation 
of MEK1 signaling modifies the development of GABAergic cortical interneurons (CINs), 
a heterogeneous population of inhibitory neurons necessary for cortical function. We show 
that GABAergic-neuron specific MEK1 hyperactivation in vivo leads to increased cleaved 
caspase-3 labeling in a subpopulation of immature neurons in the embryonic subpallium. 
Adult mutants displayed a significant loss of mature parvalbumin-expressing (PV) CINs, 
but not somatostatin-expressing CINs, during postnatal development and a modest 
reduction in perisomatic inhibitory synapse formation on excitatory neurons. Surviving 
mutant PV-CINs maintained a typical fast-spiking phenotype and minor differences in 
intrinsic electrophysiological properties. These changes coincided with an increased risk 
of seizure-like phenotypes. In contrast to other mouse models of PV-CIN loss, we 
discovered a robust increase in the accumulation of perineuronal nets, an extracellular 
structure thought to restrict plasticity in the developing brain. Indeed, we found that 
mutants exhibit a significant impairment in the acquisition of a behavioral test that relies 
on behavioral response inhibition, a process linked to ADHD-like phenotypes. Overall, our 
data suggests PV-CIN development is particularly sensitive to hyperactive MEK1 
signaling which may underlie neurological deficits frequently observed in ERK/MAPK-
linked syndromes.  
  75 
Significance Statement 
The RASopathies are a family of neurodevelopmental syndromes caused by 
mutations that lead to increased RAS/RAF/MEK/ERK signaling and are associated with 
intellectual disability, epilepsy, and ADHD. We do not fully understand how distinct 
neuronal subtypes are affected in these syndromes. Here, we show that increased MEK 
signaling in developing mice promotes the embryonic death of a specific subset of cortical 
inhibitory neurons that express parvalbumin. Surviving mutant parvalbumin neurons also 
show significant changes in crucial maturation processes, which coincide with increased 
seizure susceptibility and profound deficits in behavioral inhibition. These data suggest 
that deficits in inhibitory circuit development contribute to RASopathy neuropathogenesis 
and indicate that therapeutic strategies targeting inhibitory interneuron dysfunction may be 
beneficial for these individuals. 
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Introduction 
 Multiple developmental disorders are caused by genetic mutations linked to 
perturbation of kinase activity and altered intracellular signaling. The 
RAS/RAF/MEK/ERK (ERK/MAPK) pathway is a well-known, ubiquitous signaling 
cascade that is dynamically activated during development (Krens et al., 2006; Samuels et 
al., 2009). Mutations in classic RAS/MAPK signaling pathway components or upstream 
regulators, such as PTPN11/SHP2, NF1, or SYNGAP1, cause a family of related 
syndromes, known collectively as the RASopathies (Tidyman and Rauen, 2016). 
Moreover, MAPK3/ERK1 is present in a frequently mutated region of 16p11.2 linked to 
Autism Spectrum Disorder (ASD) and animal models of Fragile X, Rett, and Angelmann 
Syndromes also exhibit changes in ERK/MAPK signaling activity (Kumar et al., 2008; 
Pucilowska et al., 2015; Vorstman et al., 2006). These disorders are often associated with 
intellectual disability, neurodevelopmental delay, ADHD, autism, and epilepsy. Clearly, 
aberrant ERK/MAPK activity is an important molecular mediator of neurodevelopmental 
abnormalities, however, therapeutic approaches for these conditions are lacking, due in 
part to a limited understanding of the developmental stage- and cell-specific functions of 
ERK/MAPK signaling in the brain. Delineating the precise consequences of altered 
ERK/MAPK activity on specific neuronal subtypes in the developing forebrain may 
provide insight into the neuropathogenesis of multiple neurodevelopmental diseases. 
Coordinated interactions between multiple cell types are necessary for normal brain 
function, but deficits in select cellular subtypes often mediate specific neurodevelopmental 
phenotypes. Past work has shown that ERK/MAPK signaling regulates the development of 
dorsal cortex-derived glutamatergic cortical projection neurons (PNs) and glia (Aoidi et 
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al., 2018; Ehrman et al., 2014; Ishii et al., 2013; Li et al., 2012b). Upstream regulators, 
such as Syngap1, are also crucial for the early development of cortical glutamatergic 
neuron structure, excitability, and cognition (Clement et al., 2012; Ozkan et al., 2014). In 
contrast, NF1 mutations have been shown to impair aspects of spatial learning and memory 
via disruption of GABAergic, but not glutamatergic, neuron function (Cui et al 2008). 
Abnormal GABAergic circuitry is thought to be a key feature in the neuropathogenesis of 
various other neurodevelopmental disorders (Chao et al., 2010; Cui et al., 2008; 
Paluszkiewicz et al., 2011; Zhang et al., 2010). GABAergic neuron-directed Syngap1 loss 
modulates GABAergic output but does not drive major abnormalities in mouse behavior 
or seizure threshold (Berryer et al., 2016; Ozkan et al., 2014). Mutations in signaling 
components upstream of Ras differentially modulate multiple downstream pathways and 
do not provide a clear delineation of ERK/MAPK function (Anastasaki and Gutmann, 
2014; Brown et al., 2012). Here, we have hyperactivated MEK1 specifically in GABAergic 
cortical interneurons (CINs) to better understand the effects on inhibitory circuit 
development. 
In the mature cortex, locally connected parvalbumin- (PV) and somatostatin-
expressing (SST) CINs comprise the most populous and functionally diverse GABAergic 
subtypes (Kessaris et al., 2014). Reduced PV-CIN number is often observed in mouse 
models of multiple neurodevelopmental diseases, however, the mechanism of loss is poorly 
understood (Chao et al., 2010; Cui et al., 2008; Steullet et al., 2017). PV- and SST-CINs 
are generated in spatiotemporal fashion primarily from the medial ganglionic eminence 
(MGE) and migrate tangentially to the cortical plate (Gelman et al., 2009; Gelman and 
Marín, 2010; Lavdas et al., 1999; Marin and Rubenstein, 2001, 2003; Parnavelas, 2000; 
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Tamamaki et al., 1997; Wichterle et al., 1999; Wichterle et al., 2001; Wonders and 
Anderson, 2006). Tangential migration and early GABAergic circuit development is 
regulated by BDNF/TRKB, GDNF/GFRα1, HGF/MET, and NRG/ERBB4 signaling, 
which activate multiple Receptor Tyrosine Kinase (RTK)-linked intracellular kinase 
cascades, including ERK/MAPK (Bae et al., 2010; Fazzari et al., 2010; Flames et al., 2004; 
Perrinjaquet et al., 2011; Pozas and Ibanez, 2005). While the transcriptional basis of 
GABAergic neuron development has been well-studied (Lim et al., 2018; Mayer et al., 
2018; Mi et al., 2018; Paul et al., 2017), the kinase cascades that mediate GABAergic 
development in response to critical extracellular cues have received less attention. 
Here, we show that GABAergic neuron-specific expression of constitutively-active 
MEK1S217/221E (caMEK1) led to caspase-3 activation in a subset of embryonic GABAergic 
neurons. Even though caMEK1 is expressed in all CINs, we only observed a significant 
reduction in the number of mature PV-CINs, but not SST-CINs. In contrast with past 
models exhibiting PV-CIN loss, we found a surprising increase in the extent of 
perineuronal net (PNN) accumulation around these cells (Steullet et al., 2017). We 
observed an increased risk of spontaneous epileptiform activity and mild seizure-like 
activity in a subset of mutant mice that coincided with a reduction in inhibitory synapses 
on pyramidal neurons. Mutant mice exhibited normal locomotor, anxiety-like, and social 
behaviors, but we discovered deficits in behavioral response inhibition capacity, a process 
linked to ADHD-like phenotypes. Our findings indicate that GABAergic-specific MEK1 
hyperactivation is sufficient to drive widespread changes in cortical development relevant 
to cognitive phenotypes observed in RASopathies. Together, these data define the precise 
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functions of ERK/MAPK signaling in CIN development and suggest preferential 
contributions of PV-CIN pathology to ERK/MAPK-linked disorders. 
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Materials and Methods 
Mice  
All mice were handled and housed in accordance with the guidelines of the 
Institutional Animal Care and Use Committee, kept on a daily 12-hour light-dark cycle, 
and fed ad libitum. CaMek1 mice were kindly provided by Dr. Maike Krenz and Dr. Jeffrey 
Robbins while the source of the other mouse strains is listed in Table S1. Genomic DNA 
was extracted from tail or toe samples for standard genotyping by PCR using the following 
primer combinations: (listed 5’-3’): Cre – TTCGCAAGAACCTGATGGAC and 
CATTGCTGTCACTTGGTCGT to amplify a 266 bp fragment; caMek1S217/221E -
GTACCAGCTCGGCGGAGACCAA and TTGATCACAGCAATGCTAACTTTC 
amplify a 600 bp fragment; Ai3/Ai9 – AAGGGAGCTGCAGTGGAGTA, 
CCGAAAATCTGTGGGAAGTC, ACATGGTCCTGCTGGAGTTC, and 
GGCATTAAAGCAGCGTATCC amplify a 297 bp wt Rosa26 segment and a 212 bp 
Ai3/Ai9 allele. 
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Table S1. Mouse Strains 
Mouse Strain                                                                     Reference               Stock 
Number 
Nkx2.1-Cre  Xu et al., 2008 Jax labs #008661 
Slc32A1-Cre  Vong et al., 2011 Jax labs #028862 
Dlx5/6-Cre  Monory et al., 
2006 
Jax labs #008199 
Map2k1S217/221E (caMEK1)  Krenz et al., 2008  
Ai9 (Cre-dependent RFP)  Madisen et al., 
2010 
Jax labs #007909 
Ai3 (Cre-dependent GFP)  Madisen et al., 
2010 
Jax labs #007903 
 
Immunostaining and Image Analysis 
Free floating or slide-mounted sections were rinsed in PBS and blocked in a buffer 
containing 0.05 - 0.2% Triton 5% Normal Donkey Serum (NDS) in PBS before incubating 
in primary antibody solution.  The primary antibodies used in these experiments are listed 
in Table S2.  Sections were then rinsed and incubated in fluorescently-conjugated 
secondary antibody solutions containing Alexa-Fluor 488, 568, or 647 conjugated anti-
rabbit, anti-goat, or anti-chicken antibodies diluted in blocking solution. Tissue was rinsed 
in PBS and cover-slipped for microscopic analysis. Streptavidin-conjugated fluorophores 
were used to visualize WFA labeling.  
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Table S2. Antibodies  
Antibodies                                                                       Manufacturer         Catalog 
Number 
Goat anti-Parvalbumin Swant PVG213 
Rabbit anti-Somatostatin Peninsula T-4103 
Biotinylated Wisteria Floribunda Agglutinin  Vector B-1355 
Chicken anti-GFP  Aves GFP-1020 
Chicken anti-RFP  Rockland 600-901-379 
Rabbit anti-MEK1 Abcam Ab32091 
Rabbit anti-ERK2  Abcam Ab32081 
Rabbit anti-P-ERK1/2 Cell Signaling 4370 
Mouse anti-NEUN  Millipore Mab377 
Rabbit anti-cleaved caspase 3  Cell Signaling 9664L 
Rabbit anti-GFAP  Abcam Ab7260 
Rabbit anti-VGAT  Synaptic Systems 131 003 
Mouse anti-8-oxo-dg  R&D Systems 4354-MC-050 
 
Confocal images of at least three anatomically matched sections that include a brain 
region of interest were quantified for labeled cell density by observers blind to genotype. 
For estimating labeled cell density in the cortex, a column spanning all cortical layers was 
defined, the cross-sectional area measured, and the number of labeled cells was assessed. 
The proportion of cells co-labeled with Cre-dependent fluorescent reporters was also 
determined for select experiments. Quantification of cellular labeling was averaged across 
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all images collected from an individual mouse. At least three mice were collected for each 
genotype and results were analyzed using Student’s t-tests unless indicated otherwise. 
We quantified the extent of inhibitory synapse labeling in the perisomal domain of 
excitatory neurons from confocal images of VGAT/NEUN/GFP co-labeled sections. 
Confocal images were collected using optimal Airyscan settings for a 63x 1.4 NA objective 
on a Zeiss LSM800 with the same acquisition parameters, laser power, gain, and offset for 
VGAT detection. NEUN+/GFP- neurons in S1 layer 2/3 with a pyramidal morphology and 
residing 5-10μm from the tissue section surface were randomly selected by a blinded 
observer. NEUN+ soma were outlined in Photoshop and a ring 1.8μm in thickness was 
then established to specify the perisomatic space. VGAT-immunolabeling from 
perisomatic regions of interest were imported into ImageJ where the autothreshold 
algorithm, “Moments”, was utilized to define the total area of perisomatic VGAT-labeling 
in an unbiased manner. The perisomal VGAT-labeled area was then normalized to the total 
perisomatic area for that neuron. A total of 48 control and 53 mutant neurons from three 
different mice were analyzed. A similar approach was utilized to quantify VGAT labeling 
in areas enriched in dendrites by analyzing randomly selected regions of the layer 2/3 
neuropil that did not contain any NEUN-labeled soma.  
 
Slice electrophysiology 
Brain slicing and preparation was performed as reported previously (Nichols et al., 
2018). Mice were deeply anesthetized by isoflurane inhalation before decapitation. Brains 
were quickly removed and the coronal slices (350 µM) of the somatosensory cortex were 
produced on a vibratome (VT 1200; Leica, Nussloch, Germany) in fully oxygenated (95% 
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O2, 5% CO2), ice-cold artificial cerebral spinal fluid (aCSF) containing (in mM): 126 
NaCl, 26 NaHCO3, 2.5 KCl, 10 glucose, 1.25 Na2H2PO4·H2O, 1 MgSO4·7H2O, 2 
CaCl2·H2O, pH 7.4. The slices were incubated in the same aCSF at 32ºC for 30min before 
being allowed to recover at room temperature for an additional 30 min before patch clamp 
recordings were started.  
After recovery, slices were transferred into recording chamber and perfused 
continuously with aCSF of 32ºC at a rate of 1-2 ml/min. Then whole-cell patch clamp 
recordings were performed on tdTomato-positive fast-spiking (FS) interneurons in the 
somatosensory cortex layer V/VI (L5/6) by using an Axon 700B amplifier. The FS neurons 
were identified by lack of an emerging apical dendrite and their intrinsic firing response to 
current injection (Agmon & Connors, 2018; Anderson et al., 2010; McCormick et al., 
1985). Clampex 10.6 (Molecular Devices) was used to collect data and pipettes (2-5 Mῼ) 
were pulled from borosilicate glass (BF150-110-10, Sutter Instruments) by using sutter 
puller (Model P-1000, Sutter Instruments), filled with an internal solution that contains (in 
mM): 135 K-Gluconate, 4 KCl, 2 NaCl, 10 HEPES, 4 EGTA, 4 Mg ATP and 0.3 Na Tris. 
The stability of the recordings was monitored during the experiments, and only the 
recordings with the series resistances (Rs) less than both 25 Mῼ and 20% of the membrane 
resistances were chosen for analysis. For the input resistance calculation, the steady plateau 
of the voltage responding to the current input of -50 pA step with 1 s duration was used 
and intrinsic parameters were measured as previously reported (Nichols et al., 2018). 
Adaptation index was calculated as the ratio of the 1st interspike interval over the last (i.e. 
F1st ISI/Flast ISI).  The frequency (F) – current (I) slope was calculated as the number of 
induced action potentials (APs) divided by the current step (number of APs at 150pA-
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number of APs at 100pA)/(150pA-100pA). Unpaired Student’s t-test and two-way 
ANOVA with Bonferroni post hoc tests were used for statistical analysis. 
 
Behavioral Testing 
Open Field Testing 
The open field test was used to test voluntary locomotor capabilities and anxiety-
like behavior. The apparatus consisted of a 40x40cm arena enclosed by 30cm high opaque 
walls. A single 60W bulb was positioned to brightly illuminate the center of the chamber 
with dim lighting near the walls. Mice were placed into the apparatus and recorded for a 
total of 10 minutes. Video data were analyzed for total distance traveled and time spent in 
the center quadrant.  
 
Elevated Plus Maze 
The elevated plus maze was constructed from black polycarbonate, elevated 81cm 
off the ground, and oriented in a plus formation with two 12x55cm open arms and two 
12x55cm closed arms extending from an open 12x12cm center square. Closed arm walls 
were 40cm high extending from the base of the arm at the center square. The apparatus was 
lit with a 60W bulb with light concentrated on the center square. At the beginning of the 
trial, mice were placed in the center square, facing the south open arm, and recorded while 
freely exploring for 5 minutes.   
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Social Approach Assay 
The social approach apparatus was made of transparent plexiglass and contained 
three 20x30x30cm chambers (total dimensions 60x30x30cm) connected by open 
doorways. Prior to experimental social trials, mice were habituated to the apparatus and 
allowed to freely explore all three chambers for 5 minutes. At the end of the 5 minutes, 
mice were removed and placed in their home cage. A sex- and age-matched stimulus mouse 
was then placed into a small empty cage in chamber 1 of the apparatus. The experimental 
mouse was reintroduced to the center chamber (chamber 2) of the apparatus and recorded 
while freely exploring for 10 minutes. The time spent in the chamber with the stimulus 
mouse (chamber 1) or the empty chamber (chamber 3) was then measured.  
 
Fixed Minimum Interval (FMI) 
Twenty-four adult mice (12 Slc32A1:Cre mice: 5 males, 7 females; 12 caMek1, 
Slc32A1:Cre mice: 6 males, 6 females) were kept on a 12-hour reverse light-dark cycle. 
Animals had free access to water in their home cages, but access to food was gradually 
reduced in the week prior to behavioral training, where 1 hr of food access was provided 
30 min after the end of each daily training session. Body weights were maintained such 
that mice lost no more than 15% of starting body weight. Behavioral testing was conducted 
in eight MED Associates (St. Albans, VT, USA) modular test chambers (240 mm length 
 200 mm width  165 mm height; ENV-307W). Each chamber was enclosed in a sound- 
and light-attenuating cabinet (ENV-022V) equipped with a fan for ventilation that provided 
masking noise of approximately 60dB (ENV-025-F28). The back wall and hinged front 
door of each chamber were made of Plexiglas. The side walls of the chamber were made 
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of aluminum, and the right wall contained the manipulanda and reward receptacle. The 
floor was composed of thin metal bars. A circular reward receptacle was positioned in the 
center of the front panel and equipped with a head entry detector (ENV-302HD), a liquid 
dipper (ENV-302W-S), and a yellow LED (ENV-321W). The reward receptacle was 
flanked by a nose-poke device including an LED-illuminator (ENV-314M). The chamber 
was fitted with a house light (ENV-315W) at ceiling level above the back wall (ENV-
323AW) and a 4.5kHz tone generator (ENV-323HAM). Experimental programs were 
arranged via a MED PC interface connected to a PC controlled by MED-PC IV software. 
All behavioral sessions were 30 min long, including a 3-min warm-up period during which 
no stimuli were activated. 
Reinforcement Training and Autoshaping. Mice were first trained to obtain 0.1 cc 
of diluted sweetened condensed milk from the liquid dipper (the reinforcer) in the reward 
receptacle. Following the 3-min warmup period, a reinforcer was made available, followed 
by consistent reinforcer delivery at variable, pseudo-randomly selected inter-trial intervals 
(ITIs) for the remainder of the session (mean = 45 s). No stimuli were activated during 
ITIs. When the dipper was activated and a reinforcer was available, a 2.9-kHz tone, the 
head-entry LED, and the house light were turned on. The reinforcer remained available 
until it was obtained by the mouse, which deactivated the 2.9-kHz tone, the LED, and house 
light. The dipper remains activated for 2.5s after the mouse obtains the reinforcer. 
Following 5 sessions of reinforcement training, the procedure was modified for 5 
autoshaping sessions which, in the last 8s of each ITI, the LED inside of the nose-poke 
device was turned on. The nose-poke LED was then turned off and reinforcement was 
delivered as described. If the mouse nose-poked the device during the time when the LED 
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was on, it was turned off and reinforcement was delivered immediately. The autoshaping 
procedure was then modified for another 5 sessions such that reinforcement delivery was 
contingent upon a single nose-poke to the nose-poke device when its LED was illuminated 
and the ITI was reduced to 10s.  
Fixed-Minimum Interval Training. Mice were then trained on the fixed-minimum 
interval (FMI) schedule. After the 3-min warmup period, the houselight was deactivated. 
A nose-poke (initiating response) activated the nose-poke LED and marked the beginning 
of the inter-response time (IRT). A subsequent head entry into the reward receptacle 
(terminating response) terminated the IRT. Reinforcement was delivered only if the IRT 
was longer than the criterion time, which was dependent upon the FMI schedule. IRTs 
shorter than the criterion time terminated without reinforcement, deactivated the nose-poke 
LED, and another trial could be immediately initiated. IRTs greater than or equal to the 
criterion time resulted in delivery of reward, deactivation of the nose-poke LED, a 2.5s 
duration 2.9kHz tone, and subsequent removal of the liquid dipper. Houselights were then 
activated for a 10s ITI, after which houselight deactivation indicated a new trial could be 
initiated via nose-poke. The time between the end of the ITI and the nose-poke initiating 
response was measured and termed the latency to initiate (LTI). All mice were initially 
trained on an FMI schedule with a criterion time of 0.5s (FMI 0.5s) until stability was 
achieved. The FMI 0.5s condition was implemented to acclimate mice to the task and is 
not used to evaluate response inhibition capacity. Performance was considered stable when 
a non-significant linear regression for mean median IRTs across 5 consecutive sessions 
was achieved, using a significance criterion of .05. Following stability on the FMI 0.5s 
schedule, subjects experience FMI 2s, 4s, and 8s. Each subject was trained to stability.  
  89 
Data Analysis. Four parameters were tracked on a session-by-session basis: median 
latency-to-initiate trials (LTI), median inter-response time (IRT), the coefficient of quartile 
variation (CQV) of IRTs (difference between 1st and 3rd quartile divided by their sum), 
and the number of obtained reinforcers (ORs). The acquisition phase of each parameter 
was defined as the mean performance during the first five sessions of each schedule, while 
the asymptote was defined as the mean during the last five sessions. ANOVAs were 
conducted to assess statistical significance of time and genotype on FMI schedule and 
Student’s t-tests were conducted to examine parameter differences based on genotype. 
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Results 
Differential expression of ERK/MAPK components in CINs 
 The ERK/MAPK cascade is a commonly utilized intracellular signaling pathway 
that is dynamically activated during embryogenesis and in adulthood. In the embryonic 
ventricular zone, neural progenitors typically show high levels of P-ERK1/2 relative to 
immature post-mitotic neurons (Pucilowska et al., 2018; Stanco et al., 2014). In adult 
cortices, elevated P-ERK1/2 labeling is enriched in a heterogeneous set of excitatory PNs, 
primarily in layer 2, and plays a critical role in long-range PN development (Cancedda et 
al., 2003; Gauthier et al., 2007; Holter et al., 2019; Pham et al., 2004; Pucilowska et al., 
2012; Suzuki et al., 2004; Xing et al., 2016). The activation of ERK1/2 in CINs has not 
been well characterized. We generated mice expressing Slc32A1:Cre and the Cre-
dependent red fluorescent protein (RFP) reporter, Ai9 (Madisen et al., 2010; Vong et al., 
2011) (Figure1A-D). As expected, brain regions abundant with GABA-expressing neurons 
robustly expressed Ai9 (Figure 1A). Immunolabeling for MAP2K1 (MEK1) revealed 
relatively lower expression in CINs in comparison to NEUN+/RFP- presumptive PNs 
(Figure 1E-G). Layer II/III CINs also expressed low levels of MAPK1/ERK2 in 
comparison to PNs (Figure 1H-J). In agreement with previous studies, high levels of P-
ERK1/2 were observed in a subset of PNs in cortical layer II/III (Cancedda et al., 2003; 
Pham et al., 2004; Suzuki et al., 2004). However, examination of P-ERK1/2 
immunolabeling in RFP+ CINs revealed qualitatively lower levels of P-ERK1/2 in 
comparison to PNs (Figure 1K-M). In summary, CINs express relatively lower levels of 
MEK1, ERK2, and P-ERK1/2 than excitatory neurons in the adult cortex, raising the 
possibility of functionally distinct roles for this cascade between cortical neuron subtypes. 
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Figure 1. CINs exhibit low levels of ERK/MAPK expression and activity. (A-D) 
Representative confocal images of Slc32A1:Cre, Ai9 sensorimotor cortex. Note the robust 
expression of RFP in brain regions with high densities of GABAergic neurons. (Scale bar 
= 100 µm) (E-M) Immunolabeling for MEK1 (E-G) and ERK2 (H-J) showed 
comparatively low expression in inhibitory CINs (yellow outlines) when compared to 
NEUN+/Ai9- excitatory neurons (arrowheads) in layer II (n=3). Relatively lower 
expression of P-ERK1/2 was also detected in inhibitory CINs when compared to excitatory 
neurons (n=3). (Scale bar = 10 µm). 
 
GABAergic-autonomous caMEK1 expression decreases PV-CIN number 
 Increased ERK/MAPK signaling is the most common result of RASopathy-linked 
mutations (Tidyman and Rauen, 2016). We utilized a Cre-dependent, constitutively active 
CAG-Loxp-Stop-Loxp-Mek1S217/221E (caMek1) allele, which has been shown to 
hyperactivate MEK1/2-ERK1/2 signaling (Alessi et al., 1994; Bueno et al., 2000; Cowley 
et al., 1994; Klesse et al., 1999; Krenz et al., 2008; Lajiness et al., 2014; Li et al., 2012b). 
We generated caMek1, Slc32A1:Cre mice to hyperactivate MEK1 in a CIN-specific 
fashion during embryogenesis. Elevated MEK1 expression was clearly detectable in the 
E13.5 mantle zone of the ganglionic eminences, presumptive embryonic CINs migrating 
into the cortex, and adult CINs in primary somatosensory cortex (S1) (Figure S1A-H; J-
O). CaMek1, Slc32A1:Cre mice were viable and phenotypically normal, though mutants 
exhibited larger body mass than controls in adulthood (Figure S1I).  
Surprisingly, assessment of fluorescently-labeled CINs in caMek1, Slc32A1:Cre, 
Ai9 sensory cortices revealed a significant reduction in total RFP+ cell density (Figure 2A-
I). In the adult cortex, approximately 40% of CINs express PV whereas 30% express SST, 
which serve as mostly non-overlapping markers of two distinct populations of CINs 
(Kelsom and Lu, 2013; Kessaris et al., 2014; Rudy et al., 2011). Strikingly, we observed a 
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significant reduction in the proportion of PV+/RFP+ CINs, but not in the proportion of 
SST+/RFP+ CINs (Figure 2K-Q). PV, but not SST, expressing CINs displayed a significant 
increase in somal area compared to control neurons (Figure 2R-U, V). A reduced density 
of PV-CINs was detected in a separate caMek1, Dlx5/6:Cre strain that also targets 
postmitotic CINs in the developing cortex (Figure S2A-D) (Monory et al., 2006).  
Recombination within the entire GABAergic system left open the possibility that 
indirect changes in other neuroanatomical regions could alter global cortical activity and 
modulate PV-CIN number (Denaxa et al., 2018). To restrict Cre expression to primarily 
MGE-derived CINs, we generated caMek1, Nkx2.1:Cre, Ai9 mice and assessed the 
proportion of PV+/RFP+ CINs. CaMek1, Nkx2.1:Cre mice exhibited generalized growth 
delay in the second-third postnatal week and were not viable past the first postnatal month 
(n=8). Nonetheless, consistent with our previous findings, P14 caMek1, Nkx2.1:Cre, Ai9 
mice displayed a reduction in PV+/RFP+-CIN density (Figure S2E-L, M). In summary, our 
data indicate that the establishment of PV-CIN number is cell-autonomously vulnerable to 
enhanced MEK1 signaling, while SST-CIN number is not altered. 
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Figure 2. MEK1 hyperactivation leads to a selective reduction in PV-expressing CINs 
in the postnatal cortex. (A-H) caMek1, Slc32A1:Cre, Ai9 mutant P3.5 (A-D) and P60 
(E-H) primary somatosensory cortices exhibit reduced numbers of Ai9-expressing CINs 
in comparison to Slc32A1:Cre, Ai9 controls (quantification in I, n=3, mean ± SEM, * = p 
< 0.05). (Scale bar = 100 µm) (J-Q) We quantified the proportion of fluorescently co-
labeled PV/RFP or SST/RFP co-expressing CINs in the sensory cortex (J). Confocal 
micrographs of RFP-expressing CINs at P60 demonstrates that the proportion of 
PV+/RFP+ CINs, but not SST+/RFP+ CINs, was significantly decreased in mutants (N-P) 
in comparison to controls (K-M) (quantification in Q: n=3, mean ± SEM, * = p < 0.05). 
(Scale bar = 100 µm) (R-V) Mutant PV-CINs (T-U, green arrowheads in T) display 
increased soma size in comparison to control PV-CINs (R-S) (quantification in V, n = 21 
control neurons, 42 mutant neurons, mean ± SEM, * = p < 0.001). PV-/RFP+ CINs 
displayed no qualitative change in soma size (blue arrowheads). (Scale bar = 25 µm). 
 
 
Presumptive mutant PV-CINs in the embryonic subpallium undergo apoptosis 
Our analyses of RFP+ CINs in P3.5 caMek1, Slc32A1:Cre mice yielded a 
significant reduction in CIN density, thus, we hypothesized that gain-of-function MEK1 
signaling disrupted embryonic processes necessary to establish CIN number. Indeed, 
examination of RFP+ CIN density in the E17.5 cortical plate also revealed fewer CINs in 
caMek1, Slc32A1:Cre embryos (Figure S3A-D). We examined markers of neuronal death 
during mid-neurogenesis in the caMek1, Slc32A1:Cre, Ai9 subpallium. Immunolabeling 
for the apoptotic marker cleaved caspase 3 (CC3) revealed colocalization of CC3 with 
some RFP+ neurons within the mantle zone of the ganglionic eminences in E13.5 mutant, 
but not control, embryos (Figure 3A-E, F). CC3+/RFP+ neurons also presented with 
condensed, pyknotic nuclei (Figure 3G-N). We also observed CC3+/RFP+ cells with 
pyknotic nuclei in caMek1, Nkx2.1:Cre, Ai9 mantle zone (Figure 3O-Q). No apoptotic cells 
were observed in the mutant ganglionic eminence VZ or the cortical migratory streams. 
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Analysis of recombined GABAergic neuron density in the dorsal striatum did not reveal a 
significant difference from controls, suggesting that the loss of PV-CINs is not due to 
altered CIN migratory trajectory. Together, our results suggest reduced PV-CIN density in 
the postnatal cortex is due to the death of a subset of migrating CINs in the ganglionic 
eminence. 
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Figure 3. A subset of immature GABAergic neurons undergo cell death during mid-
embryogenesis. (A) E13.5 coronal section of RFP-labeled CINs in the mantle zones of the 
Slc32A1:Cre subpallium during mid-embryogenesis. (B-F) Immunolabeling for cleaved 
caspase 3 (CC3) showed a significant increase in the number of apoptotic profiles in 
caMek1, Slc32A1:Cre mutants (D-E) as compared to controls (B-C) (quantification in F; 
n=3, mean ± SEM, * = p < 0.05). (Scale bar = 100 µm) (G-Q) Representative confocal z-
stacks of CC3 labeled cells from caMek1, Slc32A1:Cre embryos (G-N, Scale bar = 2 µm) 
and caMek1, Nkx2.1:Cre embryos (O-Q) show clear colocalization with RFP and a 
condensed, pyknotic nuclear morphology. 
 
GABAergic-specific caMek1 promotes cortical hyperexcitability but does not significantly 
alter fast-spiking CIN electrophysiological properties 
 Nearly 40% of RASopathy individuals with mutations downstream of RAS 
experience seizures and epilepsy (Digilio et al., 2011; Rauen et al., 2013; Yoon et al., 
2007). Whether MEK1 hyperactivation in GABAergic circuits mediates seizure activity in 
the RASopathies is unclear. We did not detect any signs of overt generalized tonic-clonic 
seizures in mutant mice while housed in home cages. We conducted a series of behavioral 
tests by first using the open field, then the elevated plus maze, and finally the social 
approach assay. No difference in global locomotor activity, anxiety-like behavior, or 
sociability could be detected with these tests (Figure S4). However, during the initial 60 
sec of open field testing with 13 adult caMek1, Slc32A1:Cre mutants, two mutant mice 
exhibited increased head twitching, aberrant locomotor activity, and increased rearing. 
Three mutant mice displayed periods of overt sudden behavioral arrest and motionless 
staring. These behaviors were not observed in any of the control mice utilized in this study. 
Consistent with these subtle impairments, subsequent re-analysis of the first 10 sec of the 
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open field task revealed a significant reduction in distance traveled in caMek1, 
Slc32A1:Cre mutants, which was also observed in caMek1, Dlx5/6:Cre mutants.  
We performed intracortical EEG recordings to directly assess cortical activity, 
which revealed spontaneous epileptiform-like discharges in three of six caMek1, 
Slc32A1:Cre adult mice, but not control mice (Figure 4A). These six mutants also exhibited 
a significantly reduced average threshold to seizure induction in response to 
pentylenetetrazol (PTZ) administration when compared to controls (Figure 4B). Seizures 
have been shown to increase the local expression of glial fibrillary acidic protein (GFAP) 
in astrocytes (STEWARD et al., 1992; Stringer, 1996). 3 of 3 newly generated and 
untreated caMek1 Slc32A1:Cre mice immunolabeled for GFAP exhibited clusters of 
GFAP-expressing astrocytes in the cortex consistent with local reactive astrogliosis near 
hyperexcitable regions (Figure 4C-F). Overall, some of the seizure-related phenotypes we 
observed were not completely penetrant, thus, these data indicate that MEK1 
hyperactivation in CINs may be a potential risk factor for epilepsy in the RASopathies. 
PV-CINs provide a powerful source of inhibition in the cortex, firing action 
potentials at frequencies greater than 200Hz (Okaty et al., 2009). Fast-spiking (FS) 
physiology is due in part to the unique expression of the fast-inactivating potassium 
channel Kv3.1, which begins in the second postnatal week (Goldberg et al., 2011; Rosato-
Siri et al., 2015; Rudy and McBain, 2001). To determine if hyperactive MEK1 signaling 
was sufficient to alter basic physiological properties of FS CINs, we performed whole-cell 
patch clamp recordings on caMek1, Nkx2.1:Cre mice at the end of the third postnatal week. 
Current clamp recordings of fluorescently-labeled CINs revealed that both control and 
mutant neurons retained their distinctive electrophysiological fast-spiking phenotype 
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(Figure 4G, I) (Agmon & Connors, 2018; Anderson et al., 2010; McCormick et al., 1985). 
No significant differences were observed in resting membrane potential, adaptation index, 
rheobase, or action potential threshold, but a small increase in action potential amplitude 
was observed (Figure 4I). We did also detect a significant increase in FS CIN input 
resistance and a reduction in FI slope in caMek1, Nkx2.1:Cre mutant compared with 
Nkx2.1:Cre controls suggesting that mutants may have a reduction in the responsiveness 
and/or firing output of inhibitory neurons (Figure 4H-I). Overall, these data indicate that 
canonical electrophysiological features of fast-spiking CIN development were not altered 
by MEK1 hyperactivation. However, certain intrinsic properties exhibit subtle differences 
in mutant mice that might contribute to circuit-wide hyperexcitability. 
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Figure 4. CaMek1 CINs maintain typical fast-spiking properties, but a subset of mice 
exhibit seizure-like phenotypes. (A) Representative traces from forebrain-penetrating 
EEG revealed epochs of synchronous firing in 3 of 6 caMek1 Slc32A1:Cre, but not control 
mice. (B) Tail vein PTZ injections revealed a significant reduction in mean dose to seizure 
onset of PTZ (n = 6, mean ± SEM, * = p < 0.001). (C-F) caMek1 Slc32A1:Cre cortices 
display aberrant clusters of GFAP-labeled astrocytes (E, arrowheads, insets in F) that were 
not observed in controls (C-D) (n=3). (Scale bar = 100 µm) (G) Representative current 
clamp recordings of FS CINs in P21 Nkx2.1:Cre Ai9 and caMek1 Nkx2.1:Cre Ai9 mutant 
cortices. (H) Mutant CINs had a significantly reduced FI slope in comparison to controls 
(mean ± SEM, p < 0.05). (K) Summary table of FS CIN intrinsic properties. 
 
 
Inhibitory synapse formation and perineuronal net accumulation are altered by MEK1 
hyperactivity 
 PV-expressing CINs preferentially innervate pyramidal cells, often forming 
synapses on the perisomatic domain (Chattopadhyaya et al., 2004; Chattopadhyaya et al., 
2007). We assessed whether perisomatic VGAT-labeled synapses surrounding layer 2/3 
PNs were diminished in adult caMek1, Slc32A1:Cre, Ai3 mice. We found the extent of 
VGAT-immunolabeling in the perisomatic space of NEUN+/GFP- PN soma was 
significantly reduced in mutant cortices when compared to controls (Fig. 5A-F, M). 
Interestingly, the area of VGAT-labeling in the surrounding neuropil, typically innervated 
by SST-CINs, was unchanged (Fig. S5A-F). These data show that PV-CIN inhibitory 
output is selectively vulnerable to caMEK1 signaling while SST-CINs are less affected.  
 PV-CINs selectively accumulate an extracellular structure called the perineuronal 
net (PNN) derived primarily from glial chondroitin sulfate proteoglycans (CSPGs). PNNs 
are essential to cortical development, restricting plasticity during the closure of critical 
periods and protecting PV-CINs from oxidative stress associated with a high frequency 
firing rate (Cabungcal et al., 2013; Hensch, 2005b). Reductions in PNN formation have 
been noted in multiple models of neurodevelopmental disorders that exhibit loss of PV-
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CINs (Bitanihirwe and Woo, 2014; Cabungcal et al., 2013; Krencik et al., 2015; Krishnan 
et al., 2015; Steullet et al., 2017). We utilized WFA-labeling to test whether PNN formation 
was reduced in adult caMek1, Slc32A1:Cre, Ai3 mice (Figure 5H-M). Surprisingly, we 
found that surviving PV-CINs were WFA+ in mutants (Figure 5G-L). PNNs were also not 
detected on Ai3-expressing neurons that lacked PV-expression. Consistent with the larger 
somal size of mutant PV-CINs, the cross-sectional area of WFA-labeled profiles was also 
significantly increased (Figure 5G-L, N). Analysis of the quantitative level of WFA-
labeling in mutant PV-CINs revealed a robust increase in PNN accumulation as compared 
to controls (Figure 5G-L, O). Mutant WFA-labeled CINs exhibited normal expression of 
8-oxo-2’-deoxyguanosine (8-oxo-dg), a marker of DNA oxidation often altered in neurons 
with reduced PNNs (Figure S5 F-I) (Steullet et al., 2017). Collectively, MEK1 
hyperactivation clearly increases PNN accumulation, but does not trigger ectopic PNN 
formation on GABAergic neurons lacking PV. 
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Figure 5. Reduced perisomatic synapse labeling in mutant cortices coincide with a 
substantial increase in PNN formation on PV-CINs. (A-F) Representative high-
resolution confocal Airyscan images of triple immunolabeled cortical sections for 
Ai3/EYFP, VGAT, and NEUN. Excitatory neuron perisomatic domains were outlined and 
quantification of VGAT-labeled pixels revealed that mutants (D-F) have a significant 
reduction in the amount of perisomatic VGAT-labeling (Scale bar = 3 µm) in comparison 
to controls (A-C) (quantification in M; n = 48 control, 53 mutant neurons; mean ± SEM, * 
= p < 0.05). (G-L) P60 representative coronal sections of Slc32A1:Cre Ai3 (G-I) and 
caMek1 Slc32A1:Cre Ai3 (J-L) cortices immunolabeled for GFP, WFA, and PV. The WFA 
channel was imaged using the same acquisition settings for all samples. A significant 
increase in WFA-labeled area per neuron was detected in mutant cortices when compared 
to controls (quantification in N; n = 63 control, 54 mutant neurons, mean ± SEM, * = p < 
0.001). Analysis of WFA-labeling intensity yielded a significant increase in integrated 
density in mutant CINs (quantification in O; n = 63 control, 54 mutant neurons, mean ± 
SEM, * = p < 0.001). (Scale bar = 100 µm). 
 
caMek1, Slc32A1:Cre mice display delayed acquisition of FMI performance 
Attention deficit hyperactivity disorder (ADHD) is associated with a significant 
proportion of RASopathy cases (Adviento et al., 2014; Garg et al., 2013; Green et al., 2017; 
Pierpont et al., 2018; Walsh et al., 2013). Altered prefrontal cortex (PFC) function has been 
implicated in ADHD (Gabay et al., 2018), and has been shown to contribute to cognitive 
deficits in a mouse model of Fragile X Syndrome (Krueger et al., 2011). Few studies have 
examined GABAergic contributions to PFC function in the context of RASopathies. As in 
sensory cortex, we noted a reduction in Ai9-expressing CINs in the PFC of mutant mice 
(Figure 6A-B, D-E). Interestingly, we found that PNs in the PFC exhibit reduced P-ERK1/2 
expression in caMek1, Slc32A1:Cre mice (Figure 6A-F). These data indicate that MEK1 
hyperactivation in developing CINs is sufficient to drive molecular abnormalities within 
specific cortical regions important for cognition.  
Individuals with ADHD often exhibit structural changes in the PFC, which appear 
to be involved in the inhibition of reinforced responses (Seidman et al., 2006). To examine 
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response inhibition directly, we utilized a fixed minimum interval (FMI) test, a timing-
based task that requires animals to withhold a response for a fixed period. This paradigm 
is perhaps more favorable than the five-choice serial reaction time task (5-CSRTT) and 
differential reinforcement of low rates task (DRL), because its self-paced design 
dissociates response inhibition capacity from motivational aspects of behavior (Bizarro et 
al., 2003; Doughty and Richards, 2002; Hill et al., 2012; Watterson et al., 2015). Here, 
adult control and caMek1, Slc32A1:Cre mice were trained to initiate trials via a nose-poke 
which resulted in the presentation of sweetened condensed milk in the reward receptacle. 
Mice were then placed on an FMI schedule, where a time delay between the initiating nose-
poke and the availability of reinforcement in the reward receptacle was implemented 
(Figure 6G). Reward was delivered only if the time between the initiating nose-poke and 
attempt to obtain reward (inter-response time, or IRT) exceeded a pre-determined 
withholding period. If mice prematurely accessed the reward receptacle, no reward was 
delivered.  
Following initial training on a FMI with a very short (0.5s) response-withholding 
period, we measured mouse performance when the withholding period was extended to 2s, 
4s, and finally, 8s. We observed a main effect of FMI schedule irrespective of genotype, 
such that IRTs increased as the FMI withholding period increased (F (2, 62) = 535.12, p < 
0.01). Importantly, mutants showed clear evidence of impaired acquisition of the FMI task. 
We found a main effect of genotype on the mean median IRT during the first 5 days of 
each FMI schedule (acquisition period), in which mutant mice had relatively lower IRTs 
compared to control mice (F (1, 62) = 18.73, p < 0.01) (Figure 6H). In further support of 
reduced response inhibition capacity, mutant mice exhibited increased variability in their 
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IRTs as measured by the coefficient of quartile variation (CQV) during acquisition (F(1, 
62) = 31.73, p < 0.01) and asymptotic performance (defined as the last five days of the 
FMI) (F(2, 62) = 5.055, p < 0.001) across all schedules (Figure 6I). Median IRTs during 
the asymptotic phase in mutants and controls were not statistically different in any schedule 
(Figure 6H inset). Thus, these data suggest that mutant mice are capable of learning to 
inhibit reinforced responses for up to 4 s but show a significant delay in acquiring this 
capability. 
Due to Slc32A1:Cre-mediated recombination within subcortical circuitry, it is 
possible that altered reward pathway activity influenced FMI performance. The latency to 
initiate (LTI) a trial provides a measure of motivation; for example, rats administered 
amphetamine show a reduction in LTI in a related task (Rojas-Leguizamón et al., 2018). 
However, we noted that mutants did not differ from controls in the median LTI at 2s and 
4s, indicating that motivation to obtain rewards was not significantly altered between 
conditions (Tukey’s b post-hoc test - 2s: t(21) = 1.39, p=0.18; 4s: t(21) = -0.29, p=0.77) 
(Figure 6J). We found that during the 8s FMI, mutant mice exhibited a statistically 
significant increase in LTI (t(20) = 2.43, p < 0.05). This apparent loss of motivation is 
likely due to the fact that the mean median asymptotic IRT did not reach the 8s criterion 
even after 32 days of testing (control: 8.45s ± 1.04; mutant: 7.26s ± 1.09) and is also 
consistent with the statistically significant reduction in mean obtained reinforcers at the 8s 
FMI (Figure 6K). Collectively, our data indicate that altered GABAergic circuitry regulates 
acquisition of response inhibition capacity in mice and may contribute to ADHD 
phenotypes associated with the RASopathies. 
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Figure 6. caMek1 Slc32A1:Cre mice exhibit reduced behavioral response inhibition 
capacity. (A-F). P-ERK1/2 labeling in PFC PNs is significantly reduced in mutants as 
compared to controls. Note the decrease in RFP+ CINs in the mutant PFC (E) relative to 
control (B) (n=3). (Scale bar = 100 µm) (G) Schematic of the Fixed-minimum Interval 
(FMI) task. (H) Mutant mice had a significant reduction in mean median IRT during FMI 
acquisition in 2s and 4s schedules (n=12, mean ± SEM, * = p < 0.05). (I) Mutant mean 
CQV of IRTs during both acquisition and asymptotic phases was significantly increased in 
2s, 4s, and 8s FMI schedules (mean ± SEM, * = p < 0.05). (J) Median acquisition and 
asymptotic LTI was significantly increased in the FMI 8s, but not in the 2s and 4s schedules 
(mean ± SEM, * = p < 0.05). (K) Mutant mice had a reduction in mean acquisition ORs at 
4s and a significant reduction in both mean acquisition and asymptotic ORs during the 8s 
FMI (mean ± SEM, * = p < 0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  110 
Discussion 
Here, we show that GABAergic neuron-autonomous MEK1 hyperactivation causes 
the death of a subset of immature GABAergic neurons in the embryonic subpallium and is 
associated with a selective reduction in PV-CIN density, but not SST-CINs, in adulthood.  
We observed a significant reduction in perisomatic GABAergic synapses on layer 2/3 PNs 
and forebrain hyperexcitability, but a surprising increase in the extent of PNN 
accumulation in mutant PV-CINs. While mutants displayed relatively normal performance 
in assays of locomotion, sociability, and anxiety, we found notable defects in acquisition 
of behavioral response inhibition capacity, which has been linked to ADHD. These data 
suggest that GABAergic neuron-autonomous MEK1 hyperactivation selectively regulates 
embryonic PV-CIN survival and is an important contributor to seizure risk and cognitive 
deficits in the RASopathies. 
While expression of ERK/MAPK pathway components is widespread, our findings 
reinforce the notion that expression levels are variable, and activation of this cascade is 
highly cell-type dependent. Cell-specific transcriptomic experiments have reported that 
RNA levels of Mapk1/Erk2 and Map2k1/Mek1, but not Mapk3/Erk1 or Map2k2/Mek2, are 
lower in CINs relative to PNs (Mardinly et al., 2016). We have extended these findings to 
show that protein levels of MAPK1/ERK2 and MAP2K1/MEK1 are typically lower in 
CINs than in surrounding PNs. Reduced expression of pan-ERK/MAPK components may 
contribute to the relatively low levels of phosphorylated ERK1/2 in CINs. Past work has 
shown that the experience-dependent transcriptional response in V1 PV-CINs is 
significantly smaller relative to PNs (Hrvatin et al., 2018). A more stringent degree of 
ERK/MAPK recruitment in CINs might contribute to reduced activity-dependent 
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transcription. Further analysis of activity-dependent responses in ERK/MAPK-mutant 
mice may assist in defining how CIN-specific functional properties are encoded 
(Tyssowski et al., 2018).  
Defects in GABAergic circuitry have been implicated in the pathogenesis of Rett, 
Fragile X, schizophrenia and many other neurodevelopmental diseases (Chao et al., 2010; 
Cui et al., 2008; Steullet et al., 2017). Reduced PV-CIN number is often observed, 
however, the mechanism of loss is poorly understood. We show that MEK1 
hyperactivation drives the GABAergic-neuron autonomous activation of caspase-3 and 
death of a subset of immature neurons in the embryonic ganglionic eminences. The 
selective reduction in PV-CIN density in the postnatal cortex suggests these early dying 
neurons were committed to the PV lineage. The death of this specific subset of GABAergic 
neurons occurs much earlier than the typical period of programmed cell death for CINs 
(Denaxa et al., 2018; Southwell et al., 2012) . Notably, caMek1 expression in cortical 
excitatory neurons is not associated with significant neuronal loss during development 
(Nateri et al., 2007; Xing et al., 2016). Though ERK/MAPK typically acts as a promoter 
of cell survival, apoptotic death by sustained ERK/MAPK activity has been described in 
certain contexts (Cagnol and Chambard, 2010; Martin and Pognonec, 2010). It will be 
important to evaluate whether treatment with pharmacological MEK1/2 inhibitors or 
antioxidants during embryogenesis is capable of sustained restoration of CIN number in 
caMek1, Slc32A1:Cre mice. PV-CIN sensitivity to MEK1 hyperactivation may not only be 
an important factor in RASopathy neuropathology, but could be a relevant mechanism in 
other conditions that involve indirect activation of ERK/MAPK signaling during 
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embryogenesis, such as schizophrenia, Fragile X Syndrome, or prenatal stress (Fowke et 
al., 2018). 
Recent scRNAseq analyses suggest the mature transcriptional signature of cardinal 
CIN subtypes is not fully specified until CINs migrate into the cortex (Mayer et al., 2018; 
Paul et al., 2017; Sandberg et al., 2018). MEF2C, a known substrate of ERK1/2 and p38 
signaling, was identified as a transcription factor expressed early in the presumptive PV 
lineage, the deletion of which also leads to the selective reduction of PV-CINs (Mayer et 
al., 2018). Thus, regulation of MEF2C could mediate early effects of caMEK1 signaling 
on GABAergic neuron development. While further research is necessary, the selective 
vulnerability of presumptive PV-CINs to hyperactive MEK1 signaling may not be 
dependent upon a specific downstream transcriptional target. Compared to transcriptional 
networks, less is known regarding the function of many post-translational modifications 
during CIN specification. Our data hint at selective roles for kinase signaling networks at 
an early stage of CIN lineage differentiation. 
Despite the effect of caMEK1 on early GABAergic neuron survival, the 
physiological maturation of mature caMek1-expressing PV-CINs was not significantly 
impeded. Surviving PV-CINs retained a characteristic fast-spiking signature with only 
minor differences in intrinsic electrophysiological parameters. We noted a modest, but 
statistically significant decrease in perisomatic inhibitory synapse number on cortical PNs 
in mutant mice. As might be expected, a subset of mutant animals exhibited forebrain 
hyperexcitability and sudden behavioral arrest similar to that reported in animal models of 
mild seizures. Overexpression of a similar caMek1 mutation with CamKII:Cre has also 
been shown to cause seizure-like activity (Nateri et al., 2007). Overall, our findings indicate 
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that MEK1 hyperactivation in GABAergic neurons could increase the risk of epilepsy seen 
in RASopathies.  
The PNN is a critically important structure involved in the maturation of cortical 
circuitry with an important role in protecting PV-CINs from oxidative stress and limiting 
synaptic plasticity (Cabungcal et al., 2013; Hensch, 2005a; Hensch, 2005b; Morishita et 
al., 2015). Mouse models of schizophrenia, Fragile X, and ASDs often exhibit reduced PV-
CIN number and typically display a reduction in PNN formation (Steullet et al., 2017). In 
contrast to these disorders, PNNs appear to respond differently to RASopathy mutations. 
PV-CINs accumulate extracellular PNNs derived primarily from astrocyte-produced 
CSPGs (Galtrey and Fawcett, 2007; Sorg et al., 2016). RASopathic astrocytes upregulate 
secreted ECM-associated CSPGs and promote an increase in the extent of PNN 
accumulation around PV-CINs (Krencik et al., 2015). Our data is the first to indicate a PV-
CIN autonomous role for enhanced PNN accumulation in response to MEK1 
hyperactivation. It is thought that increased PNN accumulation on PV-CINs limits the 
plasticity of cortical regions (Pizzorusso et al., 2002). Modification of PNN levels may 
serve as a useful therapeutic strategy for the impaired cognitive function and intellectual 
disability frequently reported in RASopathy individuals (Tidyman and Rauen, 2016).  
In addition to intellectual disability, ADHD is frequently diagnosed in Noonan 
Syndrome and NF1, two common RASopathies (Johnson et al., 2019; Miguel et al., 2015; 
Pierpont et al., 2015). Abnormal PFC function has been linked to ADHD (Seidman et al., 
2006). Interestingly, we detected significantly reduced P-ERK1/2 levels in PFC PNs of 
mutant mice, suggesting that RASopathic CINs may alter the global development and 
function of this brain region. GABAergic signaling is known to be necessary for cortical 
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circuit maturation (Cancedda et al., 2007). We further examined ADHD-related behavioral 
phenotypes in caMek1, Slc32A1:Cre mice by assessing behavioral response inhibition 
capacity with a fixed-minimum interval (FMI) based task (Rojas-Leguizamón et al., 2018; 
Watterson et al., 2015). We detected significant deficits in the acquisition of response 
inhibition dependent behaviors in mutant mice relative to controls. It is plausible that FMI 
defects in caMEK1 mutants is due to the reduced plasticity of PFC GABAergic circuitry 
in response to heightened levels of PNN or GABAergic-dependent changes in PN 
development. These data show that GABAergic-directed MEK1 hyperactivation is 
sufficient to drive deficits in behavioral response inhibition possibly associated with 
ADHD. 
 Mutations in ‘upstream’ RASopathy genes modulate a much broader set of 
downstream cascades when compared to mutations in Raf or Mek1/2. Nf1, Ptpn11/Shp2, 
and Syngap1 mutations result in a complex constellation of cellular changes, some of which 
depend upon ERK/MAPK modulation, whereas others involve different signaling cascades 
(Anastasaki and Gutmann, 2014; Brown et al., 2012). In combination with the findings of 
(Angara et al., 2019, co-submitted), it is clear that PV-CIN development is particularly 
sensitive to convergent signaling via NF1 and ERK/MAPK. Additional studies of human 
samples will be necessary to determine whether defective GABAergic circuits are a 
component of RASopathy pathogenesis. Collectively, our research suggests that 
hyperactivation of MEK1 in GABAergic neurons represents an important candidate 
mechanism for epilepsy and cognitive defects in RASopathic individuals. 
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Figure S1. Increased MEK1 expression in embryonic and postnatal mutant brains 
(A-H) Representative coronal sections of E13.5 developing mouse forebrain 
immunolabeled for MEK1. High expression of MEK1 was detected in RFP-labeled cells 
in caMek1 Slc32A1:Cre ganglionic eminences and CIN migratory streams (compare C to 
G; D to H). (I) CaMek1 Slc32A1:Cre mice exhibited significantly increased body mass in 
adulthood as compared to controls (n = 12 controls, 12 mutants; mean ± SEM, * = p < 
0.05). (J-O) Mutant CINs display increased MEK1 expression into adulthood (n=3). (Scale 
bar = 25 µm). 
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Figure S2. Reduced PV-CINs in caMek1, Dlx5/6:Cre and caMek1, Nkx2.1:Cre brains. 
(A-D) P30 coronal sections of caMek1 Dlx5/6:Cre primary sensory cortex revealed a 
substantial qualitative decrease in the number of PV-CINs relative to controls (n=3). (E-
M) Representative confocal images of P14 caMek1 Nkx2.1:Cre sensory cortices 
immunolabeled for PV. The number of PV+/RFP+ co-expressing cells was significantly 
decreased in mutants as compared to littermate controls (quantification in M: n = 3; mean 
± SEM, * = p < 0.05). 
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Figure S3. Loss of CINs in late embryogenesis (A-D) Representative confocal 
micrographs of the E17.5 developing cortical plate. A significant decrease in the number 
of RFP+ CINs was detected in caMek1 Slc32A1:Cre embryos (quantification in E: n = 3; 
mean ± SEM, * = p < 0.05). 
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Figure S4. Mutant mice exhibit normal locomotor and anxiety-like behaviors (A-B) 
CaMek1 Slc32A1:Cre mice (n = 25 control, 13 mutant) were assessed for locomotor, 
anxiety-like behaviors, and sociability in the open field task. No significant differences in 
distance traveled or center time were observed throughout 10 min of open field testing. (C-
E) Elevated plus maze testing did not detect a significant difference in % open arm entries 
or % time spent in open arms. (F-H) In the social approach assay mutants did not 
significantly differ from controls in total entries, time spent in the social side, or social side 
entries. 
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Figure S5. Normal GABAergic synaptic area in cortical neuropil and PV-CIN 
oxidative stress (A-E) Mutant mice exhibited normal VGAT-labeling in the layer 2/3 
neuropil (quantification in E; n = 33 control, 30 mutant regions, mean ± SEM). (F-I) 
Expression of the DNA oxidation marker 8-oxo-dg expression in WFA+ caMek1 
Slc32A1:Cre CINs was qualitatively unchanged when compared to control WFA+ CINs 
(control in F-G, mutant in H-I). (Scale bar = 25 µm). 
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Abstract 
 Aberrant ERK/MAPK pathway activity is commonly observed in a family of 
neurodevelopmental syndromes called the “RASopathies.” Though many mutations in 
upstream regulators of RAS signaling and the core kinases of the ERK/MAPK pathway 
result in increased activity of the principal ERK1/2 proteins, some mutations may also 
reduce cascade activity. In addition, disorders such as 16p11.2 microdeletion syndrome 
and distal 22q11 microdeletion may also result in reduced ERK/MAPK activity. Cortical 
GABAergic interneurons (CINs) are an important, heterogeneous subgroup of neurons 
necessary for excitatory/inhibitory balance in the brain and processes such as learning and 
memory. The basic functions of ERK1/2 in CIN development and function have not been 
well studied. Here, we show that the initial establishment of CIN number does not require 
ERK1/2. No differences in the number parvalbumin-expressing (PV) CIN number were 
detected; however, we observed a striking reduction in the density of somatostatin-
expressing (SST) CINs by P14. Reduced SST-expression persisted into adulthood, 
suggesting SST-CINs require ERK1/2 for their specification. In addition, we have 
developed a unique CIN-specific chemogenetic tool to modulate GABAergic circuit 
activity. Our results suggest a CIN subtype-specific requirement for ERK1/2 during 
development and may inform future therapeutic studies aiming to repair defective 
GABAergic circuitry. 
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Introduction 
 The canonical ERK/MAPK cascade is a ubiquitously utilized intracellular kinase 
pathway that is dynamically expressed during brain development. Mutations within the 
ERK/MAPK cascade, typically resulting in increased pathway activity, drive the 
pathogenesis of a family of neurodevelopmental syndromes collectively termed the 
“RASopathies” (Rauen et al., 2013). However, copy number variants of core kinases in the 
ERK/MAPK cascade can reduce pathway activity. Loss of ERK/MAPK activity has been 
observed in 16p11.2 microdeletion syndrome, which accounts for 1% of all ASD cases, a 
locus of 11 genes that includes MAPK3/ERK1 (Pucilowska et al., 2012; Pucilowska et al., 
2008; Pucilowska et al., 2018; Pucilowska et al., 2015; Vithayathil et al., 2018). Distal 
22q11 microdeletion, a chromosomal abnormality often associated with DiGeorge 
Syndrome, results in copy number variants of MAPK1/ERK2 (Newbern et al., 2008; Saitta 
et al., 2004; Samuels et al., 2009). Recently, loss-of-function mutations within 
MAP2K2/MEK2 was implicated in rare cases of the RASopathies (Nowaczyk et al., 2014). 
Collectively, individuals with these disorders experience neurological symptoms including 
intellectual disability, developmental delay, autistic behaviors, and epilepsy (Rauen et al., 
2013). A holistic understanding of how alterations in ERK/MAPK signaling during brain 
development give rise to neurological dysfunction will be important in future therapeutic 
design. 
 The normal development and maturation of the cerebral cortex broadly requires 
ERK1/2 signaling. However, the complexity of neural circuit composition poses challenges 
in understanding the basic functions of ERK/MAPK signaling in cortical development, and 
importantly, how aberrant ERK/MAPK activity results in neurological dysfunction. In 
  125 
particular, differential expression of ERK/MAPK pathway components in cortical cell 
types suggests that individual groups of cells may be more susceptible to specific mutations 
than others. Indeed, pallial cell types such as radial glia, glutamatergic projection neurons 
(PNs), and astrocytes differentially express regulators of RAS activity such as Syngap1 and 
Nf1, and RAS downstream kinases Map2k1 and Erk2 (Loo et al., 2019; Mardinly et al., 
2016). Dysfunctional PN circuits appear to be the primary driver of neurological 
dysfunction in Syngap1 mutant mice, whereas neurological phenotypes in Nf1 mutants 
appear to be mediated primarily by abnormal GABAergic circuits (Cui et al., 2008; Ozkan 
et al., 2014). Thus, specific disease-causing gene mutations in regulators and canonical 
kinases of the ERK/MAPK pathway differentially affect unique cortical cell populations. 
Furthermore, it is unclear how downstream intracellular kinase cascades mediate 
the development individual cell types and how changes in their activity drive 
neuropathogenesis. During pallial development, loss of ERK1/2 from radial glia leads to 
the complete lack of gliogenesis and cortical thinning, which can be rescued by re-
expression of the Ets family transcription factor, Erm (Li et al., 2012b; Pucilowska et al., 
2008; Pucilowska et al., 2015). Long-range PNs populating layer 5 of the cortex require 
ERK1/2 for sustained survival, though layer 2/3 neurons are minimally affected (Xing et 
al., 2016). While the roles of ERK1/2 have been well studied in pallial cell types, it is 
currently unclear how cortical cell populations originating in the subpallium are affected 
by loss of ERK1/2.  
 Cortical GABAergic interneurons (CINs) comprise 20% of all cortical neurons and 
provide the inhibitory balance to excitation (Wonders and Anderson, 2006). CINs are 
functionally diverse and exhibit differential gene expression, morphological 
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characteristics, patterns of connectivity, and electrophysiological signatures (DeFelipe et 
al., 2013; Fino et al., 2013; Rudy et al., 2011). In particular, parvalbumin (PV) and 
somatostatin (SST) -expressing CINs constitute the most populous subtypes. PV- and SST-
CINs originate in spatiotemporal fashion primarily from the medial ganglionic eminence 
(MGE) and migrate tangentially to the cortical plate (Rudy et al., 2011). Tangential 
migration requires extensive chemotaxic regulation, and recruits ERK/MAPK-independent 
kinase pathways (Flames et al., 2004; Marin, 2013; Marin and Rubenstein, 2001; Polleux 
et al., 2002; Stanco et al., 2009). Once in the cortical plate, neuregulin-3 signaling mediates 
the transition to radial migration and is subsequently important for laminar allocation of 
CINs (Bartolini et al., 2017). Despite a significant transcriptomic basis for CIN identity 
(Lim et al., 2018; Mi et al., 2018), recent evidence suggests differential activation of 
intracellular signaling cascades may be essential for certain aspects of CIN development 
(McKenzie et al., 2019). Interestingly, Ryk-dependent Wnt signaling controls the balance 
between PV- and SST-CIN generation in the MGE (McKenzie et al., 2019). Furthermore, 
abnormal receptor tyrosine kinase (RTK) signaling disrupts GABAergic interneuron 
maturation in the postnatal cortex (Fazzari et al., 2010). Hyperactive MEK1 downstream 
of RTKs in the developing subpallium disrupts early postmitotic PV-CIN maturation and 
drives the death of a subset of these cells (Holter et al., 2019; unpublished). The basic roles 
of principal ERK1/2 isoforms in CIN development have not been explored. 
 Here we examined the functions of ERK1/2 signaling in CIN development. We 
show that ERK1/2 is dispensable for the initial establishment of CIN number. Interestingly, 
we observed a significant reduction in the expression of SST in the postnatal cortex, but 
normal densities of PV-expressing CINs. Consistent with these observations, we found 
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qualitatively normal perineuronal net (PNN) accumulation, a major extracellular matrix 
(ECM) structure necessary for the functional maturation of PV-CINs and cortical circuits. 
Adult mutant mice exhibited a significant reduction in total distance travelled in the Open 
Field task. Additionally, we observed a global reduction in the cortical projection neuron 
(PN) expression of the activity-dependent gene, Arc. To determine whether major ERK1/2 
related phenotypes could be rescued through ERK/MAPK independent means, we 
generated mice expressing an HM3Dq chemogenetic construct selectively in CINs to 
mimic glutamatergic input in inhibitory circuits in adulthood. Collectively, our results 
suggest a critically important role for ERK1/2 in the maturation of GABAergic circuits that 
may underlie some aspects of ERK/MAPK-linked neuropathology. 
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Materials and Methods 
Mice  
All mice were handled and housed in accordance with the guidelines of the 
Institutional Animal Care and Use Committee at Arizona State University. Mice were free 
to feed ad libitum and were housed under a daily 12-hour light-dark cycle. To generate 
ERK1/2 loss-of-function mutants, mice expressing Slc32A1:Cre+/+, Dlx5/6:Cre+/-, or 
Nkx2.1:Cre+/- to mice possessing a neo-insertion in exons 1-7 in the Mapk3/Erk1 gene 
(herein referred to as Mapk3/Erk1-/-). Transgenic mice were then bred with another strain 
containing a loxp flanked exon 2 in the Mapk1/Erk2 gene (referred to as Mapk1/Erk2fl/fl). 
Littermates expressing Cre-Recombinase containing one functional copy of Mapk1/Erk2 
in CINs were used as controls. Either a cre-dependent tdTomato (Ai9) or eYFP (Ai3) strain 
was used to visualize fluorescently-labeled cre-expressing cells. We extracted genomic 
DNA from tail or toe samples for genotyping by PCR. The primers used for genotyping 
were as follows: (listed 5’-3’): Cre – TTCGCAAGAACCTGATGGAC and 
CATTGCTGTCACTTGGTCGT to amplify a 266 bp fragment; Mapk3/Erk1 –
AAGGTTAACATCCGGTCCAGCA, AAGCAAGGCTAAGCCGTACC, and 
CATGCTCCAGACTGCCTTGG to amplify a 571 bp segment wild type and a 250 bp 
segment KO allele; Mapk1/Erk2 – AGCCAACAATCCCAAACCTG, and 
GGCTGCAACCATCTCACAAT amplify 275 bp wild-type and 350 bp floxed 
alleles; Ai3/Ai9 – four primers were used - AAGGGAGCTGCAGTGGAGTA, 
CCGAAAATCTGTGGGAAGTC, ACATGGTCCTGCTGGAGTTC, and 
GGCATTAAAGCAGCGTATCC amplify a 297 bp wt Rosa26 segment and a 212 bp 
  129 
Ai3/Ai9 allele; and hM3Dq – CGCCACCATGTACCCATAC and 
GTGGTACCGTCTGGAGAGGA to amplify a 204 bp fragment. 
 
Tissue Preparation and Immunostaining  
Mice of the specified age were anesthetized and perfused with cold 1X PBS 
followed by a 4% PFA in 1X PBS solution. Brains were then removed and post-fixed 
overnight at 4C. Brains were then sliced with a vibratome or were cryoprotected for 
preparation on a cryostat. Sectioned brain tissue was then incubated overnight at 4C in a 
primary antibody solution diluted in 0.05 – 0.2% Triton in 1X PBS with 5% Normal 
Donkey Serum (NDS). Primary antibodies were: rabbit anti-Somatostatin (Peninsula, 
1:1000), Parvalbumin (Swant, 1:1000), rabbit anti-Arc (Synaptic Systems, 1:1000), chick 
anti-GFP (Aves, 1:1000), chick anti-RFP (Rockland, 1:1000), biotin-conjugated WFA 
(Vector, 60ug/mL), rabbit anti-Erk2 (Abcam, 1:1000), mouse anti-NeuN (Millipore, 
1:1000), and  anti-HA (Biolegend, 1:1000). Tissue incubated in primary solution was then 
washed three times 1X PBS 0.05% Triton and incubated in a solution containing Alexa-
Fluor 488, 568, and 647 conjugated anti-rabbit, anti-goat, and anti-chick secondary 
antibodies. Secondaries were diluted to 1:1000 in 1X PBS 0.05 – 0.2% Triton and 5% NDS. 
A separate streptavidin-conjugated fluorophore was used specifically for WFA-labeled 
tissue. A Zeiss (LSM710 & LSM800) laser scanning confocal microscope was to collect 
representative images which were optimized for brightness and contrast in Adobe 
Photoshop and prepared for presentation purposes in Adobe Illustrator. 
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Image Analysis 
 Images from no fewer than three regions of interest per mouse were quantified for 
cell density by an observer blinded to genotype. In order to estimate cortical cell density, a 
cortical column was defined in Photoshop, the area was acquired, and labeled cells were 
quantified. For some experiments, cell densities were performed on endogenously-labeled 
cells by examination of the cre-dependent fluorescent protein. The mean cell density from 
three or more regions of interest was calculated for each mouse. A minimum of three mice 
were collected for each genotype and results were statistically analyzed by Student’s t-test. 
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Results 
Loss of ERK1/2 signaling does not alter CIN number  
ERK/MAPK activity is necessary for the survival and physiological maturation of 
select dorsal-derived PNs (Li et al., 2012b; Xing et al., 2016), but it is unclear if 
ERK/MAPK regulates CIN number in vivo. We therefore generated quadruple transgenic 
mice with germline deletion of Mapk3/Erk1 (Erk1-/-), CKO of Mapk1/Erk2 alleles (Erk2fl/fl) 
and Ai9 with Slc32A1:Cre expressing strain. Erk1-/-, Erk2fl/fl, Ai9, Slc32A1:Cre mice were 
obtained at normal Mendelian ratios, but exhibited profound growth delay by the end of 
the first postnatal week and lethality in the second to third postnatal week (n=10). No gross 
neuroanatomical abnormalities between mutant and control brains were observed in the 
first postnatal week (Figure 1A, B). ERK2 immunolabeling confirmed a reduction of ERK2 
protein in mutant CINs in comparison to controls (Figure 1C-H). We then examined the 
relative density of RFP+ CINs in mutant cortices to controls. No significant difference in 
the relative density of CINs was observed between mutant and control cortices (Figure 1I-
L, M). Similar results were obtained in the S1 of Erk1-/-, Erk2fl/fl, Dlx5/6:Cre, Ai3 mice, 
which also restricts recombination to post-mitotic CINs in the ventral telencephalon 
(Supplemental Figure 1A-D). Early growth delay and lethality limited further assessment 
of GABAergic maturation and subtype specification in both Erk1-/-, Erk2fl/fl, Dlx5/6:Cre 
and Slc32A1:Cre brains. Nonetheless, these data suggest that ERK/MAPK signaling is 
dispensable for the initial establishment of CIN number. 
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Figure 1. Loss of ERK1/2 does not alter CIN number. (A-B) Representative images of 
P6 coronal brain slices show no gross anatomical defects between Erk1-/-, Erk2fl/fl, 
Slc32A1:Cre, Ai9 mutants and Erk1-/-, Erk2fl/wt, Slc32A1:Cre, Ai9 controls. (C-H) Reduced 
ERK2 protein was observed in layer V Ai9-expressing CINs in mutant primary 
somatosensory cortices in comparison to controls. (Scale bar = 3 µm) (I-L) No difference 
in the density of Ai9-expressing CINs was observed between mutants and controls 
(quantification in M; n=3, mean ± SEM, p > 0.05). (Scale bar = 100 µm). 
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ERK1/2 is required for the specification of SST-expressing CINs but not PV-CINs 
 PV-CINs are sensitive to RASopathy-linked mutations (Holter et al., 2019 
unpublished; Krenick et al., 2015). The onset of the expression PV occurs within the second 
postnatal week (del Río et al., 1994; Huang et al., 1999; Soriano et al., 1992). Neonatal 
death of Erk1-/-, Erk2fl/fl, Ai9, Slc32A1:Cre mice therefore barred further assessment of 
Erk1/2 loss on maturing PV- and SST-CINs. To further assess subtype-specific effects of 
ERK1/2 CKO on CINs, we generated Erk1-/-, Erk2fl/fl, Nkx2.1:Cre, Ai3 mice to restrict Cre-
mediated recombination to forebrain cells derived from the MGE. Mutant mice were fully 
viable with mild growth abnormalities, and adult brains were normal in appearance with 
no apparent differences in size. Consistent with our findings from Erk1-/-, Erk2fl/fl, Ai9, 
Slc32A1:Cre mice, quantitative assessment of fluorescently-labeled CINs in Erk1-/-, 
Erk2fl/fl, Nkx2.1:Cre, Ai3 P14 mutant sensory cortices revealed no change in EYFP-cell 
density as compared to Erk1-/-, Erk2fl/wt, Nkx2.1:Cre, Ai3 controls (Figure 2A-H, Q). 
Immunolabeling for PV revealed no change in PV-CIN density (Figure 2C, G, R), however, 
we observed a significant reduction in the density of SST immunoreactive CINs at the end 
of the second postnatal week (Figure 2D, H, R). Furthermore, the density of EYFP-
expressing cells was unchanged in the adult sensory cortex (Figure 2I-P, Q). Reduced SST-
immunoreactivity persisted into the adult cortex (Figure 2L, P, Q). Taken together, loss of 
ERK1/2 signaling is sufficient to disrupt specific aspects of SST-CIN identity but does not 
appear to alter PV-CIN specification. 
 
 
  134 
 
  135 
Figure 2. SST-CINs are selectively vulnerable to reduced ERK1/2 signaling. (A-H) 
Representative confocal images of P14 Erk1-/-, Erk2fl/wt, Nkx2.1:Cre, Ai3 and Erk1-/-, 
Erk2fl/fl, Nkx2.1:Cre, Ai3 mouse sensory cortices. No difference in the density of EYFP-
expressing cells was detected (B, F, quantification in Q; mean ± SEM, p > 0.05). No 
difference in PV-CINs was detected between mutants and controls (C, G, quantification in 
R; mean ± SEM, p > 0.05). A significant decrease in the density of SST/EYFP cells was 
detected in the mutant sensory cortex (D, H, quantification in R; mean ± SEM, p < 0.05). 
(I-P) Confocal micrographs of P60 Erk1-/-, Erk2fl/wt, Nkx2.1:Cre, Ai3 and Erk1-/-, Erk2fl/fl, 
Nkx2.1:Cre, Ai3 mature sensory cortices. We detected no change in the density of EYFP+ 
CINs (J, N, quantification in Q; mean ± SEM, p > 0.05). PV-CIN density was unchanged 
in the sensory cortex (K, O, quantification in R; mean ± SEM, p > 0.05). Reduced SST-
expression persisted into adulthood (L, P, quantification in Q; mean ± SEM, p < 0.05). 
Images and graphs generated by Johan Martinez and prepped for presentation by Michael 
Holter. 
 
 
PV-CINs do not require ERK1/2 for perineuronal net formation 
 Extracellular matrix (ECM) remodeling constitutes the end of critical period 
plasticity and is a fundamental process in the maturation of cortical circuits (Hensch, 
2005a; Hensch, 2005b). PV-CINs preferentially sequester members of the chondroitin 
sulfate proteoglycan (CSPG) family derived primarily from protoplasmic astrocytes. 
Aberrant PNN formation has been observed in numerous neurodevelopmental disease 
states (Steullet et al., 2017) and may be a primary contributor to the pathology of the 
RASopathies (Krencik et al., 2015). Gain-of-function ERK/MAPK signaling in CINs or 
astrocytes is sufficient to increase accumulation of PNN components (Holter et al., 2019, 
unpublished; Krencik et al., 2015), though reduced PNN accumulation has been observed 
in other models of neurodevelopmental disease (Bitanihirwe and Woo, 2014; Cabungcal et 
al., 2013; Krishnan et al., 2015; Steullet et al., 2017). We therefore asked whether loss of 
ERK1/2 in CINs was sufficient to disrupt PNN formation. 
 To assess the extent of PNN sequestering around PV-CINs, we stained Erk1-/-, 
Erk2fl/fl, Nkx2.1:Cre, Ai3 mutant and Erk1-/-, Erk2fl/wt, Nkx2.1:Cre, Ai3 control brain 
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sections with the lectin wisteria floribunda agglutinin (WFA) (Figure 3A-D). We observed 
no change in the pattern of cortical WFA-labeling, and all PV-expressing CINs in the adult 
mutant sensory cortex co-labeled with WFA (Figure 3, compare A to C). The extent of 
PNN accumulation around PV-CINs appeared qualitatively normal between mutant and 
control cortices (Figure 3B, D). We did not observe aberrant accumulation of PNNs around 
PV- CINs. Collectively, these findings suggest that loss of ERK1/2 in developing 
GABAergic circuits was not sufficient to alter PV-CIN maturation and critical ECM 
remodeling processes. 
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Figure 3. The extent of PNN accumulation around PV-CINs is unchanged in ERK1/2 
CKO mice. (A-D) Representative confocal micrographs of adult Erk1-/-, Erk2fl/wt, 
Nkx2.1:Cre and Erk1-/-, Erk2fl/fl, Nkx2.1:Cre sensory cortices. The pattern of WFA labeling 
did not appear to differ between controls and mutants. All PV-CINs in the mutant sensory 
cortex accumulated a PNN (compare A to C). Qualitative assessment suggests that PNN 
formation is unaltered in response to ERK1/2 deletion from MGE-derived CINs. 
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Reduction of activity-dependent gene expression in cortical projection neurons 
During the first postnatal week, GABA binding exerts trophic effects in cortical 
circuits that are essential for normal maturation of PNs (Ben-Ari, 2002; Cancedda et al., 
2007; Pan et al., 2019). GABA signaling becomes inhibitory near the end of the first 
postnatal week after cortical expression of KCC2, which reverses the Cl- gradient. Early 
PN neurite outgrowth and subsequent dendritic arborization requires inotropic and 
metabotropic GABAergic stimulation (Cancedda et al., 2007). SST-expressing CINs form 
synaptic contacts primarily in the dendrites of PNs and participate broadly in neural 
computation. We therefore hypothesized that abnormalities in SST-CIN development in 
Erk1-/-, Erk2fl/fl, Nkx2.1:Cre mice may therefore alter specific processes in PN development 
and drive changes in PN excitability. To understand cortical circuit-wide ramifications of 
abnormal SST-CIN development, we examined global levels of activity-dependent gene 
expression in adult mice (Figure 4). Interestingly, we found that Erk1-/-, Erk2fl/fl, 
Nkx2.1:Cre, Ai3 mutant brains had a significant reduction in cortical layer 2/3 expression 
of Activity-regulated cytoskeletal (Arc) protein than Erk1-/-, Erk2fl/wt, Nkx2.1:Cre, Ai3 
controls (Figure 4A, B). Taken together, loss of ERK1/2 from CINs is sufficient to disrupt 
broad cortical circuit activity in adulthood.  
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Figure 4. Disrupted Arc expression in layer 2/3 cortical PNs. (A, B) Representative 
regions of adult Erk1-/-, Erk2fl/wt, Nkx2.1:Cre and Erk1-/-, Erk2fl/fl, Nkx2.1:Cre cortices. We 
observed a significant decrease in the expression of Arc in PNs populating layer 2/3 of the 
mutant cortex in comparison to controls. No qualitative changes in deep layer 5/6 Arc 
expression was observed in mutant cortices. Images generated by Johan Martinez. 
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Generation of Erk1-/-, Erk2fl/fl, hM3Dq, Nkx2.1:Cre mice 
 Neural activity through cortical circuits is imperative for the normal maturation of 
specific groups of neurons, including both excitatory and inhibitory neurons (Bartolini et 
al., 2013; Chattopadhyaya et al., 2004; Close et al., 2012; Le Magueresse and Monyer, 
2013; Mardinly et al., 2016; Pan et al., 2019; Wamsley and Fishell, 2017). Recent 
developments of chemogenetic tools termed Designer Receptors Exclusively Activated by 
Designer Drugs (DREADDs) have made possible the non-invasive modulation of neural 
circuit activity (Armbruster et al., 2007; Dimidschstein et al., 2016; Roth, 2016). We 
hypothesized that increased activation of ERK/MAPK-deleted CINs in adulthood is 
sufficient to rescue global cortical hypoexcitability. We therefore generated   Erk1-/-, 
Erk2fl/fl, hM3Dq, Nkx2.1:Cre mice, which express a genetically encoded human muscarinic 
receptor to activate neural circuits in response to clozapine N-oxide (CNO) administration 
(Figure 5) (Armbruster et al., 2007; Roth, 2016). CNO binding increases levels of 
intracellular calcium, allowing for temporal control over neural circuit activity (Roth, 
2016). 
Expression of the hemagglutinin (HA)-tagged hM3Dq localized to the membrane 
of MGE-derived CIN subtypes, including some PV-CINs (Figure 5A-C). Expression of 
HA was observed throughout the cortical layers and localized to CIN soma, dendrites, and 
axonal projections (Figure 5C). Consistent with previous reports of some PV-CINs 
generated by non-Nkx2.1 expressing progenitors (Miyoshi et al., 2010), we detected PV-
CINs that did not express the HA-tag populating the superficial cortical layers (Figure 5D-
F, yellow inset). Furthermore, we observed co-labeling of HA with PV in deeper cortical 
layers, consistent with migration tendencies of PV-CINs derived from the MGE (Bartolini 
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et al., 2017) (Figure 5G-I). The specificity of hM3Dq for CINs in this model may provide 
a powerful tool for modulating GABAergic circuit activity and exploration of repairing 
cortical circuit abnormalities in response to CIN-specific ERK1/2 CKO.  
 
 
 
 
 
 
 
 
 
 
 
 
  142 
 
Figure 5. hM3Dq expression is detectable in ERK1/2-deleted CINs. (A-C) 
Representative confocal micrographs of HA and PV immunolabeling in Erk1-/-, Erk2fl/fl, 
hM3Dq, Nkx2.1:Cre mutant mice. (A) Colocalization of the HA-tagged hM3Dq receptor 
was observed in PV-expressing CINs throughout the cortex. (B) PV-CIN distribution 
within the CIN-specific ERK1/2 CKO sensory cortex. (C) HA immunolabeling shows 
extensive dendritic and axonal distribution of hM3Dq in CINs. (D-F) Some PV+ CINs 
located in layer 2/3 did not express HA (yellow arrows). (G-I) Deep layer PV-CINs 
expressed high levels of HA. (Cortical bar: scale bar = 100μm; insets: scale bar = 25μm). 
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Discussion 
 
 Here, we show that loss of ERK1/2 signaling during CIN development disrupts the 
specification of SST-CINs. Interestingly, reduced ERK1/2 signaling in developing 
GABAergic circuits did not regulate the number of mature CINs. We observed no 
significant differences in the density or distribution of PV-expressing CINs at the end of 
the second postnatal week and into adulthood. All PV-CINs developed a PNN and 
exhibited a normal extent of PNN labeling. We did not detect aberrant formation of PNNs 
around PV- interneurons. Interestingly, we detected a significant decrease in the cortical 
expression of SST, suggesting that ERK1/2 is required for the specification and maturation 
of SST-CINs. These data suggest that canonical ERK/MAPK signaling has differential 
roles in the development of specific CIN subtypes and may be particularly impactful for 
future therapeutic design. 
Aberrant GABAergic circuit function is observed in a number of neurodevelopment 
syndromes (Chao et al., 2010; Cui et al., 2008; Pizzarelli and Cherubini, 2011). How 
changes in intracellular signaling pathways translate to changes in CIN development have 
only begun to be elucidated. We show that the principal kinases of the canonical 
ERK/MAPK pathway, ERK1/2, are required for the specification of SST-expressing CINs. 
Consistent with past studies, we show that loss of ERK1/2 does not regulate CIN migration 
from subpallial ganglionic eminences (Polleux et al., 2002). Interestingly, we detected a 
significant decrease in the amount of cortical SST-labeling but no change in the number of 
endogenously-labeled CINs. This selective loss of SST-expression suggests that 
ERK/MAPK signaling regulates crucial steps of SST-CIN development. During 
neurogenesis, SST transcripts can be detected in postmitotic GABAergic neurons as early 
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as E13.5 (Batista-Brito et al., 2008), and cortical expression of SST persists into adulthood. 
The events governing the loss of SST expression in the adult cortex are incompletely 
understood. SST expression is thought to be regulated in part by binding of the CRE 
response element in its promoter by P-CREB (Cha-Molstad et al., 2004; Gonzalez et al., 
1989). Thus, loss of SST expression may be driven by reduced phosphorylation of CREB 
in the absence of the ERK1/2 kinases. Moreover, it will be important to determine the 
temporal dynamics of SST expression loss. Recent work has shown that modulation of Ryk 
signaling during embryogenesis establishes the rostro-caudal axis of the MGE and biases 
progenitor divisions to specific CIN subtype fates (McKenzie et al., 2019). It is possible 
that SST-specification is altered at the progenitor stage in Erk1-/-, Erk2fl/fl, Nkx2.1:Cre 
embryos though unlikely due to the normal densities of PV-CINs in the adult cortex. 
Further work assessing the temporal dynamics of SST expression will be necessary to 
address this possibility and will be informative in understanding the basic functions of 
ERK1/2 in CIN generation and post-mitotic differentiation. 
Perturbation of GABA excitatory action during the first week of postnatal life leads 
to significant morphological defects of cortical PNs and may lead to abnormal behaviors 
(Cancedda et al., 2007). Here, we show that ERK1/2 deletion from a subset of CINs drives 
global changes in cortical expression of Arc, an immediate early gene highly expressed by 
PNs. Disruption of key PN dendritic arborization processes linked to aberrant GABA 
signaling may be an underlying cause of cortical hypoexcitability. Due to high affinity for 
SST synaptogenesis in the cortical neuropil (Fino et al., 2013), it is likely that abnormal 
SST development in the absence of ERK1/2 led to changes in PN morphological 
complexity. Furthermore, we have generated a CIN-specific hM3Dq chemogenetic mouse 
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line to examine the reversibility of SST expression loss and rescue of broad cortical circuit 
level abnormalities. It will be important to examine multiple temporal windows for 
prevention of these phenotypes, in particular due to drastic changes of GABA action in 
early postnatal cortical development (Ben-Ari, 2002). Reversibility of these phenotypes by 
modulation of neural activity would provide unprecedented insight into treating 
neurodevelopmental syndromes. 
Canonical ERK/MAPK signaling is a known regulator of morphological and 
electrophysiological maturation of cortical PNs (Xing et al., 2016). However, it is unclear 
if ERK/MAPK regulates these processes in CIN populations. In contrast to PNs, 
ERK/MAPK pathway activity is not required for the survival of CIN populations. We 
therefore suggest that loss of ERK1/2 signaling during CIN development may also regulate 
dendritic arborization and intrinsic electrophysiological properties. In support of this 
hypothesis, the receptor tyrosine kinase ERBB4, which lies upstream of the canonical 
ERK/MAPK cascade, is highly enriched in PV-expressing CINs and is important for 
GABAergic synaptic transmission (Fazzari et al., 2010). We suggest that loss of ERK1/2 
may drive similar alterations in CIN physiology.  
A number of neurological disorders implicate abnormal PV-CIN development and 
function in neuropathogenesis (Bitanihirwe and Woo, 2014; Cabungcal et al., 2013; 
Fazzari et al., 2010; Selby et al., 2007; Steullet et al., 2017; Xu et al., 2018). However, we 
did not detect overt PV-CIN developmental abnormalities in Erk1-/-, Erk2fl/fl, Nkx2.1:Cre 
cortices. In contrast to increased ERK/MAPK pathway activity during CIN development 
(Holter et al., 2019; unpublished), loss of ERK1/2 signaling did not disrupt the number of 
PV-expressing CINs in the adult cortex. Moreover, we did not observe differences in the 
  146 
extent of cortical PNN-labeling, suggesting that PV-CIN maturation in ERK1/2 CKO 
mutants is intact. Thus, there appear to be distinct requirements of ERK1/2 for specific 
CIN subtypes. The most common pathogenic mechanism driving RASopathy 
neuropathogenesis is an increase in canonical ERK/MAPK pathway activity. Our data 
suggest that therapies aimed at normalizing ERK/MAPK activity during CIN development 
may significantly impair processes necessary for normal SST-CIN maturation. Together, 
this work provides insight into the basic biological functions of ERK1/2 in CIN 
development and highlights subtype-specific requirements for ERK1/2 in GABAergic 
circuits. 
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Supplemental Figures 
 
 
Supplemental Figure 1. PV-CIN density is unaltered in Erk1-/- Erk2fl/fl, Dlx5/6:cre 
mutant cortices (A-D) Representative saggital sections of P14 Erk1-/-, Erk2fl/fl, 
Dlx5/6:Cre, Ai3 mutants and Erk1-/-, Erk2fl/wt, Dlx5/6:Cre, Ai3 controls labeled for ERK2. 
(E-F) Reduced ERK2 protein was detected in mutant CINs as compared to controls (yellow 
arrowheads). (G-L) P14 coronal sections of Erk1-/-, Erk2fl/fl, Slc32A1:Cre, Ai3 and Erk1-/-, 
Erk2fl/wt, Slc32A1:Cre, Ai3 primary S1 immunolabeled for PV showed no qualitative 
decrease in the number of Ai3+ CINs (n=3). 
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CHAPTER 5 
 
CONCLUSION 
 
 The canonical ERK/MAPK cascade is important for the construction of the brain, 
including complex structures such as the cerebral cortex. Perturbations to ERK/MAPK 
signaling during development give rise to a family of neurodevelopmental syndromes 
collectively termed the “RASopathies.” Here, I aimed to further the understanding of how 
specific mutations that drive changes in ERK/MAPK pathway activity affect the 
development and function of cortical circuits. My data argues for the generation of patient-
specific molecular therapeutics and suggests that modulation of GABAergic circuits may 
be a particularly effective treatment option for some RASopathy individuals. 
 
Differential neurocognitive outcomes in the RASopathies 
RASopathy individuals present with a variety of neurological phenotypes that 
include intellectual disability, ADHD, developmental delay, and seizures (Adviento et al., 
2014; Rauen et al., 2013; Tidyman and Rauen, 2016). Individuals with unique RASopathy-
associated mutations often display overlapping neurological phenotypes, though many are 
incompletely penetrant and of varying severity (Pierpont et al., 2018; Pierpont et al., 2009; 
Pierpont et al., 2010b; Pierpont et al., 2013). Due to the heterogeneity of neurological 
outcomes of RASopathy mutations, continued study of individual genes will be necessary 
to treat patients effectively and efficiently. For example, a Polish family consisting of 
several individuals with the Noonan Syndrome-associated RAF1L613V mutation display 
diversity in intellectual functioning (Pandit et al., 2007; Razzaque et al., 2007). While 
RAF1L613V did result in intellectual disability in two family members, a third had 
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considerably better than average performance on an IQ test (E. Ciara et al., 2009, ASHG, 
abstract). Other studies of adaptive behavior in RASopathy individuals have shown that 
people with mutations in BRAF, SOS1, and PTPN11 have heterogeneous capabilities and 
therefore require different levels of care (Pierpont et al., 2009; Pierpont et al., 2010a; 
Pierpont et al., 2013). Furthermore, individuals with the same mutation do not necessarily 
experience the same neurological outcomes. Individuals with point mutations in upstream 
regulators of ERK/MAPK signaling, which typically comprise the majority of RASopathy 
cases, have heterogenous neurocognitive outcomes (Pierpont et al., 2018; Pierpont et al., 
2009; Rauen et al., 2015; Tidyman and Rauen, 2016). 
Interestingly, individuals with mutations in kinases downstream of RAS, such as 
BRAF and MEK isoforms, tend to have increased severity of neurocognitive dysfunction 
(Pierpont et al., 2010b). It is therefore likely that aberrant ERK/MAPK activity is a central 
regulator of RASopathy neurological phenotypes, though the mechanisms by which 
ERK/MAPK mediates neurocognitive phenotypes in patients is still under investigation. 
Furthermore, it is unclear how unique mutations in different regulators and core kinases of 
the ERK/MAPK pathway affect the development of specific cell types and subsequent 
formation and function of neurobiological circuits. Thus, broad characterization of 
individual patient mutations and requirements of RASopathy-linked genes in the 
development of neural cell types will be necessary to understand the molecular and cellular 
events that give rise to the RASopathies. This work will be beneficial to our collective 
efforts in the basic understanding of canonical ERK/MAPK pathway activity in 
neurodevelopment as well as the design of new therapeutics for RASopathic individuals. 
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Raf1L613V drives changes in glial development 
Here, I have provided the first data to characterize neurological phenotypes in a 
germline Raf1L613V mouse model of Noonan Syndrome. Mutations in core kinases of the 
ERK/MAPK pathway downstream of RAS are associated with profound deficits in 
intellectual ability (Pierpont et al., 2010b). However, we report the first germline 
RASopathy mouse model to drive enhanced spatial reference and working memory, and 
improved fear learning. Improvements in learning coincided with modest yet significant 
increases in the density of cortical and hippocampal astrocytes, and a significant increase 
in the density of cortical OPCs.  
 Abnormal development of glial cells such as astrocytes and oligodendrocytes is 
thought to contribute to neurodevelopmental disease (Koini et al., 2017; Molofsky et al., 
2012). Previous work had identified essential trophic stimuli, such as cardiotrophin-1, 
ciliary neurotrophic factor (CNTF), and leukemia inhibitory factor (LIF), that were 
necessary to shift radial glia into a gliogenic state (Miller and Gauthier, 2007; Nakashima 
et al., 2001; Nakashima et al., 1999; Ware et al., 1995). However, knowledge of 
intracellular molecular events mediating this process downstream of receptor activation 
were relatively unresolved. The gp130/JAK-STAT pathway was revealed as the major 
molecular cascade necessary for the switch to astrogenesis during embryonic brain 
development, and mouse cortices lacking the gp130 receptor did not produce astrocytes 
(Nakashima et al., 1999). During corticogenesis, the ERK/MAPK cascade is a key 
instructor in the neuro- to gliogenic switch (Li et al., 2012b). Furthermore, both loss- and 
gain-of-function MEK mutations have profound effects on the number of astrocytes 
generated during gliogenesis (Li et al., 2012b). These phenotypes arise due to an abnormal 
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temporal shift in radial glial production of astrocytes during mouse corticogenesis and 
suggests that ERK/MAPK regulation of gliogenic genes is the key to the initial generation 
of astrocytes. In comparison, the gain-of-function Raf1L613V mutation drove modest 
increases in glial number in the mouse sensory cortex and hippocampus. Raf1L613V mutant 
mice had significantly increased densities of GFAP+ astrocytes and PDGFRα+ OPCs in the 
adult cortex. These data are consistent with previous reports of abnormal glial development 
in response to changes in ERK/MAPK signaling (Breunig et al., 2015; Gauthier et al., 
2007; Krencik et al., 2015; Li et al., 2012b; Rizvi et al., 1999; Tien et al., 2012; Zhu et al., 
2005). 
 Interestingly, we detected no differences in the density of astrocytes and OPCs 
during the second postnatal week. These findings contrast with previous RASopathy 
literature showing that hyperactive ERK/MAPK mutations drive changes in early gliogenic 
processes and subsequent astrocyte and oligodendrocyte overproduction (Ehrman et al., 
2014; Li et al., 2012b). Our data suggests that the Raf1L613V mutation works through an 
independent mechanism, by which a postnatal proliferative event may be responsible for 
increased glial density in Raf1L613V cortices. Consistent with this hypothesis, we detected 
an increased density of PDGFRα+ non-myelinating OPCs in the mouse sensory cortex. 
OPCs remain quiescent but maintain proliferative capabilities in adulthood (Dawson et al., 
2003; Fernandez-Castaneda and Gaultier, 2016; Wang et al., 2006). Whether or not OPC 
proliferation, increased astrocytic divisions, or invasion of glia from other brain regions is 
responsible for increased glial cell density in the Raf1L613V cortex remains open for 
exploration. Conditional studies utilizing a Cre-dependent Raf1L613V mutation will be 
necessary for a comprehensive understanding of gliobiological events in Raf1L613V mutant 
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mice. Study of these events will be particularly impactful for therapeutic design due to the 
late temporal onset of this phenotype. 
 Despite modest changes in glial number, we detected no overt signs of glial 
dysfunction in Raf1L613V mice. Diffusion tensor imaging (DTI) of RASopathy and ASD 
patient brains often show changes in white matter structure, which may be driven by 
specific changes in oligodendrocyte development (Filges et al., 2014; Koini et al., 2017; 
Owen et al., 2014). Interestingly, assessment of myelination in the Raf1L613V corpus 
callosum revealed no change in the extent of myelin sheath thickness around individual PN 
axons, suggesting that processes linked to myelinogenesis are relatively intact. We also 
observed no changes in the initiation of myelination in Raf1L613V cortices. Furthermore, key 
extracellular matrix remodeling processes mediated by astrocytes were unaltered in 
Raf1L613V mutants. We observed no significant differences in the extent of PNN 
accumulation around PV CINs in the hippocampus. 
The unique biochemical properties of distinct RASopathy mutations result in 
differential activation of the principal ERK1/2 kinases (Rodriguez-Viciana et al., 2008). 
Differences in RASopathy biochemical dynamics may therefore underlie contrasting 
cellular phenotypes in RASopathy disease states. For instance, the Raf1L613V mutation 
induces qualitatively weak phosphorylation of ERK1/2 when compared to other 
RASopathy mutations (Holter et al., 2019; Rodriguez-Viciana et al., 2008). In Raf1L613V 
cortices, we detected subtle increases in the number of high P-ERK1/2-expressing PNs in 
layer 2/3 in adulthood. We observed no differences in the protein levels of P-ERK1/2 
across all cortical layers during the third postnatal week at the peak level of ERK/MAPK 
pathway activity. Due to Raf1L613V driving only subtle changes in RAF1 biochemical 
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activity in non-neuronal cell types (Wu et al., 2011), it is likely that slight increases in 
ERK/MAPK activity are not sufficient to broadly alter cortical architecture. However, glial 
cells appear to be sensitive to changes in ERK/MAPK activity, potentially due to 
heightened expression of canonical ERK/MAPK pathway components. It will be important 
to understand how changes in the Raf1L613V mouse brain translate to human 
neuropathology. To date, few individuals with the RAF1L613V mutation have been 
documented and none have been extensively characterized (E. Ciara et al., 2009, ASHG, 
abstract; Pandit et al., 2007; Razzaque et al., 2007). Cell-specific studies and neuroimaging 
of individuals with the RAF1L613V mutation will reinforce our understanding of 
neurocognitive heterogeneity in the RASopathies and provide further insight into the 
neuropathology of other RASopathy disorders.  
 
Effects of RASopathy mutations on cognition 
 The cellular underpinnings of neurocognitive disability in the RASopathies remains 
unclear. Germline and cell-specific studies of RASopathy-linked mutations yielded mixed 
results in determining the origins of neurocognitive dysfunction (Clement et al., 2012; 
Costa et al., 2002; Cui et al., 2008; Holter et al., 2019; Kushner et al., 2005; Lee et al., 
2014; Lee and Silva, 2009; Ozkan et al., 2014; Schreiber et al., 2017). In the germline, the 
Costello Syndrome-linked HrasG12V mutation drove impaired hippocampal-dependent 
memory (Schreiber et al., 2017); however, mutant mice expressing HrasG12V specifically 
in glutamatergic circuits exhibited significant improvements in spatial reference memory 
(Kushner et al., 2005). These results therefore suggest that glutamatergic circuits in 
HrasG12V mice do not significantly contribute to the neurocognitive impairments observed 
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in germline mutants. Moreover, neurocognitive dysfunction in germline HrasG12V mice is 
either mediated by other neurotransmitter systems, complex cell-cell interactions, or 
combinatorial effects of multiple defective neural circuits.  
These data contrast with other related mutations in regulators of RAS activity. 
Syngap1 mutant mice exhibit significant neurological deficits that are primarily driven by 
defective glutamatergic circuitry (Ozkan et al., 2014). Surprisingly, glutamatergic-directed 
mutations in Nf1 lead to no change in spatial reference memory (Cui et al., 2008). Deletion 
of Nf1 from GABAergic circuits was sufficient to drive impairments in hippocampal-
dependent memory, which therefore suggests that contributions of individual neuron 
subtypes may be dependent on gene mutation and differential expression patterns of 
RASopathy-linked genes. Further cell-specific studies of a broad array of RASopathy-
linked mutations will be informative for understanding the cellular underpinnings of 
RASopathy neuropathogenesis and elucidate potential targets for molecular therapeutics.  
The circuit mechanisms driving enhanced spatial reference, working, and fear 
memory in Raf1L613V mice remain unclear. We hypothesized that significant increases in 
hippocampal GFAP+ astrocyte density may contribute to improved spatial reference and 
working memory. Importantly, previous studies have shown that modest increases in the 
release of inflammatory cytokines, such as TNFα, from hippocampal astrocytes is 
correlated with improved memory (Camara et al., 2015; Camara et al., 2013; Han et al., 
2013). We detected no significant differences in the amount of TNFα labeling, suggesting 
that other molecular mechanisms underlie enhanced behavioral performance in these mice. 
Whether a single neurotransmitter system is responsible for memory improvements in these 
Raf1L613V mutants is unclear, though this may be mediated by glutamatergic-driven 
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improvements in LTP within the hippocampal microcircuit (Kushner et al., 2005). LTP 
assays in conjunction with local field potentials in Raf1L613V Schaffer collaterals will be 
instructive in understanding the circuit mechanisms responsible for enhanced cognitive 
performance in these mice. Further cell-specific studies of the Raf1L613V mutation will 
definitively determine the circuit origins of improved learning. 
 
Dysfunctional GABAergic circuits in the RASopathies 
Previous studies have had mixed results concerning GABAergic circuit 
involvement in RASopathy neuropathogenesis (Cui et al., 2008; Krencik et al., 2015; 
Kushner et al., 2005; Ozkan et al., 2014). It is likely that heterogeneity in GABAergic 
circuit dysfunction is mediated by a combination of factors such as 1) low expression of 
some RASopathy-related genes and 2) differential activation of downstream kinase 
cascades. In support of these hypotheses, CINs express low levels of Syngap1 in 
comparison to PNs, which may render them less susceptible to specific mutations within 
this gene (Mardinly et al., 2016). Furthermore, expression of canonical ERK/MAPK 
components Map2k1/Mek1 and Mapk1/Erk2 is substantially lower in CINs as compared to 
other neuron subtypes and glia (Loo et al., 2019; Mardinly et al., 2016). Thus, the naturally 
low levels of these kinases may render CIN populations more susceptible to gain-of-
function RASopathy mutations within the canonical ERK/MAPK pathway. 
 Here I’ve shown that increased MEK1 signaling during embryogenesis disrupts 
the establishment of PV-CIN number by cleaved-caspase 3 (CC3) mediated apoptosis. 
Surprisingly, SST-CIN number remained intact in adult mutant cortices. Reduced PV-CIN 
number was correlated with increased seizure susceptibility and defects in prefrontal cortex 
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function. The mature mutant cortex had a significant reduction in PN perisomatic 
GABAergic synapses, likely driven by the loss of  PV-CIN basket cells (Fino et al., 2013). 
Interestingly, surviving PV-CINs exhibited a significant increase in somal area, but did not 
display significant alterations in intrinsic electrophysiological properties. Developmental 
disease mutations that affect PV-CIN number typically result in increased oxidative stress 
and a coinciding reduction in the extent of PNN labeling. However, gain-of-function 
MEK1 signaling within GABAergic circuits led to a significant increase in the sequestering 
of CSPGs around surviving PV-CINs as assessed by WFA labeling. Collectively, abnormal 
PV-CIN development may mediate aspects of neuropathogenesis in some disorders of the 
RASopathy family. 
The mechanism by which caMek1 drives the death of embryonic PV-CINs is yet to 
be determined. Due to a small proportion of dying cells in the mantle zone of the MGE, it 
is difficult to pinpoint the precise cause of death by standard biochemical and 
transcriptomic methods. In vitro methods such as MGE cultures may be particularly 
informative in identifying molecular pathways associated with PV-CIN death. This method 
can be further optimized by adding antagonists of Wnt signaling, which has recently been 
shown to bias MGE progenitors toward PV-CIN generation at the expense of SST-CINs 
(McKenzie et al., 2019). Interestingly, upregulation of death cascades by sustained 
ERK/MAPK activation has been reported in numerous cancer and developmental models 
(Cagnol and Chambard, 2010). Adult PV-CINs have markedly high densities of 
mitochondria, therefore implicating mitochondrial-regulated death pathways as attractive 
candidate mediators of PV-CIN apoptosis. 
  157 
 We have established a role for aberrant GABAergic circuit development in 
RASopathy-linked ADHD, a co-morbid condition that affects approximately 40% of 
RASopathy individuals (Boyd et al., 2009; Green et al., 2017; Johnson et al., 2019; Miguel 
et al., 2015; Pierpont et al., 2018; Pierpont et al., 2015; Walsh et al., 2013). Previous studies 
of neurodevelopmental disease have suggested that defective glutamatergic circuitry 
mediates prefrontal cortex (PFC) dysfunction (Krueger et al., 2011). We show that 
abnormal GABAergic circuit development in response to gain-of-function ERK/MAPK 
pathway activity disrupts FMI performance. However, it is not clear if FMI deficits in 
caMek1 Slc32A1:Cre mice are mediated solely by cortical circuit dysfunction. The 
interface of the PFC to regions of the basal ganglia, such as the striatum, is essential to 
timing-related behaviors (Kim et al., 2018). The GABA-expressing D1 medium spiny 
neurons (MSNs) of the striatum have been previously shown to mediate aspects of temporal 
control (Narayanan et al., 2012). It will therefore be interesting to examine whether 
changes in D1-MSN development coincide with FMI performance deficits in caMek1 
Slc32A1:Cre mice (Hutton et al., 2017). 
While altered GABAergic output may disrupt the function of the PFC, it is also 
likely that GABA-mediated disruption of layer 2/3 PFC glutamatergic neurons drives 
deficits in behavioral response inhibition. PNs in the mutant PFC expressed significantly 
lower levels of P-ERK1/2 than controls, which may be due to changes in inhibition during 
perinatal development. Aberrant GABA signaling during the first postnatal week is 
sufficient to disrupt morphological features of PNs in the developing cortex (Cancedda et 
al., 2007). SST-CINs primarily form synaptic contacts in the cortical neuropil, and though 
SST-CIN density remained unchanged, reduced P-ERK1/2 in PNs may be mediated by 
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improper activity-dependent maturation in response to abnormal SST-CIN input. However, 
our data provides evidence that dysfunctional GABA signaling by PV-CINs drives cortical 
circuit-wide abnormalities that may underlie significant changes in behavioral response 
inhibition. 
In contrast to gain-of-function MEK1 signaling, we show that loss of ERK1/2 in 
developing CINs had little effect on PV-CIN development and postnatal maturation. 
Furthermore, PV-CINs were present in normal densities and distributions within the cortex. 
We observed normal sequestering of PNN components in Erk1-/-, Erk2fl/fl, Nkx2.1:Cre 
mutant mice, suggesting that the specific expression of the principal ERK1/2 proteins by 
CINs is non-essential to the formation of the PNN. Unlike cortical PNs, we show that 
canonical ERK/MAPK signaling does not regulate CIN number (Xing et al., 2016). 
However, immunolabeling for the major CIN subtypes, PV and SST, revealed a significant 
decrease in the density of SST-immunoreactive cells in the adult cortex. We further show 
that loss of SST expression is detectable by the end of the second postnatal week. It is 
therefore likely that this phenotype is due to either aberrant specification of SST-CINs 
during embryonic development or potentially due to the disruption of activity-dependent 
maturation during perinatal development. Assessment of SST expression patterns at birth 
and in the embryo will be necessary to inform these possibilities. 
The Somatostatin gene contains a CRE sequence that can be bound by the 
phosphorylated form of cAMP Response Element-binding Protein (CREB) (Cha-Molstad 
et al., 2004; Gonzalez et al., 1989). CREB activation lies downstream of canonical ERK1/2 
signaling, and in the nervous system, can be stimulated by calcium currents during neural 
activity (Wu et al., 2001). Regulation of P-CREB is primarily mediated by Calmodulin 
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Kinase (CaMK) stimulation and is activated slowly by ERK/MAPK pathway activity (Wu 
et al., 2001). Furthermore, dominant negative RAS is sufficient to disrupt phosphorylation 
of CREB by both ERK1/2 and CaMK-dependent pathways (Wu et al., 2001). Loss of SST 
expression in response to reduced ERK1/2 in the postnatal cortex may therefore be due to 
aberrant activity-dependent maturation of SST-CINs. Enhanced excitation of SST-CINs in 
critical windows of CIN development may be sufficient to restore SST expression in this 
population of CINs. We thus hypothesized that chemogenetic activation of SST-CINs is 
sufficient to increase SST expression. Stimulation of the hM3Dq receptor by its ligand 
CNO has previously been shown to increase intracellular calcium release (Roth, 2016). 
Whether it is possible to treat an ERK1/2-linked phenotype by modulation of cellular 
activity is currently unknown. Successful reversal of an ERK1/2-linked phenotype by 
independent molecular pathways will provide unprecedented insight into RASopathy 
therapeutics. Collectively, our work highlights specific roles of ERK1/2 signaling in the 
development of CIN subpopulations and suggests that modulation of GABAergic signaling 
may be an effective treatment option for RASopathic individuals. 
 
Pharmacological intervention in the RASopathies 
Excitingly, pharmacological intervention with ERK/MAPK pathway inhibitors has 
shown promise in the treatment of RASopathy phenotypes. Administration of the second-
generation inhibitor of MEK1, PD0325901 (PD), was sufficient to rescue cardiac and 
skeletal defects in Raf1L613V mice (Wu et al., 2011). Importantly, IP administration of PD 
from 4-10 weeks of age once daily was sufficient to reverse phenotypes related to the 
Raf1L613V mutation. These data provide critical evidence that specific RASopathy 
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phenotypes may be able to be reversed in humans in late embryonic and early postnatal 
development. Furthermore, it is unclear if modulation of ERK/MAPK signaling in the 
Raf1L613V mouse model would result in phenotypically normal spatial reference and 
working memory, potentially minimizing the benefits of this mutation in mice. In addition, 
PD treatment in a separate Ptpn11D61G mouse model of Noonan Syndrome provided 
evidence that Mek1 inhibitors can normalize neurological dysfunction in adulthood, a 
promising finding for RASopathy individuals (Lee et al., 2014). Moreover, these findings 
also suggest that neurocognitive impairments in individuals with mutations in upstream 
regulators of RAS signaling may be due to altered canonical ERK/MAPK signaling. 
The majority of RASopathy-causing mutations lie in upstream regulators of RAS 
signaling (Rauen et al., 2013). Therefore, it will be important to explore how modulation 
of ERK/MAPK-independent parallel cascades affect neurocognition. Indeed, 
pharmacological normalization of ROCK, NOTCH, PKC, and cAMP/PKA pathways 
downstream of RAS are sufficient to reverse cellular deficits driven by mutations in NF1 
(Anastasaki and Gutmann, 2014; Brown et al., 2012; Kaul et al., 2015). These data suggest 
that these signaling cascades may have important contributions to behavioral deficits 
observed in the RASopathies. Further study of how normalization of these pathways in the 
RASopathies influences behavioral outcome will be necessary to understand broad 
contributions of cell signaling to defects in neurocognition.  
Clinical trials assessing the therapeutic benefits of RAS activity modulation have 
yielded mixed results. Individuals with Neurofibromatosis Type 1 treated with the 3-
hydroxy-3-methylglutamyl coenzyme A reductase inhibitor, simvastatin, had no 
improvement in cognitive function at the end of a twelve-week administration period (Krab 
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et al., 2008). Interestingly, separate clinical trials examining the efficacy of lovastatin 
treatment, a small molecule with a similar mechanism of action to simvastatin, yielded 
exciting results. Individuals with Neurofibromatosis Type 1 treated with lovastatin for 
three months exhibited significant improvements in both verbal and non-verbal memory 
(Acosta et al., 2011; Bearden et al., 2016). However, other neurocognitive phenotypes 
associated with NF1, including visuospatial memory and attention, do not appear to 
improve in response to lovastatin treatment (Payne et al., 2016). Recently, a small clinical 
trial consisting of two Noonan Syndrome patients examined the effects of trametinib, a 
MEK1/2 inhibitor, on cardiac hypertrophy (Andelfinger et al., 2019). Trametinib was 
administered to the affected infants beginning at 13 and 14 weeks of age, and treatment 
lasted for three months. Upon completion of treatment, both Noonan Syndrome infants had 
dramatic improvements in cardiac structure and function (Andelfinger et al., 2019). The 
study provides promising results of MEK1/2 modulation for the treatment of Noonan 
Syndrome symptoms. The successes of these treatments lays the foundation for widespread 
examination of canonical ERK/MAPK pathway modulation for neurocognitive therapies 
in humans. Importantly, the reversal of some neurocognitive abnormalities in NF1 
individuals in conjunction with extensive mouse studies provides essential information that 
some phenotypes may be able to be resolved after the onset of symptoms in the early years 
of life. 
RASopathy individuals experience neurological symptoms that often include 
intellectual disability, ADHD, motor delay, and seizures. Importantly, an increased interest 
in the genetic origin of the RASopathies has led to the characterization of many unique 
point mutations and disease-causing genes. Within individual genes, multiple distinct point 
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mutations have been discovered that can give rise to RASopathy neuropathogenesis. 
Though the cellular origins underlying neurobehavioral phenotypes in RASopathy 
individuals is still under investigation, promising results from Phase II clinical trials have 
suggested that normalization of ERK/MAPK signaling may be effective for many 
RASopathy individuals. Here, we show that characterization of RASopathy mutations is 
important in understanding how unique genes influence cellular pathology and affect 
behavior. We find that subpopulations of neural cell types, including neurons and glia, are 
differentially affected by specific RASopathy point-mutations. Furthermore, we have 
shown that aberrant ERK/MAPK pathway activity disrupts the early formation of 
GABAergic circuits and drives impairments in cognition. Collectively, our data suggest 
that normalization of GABAergic signaling may be a particularly effective treatment option 
in some instances of the RASopathies and ultimately lead to a better quality of life for 
affected individuals.  
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